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The molecular mechanisms that mediate endometrial cancer invasion and metastasis
remain poorly understood. This is a significant clinical problem, as there is no definitive cure for
metastatic disease. The purinergic pathway’s generation of adenosine and its activation of the
adenosine receptor A2B (A2BR) induces cell-cell adhesion to promote barrier function. This
barrier function is known to be important in maintaining homeostasis during hypoxia, trauma, and
sepsis. Loss of this epithelial barrier function provides a considerable advantage for carcinoma
progression, as loss of cell-cell adhesions supports proliferation, aberrant signaling, epithelial-tomesenchymal transition, invasion, and metastasis. The present work provides strong evidence that
CD73-generated adenosine actively promotes cell-cell adhesion in carcinoma cells by filopodiainduced zippering.

Adenosine-generating ecto-enzyme, CD73, was down-regulated in

moderately- and poorly-differentiated, invasive, and metastatic endometrial carcinomas. CD73
expression and enzyme activity in normal endometrium and endometrial carcinomas was
significantly correlated to the epithelial phenotype. Barrier function in normal epithelial cells of
the endometrium was dependent on stress-induced generation of adenosine by CD73 and
adenosine’s activation of A2BR. This same mechanism inhibited endometrial carcinoma cell
migration and invasion.

Finally, adenosine’s activation of A2BR induced the formation of

filopodia that promoted the re-forming of cell-cell adhesions in carcinoma cells. Overall, these
studies identified purinergic pathway-induced filopodia to be a novel mechanism of adenosine’s
barrier function and a mechanism that has to be avoided/down-regulated by endometrial
carcinoma cells attempting to lose attachment with their neighboring cells. These results provide
insight into the molecular mechanisms of endometrial cancer invasion. In addition, because loss

iv

of cell-cell adhesions has been closely linked to therapy resistance in cancer, these results provide
a rational clinical strategy for the re-establishment of cell-cell adhesions to potentially increase
therapeutic sensitivity. In contrast to other molecular mechanisms regulating cell-cell adhesions,
the purinergic pathway is clinically druggable, with agonists and antagonists currently being tested
in clinical trials of various diseases.
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CHAPTER ONE
Prelude
Cancer remains a significant health concern as it is the second most common cause of
death in the United States. Lifetime risk for developing cancer is slightly less than 50% for men;
for women, the risk is a little more than 33% (1). Defined as a malignant growth caused by
uncontrolled cell growth, cancer can arise in all tissue types. Cancers arising from transformation
of epithelial cells (carcinomas) are the most common.

In 2011, an estimated 1.5 million

Americans are expected to be newly diagnosed with cancer. A mortality rate of 1,500 deaths per
day is also expected (1). Though mortality rates for cancers arising in the breast, colon, and cervix
have slowly declined as a result of regular screenings, mortality rates among many cancers remain
unchanged. Lack of early detection methods and absence of clear, defined symptoms that present
with early stage disease have contributed to the lack of declining mortality rates among these
cancers (1). Consequently, many individuals diagnosed with cancer have dissemination of the
disease at the initial time of its discovery.
For these individuals the life-threatening concern will not come from the primary site of
the disease. The dissemination of cancer cells, known as metastasis, is the greatest concern, as
metastasis accounts for greater than 90% of all cancer related mortalities. Once a cancer has
metastasized there is no definitive cure, and in many cases clinical focus shifts from cure to
slowing the spread of the disease. Stable disease, recognized as a period by which a metastatic
site is not growing or spreading, is currently the most sought-after clinical achievement for
patients with metastatic disease. Though many patients experience a period of stable disease, the
effect is often short-lived with time to progression being defined in months. A clinical concern
with these patients is that all treatment modalities will eventually be exhausted in attempting to
maintain stable disease.
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A great amount of effort has gone into identifying and understanding the important events
and molecular players that are central to metastasis and therapy resistance. From these efforts
many targets having potential for clinical benefit have been identified. However, movement of
these targets into pre-clinical development has been limited as a result of many targets failing to be
“druggable” by small molecules/pharmacological agents, antibodies, or ligand-binding agents.
This has led to the dismissal of many worthwhile targets. One such target has been cell-cell
adhesions and the individual proteins that regulate such structures. Re-expression of cell-cell
adhesion proteins in carcinoma cells has the potential to improve or re-sensitize carcinoma cells to
therapeutic agents. Currently, there are no known druggable schemes for re-establishing cell-cell
adhesions or their individual proteins in carcinoma cells.
The work reported in this dissertation is innovative in that it establishes adenosine’s
relation to the reforming of cell-cell adhesions in stressed carcinoma cells.

The purinergic

pathway being a highly drug targeted pathway raises the question to whether pharmacological
agents could be used to re-establish cell-cell adhesions in carcinoma cells to provide therapeutic
benefit in patients with metastatic disease. The purinergic pathway’s generation of adenosine and
adenosine’s signaling has a history of providing epithelial cell-cell adhesion in the form of barrier
function. Such epithelial barrier function is critical in maintaining homeostasis during sepsis,
hypoxia, and trauma. However, the purinergic pathway is not well-studied in cancer and its exact
effect on cell-cell adhesions and the individual proteins associated with such adhesions remains
unclear.

Using endometrial carcinoma as a model system, we have put much effort into

establishing this pathway and its generation of adenosine and its relatedness to barrier function
and cell-cell adhesions.

The studies described within this dissertation utilize commercially

available carcinoma cell lines and pharmacological agents, endometrial carcinomas obtained from
FIGO stage I-IV patients, and mouse models. Overall, our objective of this work was to establish
CD73’s generation of adenosine to induce barrier function in epithelial cells of the endometrium
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and to establish adenosine’s ability to regulate cell-cell adhesion events or proteins in carcinoma
cells. This work provides the foundation and understanding of adenosine and its regulation of
cell-cell adhesions in carcinoma cells, which are important to the future progression of this work
into pre-clinical studies. Such movement of these findings may later lend to provide therapeutic
benefit to patients with metastatic disease.
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CHAPTER TWO
General Introduction
Endometrial Cancer
Carcinomas of the female reproductive tract account for almost 15% of all cancers
diagnosed in women. The most common of these malignancies is uterine cancer, specifically
endometrial cancer. Endometrial cancer (EC) arises in the epithelial lining of the uterus, the
endometrium.

In the United States an estimated 46,470 women are expected to be newly

diagnosed with the disease in 2011 (1). An estimated mortality of 8,120 women is also expected.
The prevalence of EC among all cancers is preceded only by cancers of the breast, lung, and colon
(1). The incidence of EC over the past 10 years has continued to increase at a concerning rate (1,
2). Increased life expectancy and obesity has contributed to increased diagnoses (3, 4).
Histological subtype is a well-known independent prognostic indicator of survival in EC
(5, 6). Subtypes of EC are classified according to differentiation patterns and architectural grade.
The majority of ECs, 80%, are of the endometrioid subtype. Endometrioid refers to endometrialtype glands of varying differentiation that resemble proliferative-phase endometrium. Variants
include secretory, villoglandular, endometrioid with squamous differentiation, and endometrioid
with ciliated cells. Architectural grade divides endometrioid tumors into Grade 1, Grade 2, and
Grade 3. A Grade 1 classification consists of well-differentiated glands with no more than 5%
solid growth. Grade 2 endometrioid includes moderately-differentiated glands and 6-50% solid
growth, and Grade 3 consists of poorly-differentiated glands and more than 50% solid growth (6).
When separated by grades, Grade 3 endometrioid has the poorest prognostic outcome (6). Grade 3
survival rates are relatively similar to non-endometrioid subtypes when stage of disease is
compared (6).

The remaining 20% of endometrial carcinomas are represented by non-

endometrioid subtypes, such as uterine papillary serous, clear cell, and malignant mixed Müllerian
tumor (MMMT; carcinosarcoma). Based on the histological similarity seen among EC subtypes
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and including clinical, genetic, and molecular features, EC can be divided into two broad
categories, Type I and Type II disease (7-10). Type I ECs consist of low-grade, Grade 1 and
Grade 2, endometrioid ECs that typically arise from a history of unopposed estrogen exposure, are
of low metastatic potential (confined to the uterine corpus), and have favorable prognostic
outcomes. Type II ECs includes Grade 3 endometrioid and non-endometrioid subtypes. Type II
ECs appear to be un-related to high estrogen levels and are highly aggressive with metastasis
common at the time of diagnosis (7). Unlike Type I that arises in a background of hyperplasia
(11), Type II ECs arise in an atrophic endometrium in relatively older women. Common genetic
and molecular abnormalities that occur in Type I ECs and Grade 3 endometrioid include
microsatellite instability, 20-40% (12-15), inactivation of phosphatase and tensin homolog
(PTEN), ~80% (16-18), and mutations in K-ras, 15-30% (19, 20), PIK3CA, 25-30% (21-24), and
CTNNB1 (encodes β-catenin), 25-40% (25-30).

In contrast, Type II ECs frequently show

inactivation of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16), 40%, and E-cadherin, 8090% (31), p53 mutations, 90% (32-34), amplification of human epidermal growth factor receptor
2 (ErbB-2; Her2/neu), 10-30% (35), and chromosomal instability. While Type II abnormalities,
such as p53 mutations, E-cadherin inactivation, and Her2/neu amplification are seen among the
endometrioid subtype, albeit in lower percentages, this is mostly attributed to Grade 3
endometrioid ECs. Not all ECs associate directly with Type I or Type II, as a limited number of
ECs show mixed or overlapping features.

This has lead to the consideration that non-

endometrioid ECs may develop by two differing pathways: (1) de novo, via p53 mutation, or loss
of heterozygosity at several loci; or (36) dedifferentiation from a pre-existing endometrioid ECs
(9, 37). Whether either or both pathways occur is currently unclear.
Despite great advances in understanding the molecular and genetic events associated with
the two types of EC and their development, very little is known regarding the molecular
mechanisms of how endometrial carcinomas invade and metastasize. Consequently, the outlook
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for patients with metastatic disease remains poor. The overall low mortality rate, a statistic
attributed to 72% of initially diagnosed patients having uterine-confined disease cured by surgery
alone (38), has overshadowed issues relating to metastatic disease, including persistence of
therapy resistance and lack of targeted agents for EC. Current adjuvant therapies of combined
chemotherapy, involving paclitaxel-cisplatin or doxorubicin-cisplatin, radiation, and/or hormonal
therapy remain to have little to no benefit for women with metastatic EC (reviewed, (39)). Few
advances have been made in identifying and developing novel therapeutic strategies for this
disease. Consequently, metastatic EC patients are increasingly seeking Phase I clinical trials as a
result of other options not being available for this disease. With this continuing trend, the outlook
for these women will continue to be dismal.
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The Effects of the Loss of Cell-Cell Adhesions in Carcinomas
The term metastasis was first proposed by Jean Claude Recamier in 1829. Since then it
has been well-described that cancer cells undertake a cascade of events (metastatic cascade –
initially proposed by Garth Nicolson and Jeffrey Winkelhake (40)) in order to survive and
propagate in distant sites, and that the outcome of metastasis in a defined tissue or organ is not
random but due to compatibility between the “seed” (cancer cells) and “soil” (metastatic site).
This “seed and soil” hypothesis was first proposed by Stephan Paget in 1889 (41). Like other
cancer types, ECs tend to metastasize to preferred sites, including the lung, (frequency, 41%),
peritoneum and/or omentum (39%), ovary (34%), liver (29%), bowel (29%), and bladder (23%)
(42).

Each step of the metastatic cascade is comprised of a complex change of molecular and

genetic events within the cancer cells and cells of the surrounding microenvironment. Steps of the
metastatic cascade include proliferation and vascularization, invasion, embolism, transport through
circulation, arrestment in organs or tissues, extravasation, establishment of a microenvironment,
and proliferation and re-vascularization of the cancer cells at metastatic site(s). For a cancer cell
to form a metastasis, it must successfully navigate each step (reviewed, (43)). It is believed that
very few cancer cells, less than 0.01%, are able to successfully complete this cascade (44, 45).
In the initial steps of the metastatic cascade, carcinoma cells will shed their prototypical
epithelial characteristics, such as cell-cell adhesions, apical-basolateral polarity, barrier function,
basement membrane restriction, and cobblestone differentiation. These actions provide carcinoma
cells with a phenotype that is more influencing of metastatic behavior. The loss of individual cellcell adhesion proteins contributes to the metastatic progression of carcinoma cells. Initially
recognized only for contributing to carcinoma cell migration and invasion, loss of cell-cell
adhesion proteins and their structures are now known to impact proliferation and transcriptional
control, basolateral receptor activity, and polarity. These events contribute significantly to the
metastatic phenotype of carcinoma cells, as will be introduced with the following. Therefore, loss
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of cell-cell adhesions and their individual proteins is not a passive event in the metastatic
progression of carcinoma cells. Cell-cell adhesion structures common among epithelial cells
include tight junctions, adherens junctions, and desmosomes. Cell-cell adhesion structures are
comprised of an array of integral membrane, peripheral plaque, and cytoskeletal associated
proteins. Proteins composing cell-cell adhesion structures are illustrated in Figure 2.1 (46).

Regulation of Proliferation and Transcriptional Control by Cell-Cell Adhesions
The indication that cell-cell adhesion structures had important roles in controlling
carcinoma cell proliferation and transcription of metastasis-impacting genes came from studies
that identified transcription factors to be sequestered to the membrane of cell-cell adhesions.
Sequestered transcription factors include ZO-1 associated nucleic acid binding protein (ZONAB),
Jun, Fos, CCAAT-enhancer binding protein (C/EBP), β-catenin, and γ-catenin.

ZONAB is a Y

box transcription factor that regulates the G0/G1 to S cell cycle phase transition by interacting with
cyclin dependent kinase 4 (CDK4) and inducing transcription of cyclin D1 and proliferating cell
nuclear antigen (PCNA) (47-49). ZONAB also regulates the expression of the known oncogenic
receptor, Her2/neu (47). ZONAB is sequestered to the membrane by peripheral plaque and tight
junction protein, zona occludens 1 (ZO-1) (47). Release of ZONAB from ZO-1, as a result of ZO1 loss or membrane delocalization, is associated with uveal melanoma cell proliferation and
progression (50). Absence of ZO-1 is correlated with disease progression in breast carcinomas
(51). The transcription factors Jun, Fos, activator protein 1 (AP-1), and C/EBP are bound by the
peripheral plaque and tight junction protein, zona occludens 2 (ZO-2). ZO-2 contains nuclear
import and export signals and therefore shuttles between the nucleus and tight junctions (52). ZO2 can be found associated with Jun, Fos, and C/EBP in the nucleus where it acts to negatively
regulate Jun, Fos, and C/EBP transcription activity (53). However, to provide function to tight
junctions, ZO-2 will translocate from the nucleus to tight junctions, bringing with
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Figure 2.1.

Schematic summary of epithelial cell-cell adhesion structures and their

associated proteins. Cell-cell adhesion structures common among epithelial cells include tight
junctions, adherens junctions, and desmosomes. Cell-cell adhesion structures are comprised of a
diverse array of integral membrane, peripheral plaque, and cytoskeletal associated proteins. Tight
junction: integral membrane proteins, claudins, occludin, and junctional adhesion molecules
(JAMs); peripheral plaque proteins, zona occludens (53); cytoskeletal associated proteins, F-actin.
Adherens junction: integral membrane proteins, cadherins and nectin; peripheral plaque proteins,
β-catenin, α-catenin, γ-catenin (plakoglobin), vinculin, α-actinin; cytoskeletal associated proteins,
F-actin Descmosomes: integral membrane proteins, desmocollin and desmoglein; peripheral
plaque proteins, γ-catenin (plakoglobin) and desmoplakin; cytoskeletal associated proteins (not
shown), intermediate filament proteins, such as keratins and vimentin. Tyrosine kinase receptors,
epidermal growth factor receptor (EGFR), Met, and insulin growth factor 1 receptor (IGF1R) are
bound and activity inhibited by adherens junction protein E-cadherin (54).

Transport of

transforming growth factor β receptor 1 to the basolateral membrane requires occludin binding
(55). Occludin-TGFβ1 interact with partitioning-defective protein-6 (Par6), a polarity protein of
the Par6-partitioning-defective protein 3 (Par3)-atypical protein kinase C (aPKC) polarity complex
(56). Modified from Thiery, J.P. and Sleeman, J.P. Complex networks orchestrate epithelialmesenchymal transitions, Nature Reviews Molecular Cell Biology, 2006, 7:131-142.

Image

modified courtesy of Kim Vu, Department of Pathology, the University of Texas MD Anderson
Cancer Center. Image reference: (46)
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Figure 2.1
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it Jun, Fos, and C/EBP (53). c-Jun promotes carcinoma cell proliferation by inducing cyclin D1
and concomitantly repressing p53 transcription in the absence of ZO-2 (57, 58). Fos activation in
mouse mammary epithelial cells promotes epithelial-to-mesenchymal transition (EMT), a
phenotype transitioning event later described in this introduction, by induction of βcatenin/lymphoid enhancer binding factor-1 transcriptional activity (59). β-catenin is a peripheral
plaque protein of adherens junctions that binds the integral membrane protein E-cadherin. βcatenin is also central to the canonical Wnt signaling pathway as a transcriptional co-regulator.
Along with T-cell factor/lymphoid enhancer-binding factor 1 (TCF/LEF1) family members βcatenin can transcribe an array of proliferative and metastasis-influencing genes, such as c-myc,
cyclin D1, fibronectin, matrix metalloproteinase-7 (MMP-7), cyclooxygenase 2 (COX-2), CD44,
P-glycoprotein, and Snail (60) (reviewed, (61)).

β-catenin stability in the cytoplasm is the

determining factor for its function as a transcription factor (62, 63). Loss of E-cadherin in
carcinoma cells leads to β-catenin cytoplasmic accumulation, which contributes to β-catenin’s
transcriptional activity (62, 63). In many cancers, including colon (64), melanoma (65), ovarian
(66), hepatocellular (67), and endometrial (reviewed, (37)) single-base missense mutations of βcatenin prevent cytoplasmic degradation of β-catenin by its degradation complex, Axin-glycogen
synthase kinase-3β-adenomatous polyposis coli (Axin-GSK3β-APC) additively contributing to βcatenin’s transcriptional activities. γ-catenin, known as plakoglobin, is a peripheral plaque protein
of adherens junctions and desmosomes. γ-catenin binds E-cadherin at adherens junctions and
integral membrane proteins, desmocollin and desmoglein, at desmosomes.

γ-catenin is a

homologue of β-catenin and is found to have similar Wnt signaling roles as β-catenin (68, 69).
The lack of membrane E-cadherin expression and γ-catenin nuclear accumulation correlates with
lymph node metastasis and/or poor prognosis in head and neck (70), non-small cell lung cancer
(NSCLC) (71), and bladder (72) cancers.
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Regulation of Basolateral Receptor Activity by Cell-Cell Adhesions
At the basolateral membrane, integral cell-cell adhesion proteins, occludin and Ecadherin, directly bind to and control the activity of receptors located among cell-cell adhesion
structures. These receptors include transforming growth factor-β receptor 1 (TGFβR1) (55) and
receptor tyrosine kinase receptors, epidermal growth factor receptor (EGFR), Met, and insulin
growth factor 1 receptor (IGF1R) (54). The loss of tight junction proteins, including claudin-1,
ZO-1, and ZO-2, relieves paracellular selectivity and lends to the movement of apically
sequestered ligands along the basolateral membrane. TGFβR1, known as activin receptor-like
kinase 5 (ALK5), is positioned at tight junctions by occludin, an integral membrane protein of
tight junctions (55). When ligand is present, active recruitment of TGFβR2 and its complex with
TGFβR1 initiates signaling cascades that cause small GTPase (Rac and Rho)-induced cytoskeleton
reorganization, loss of polarity, matrix metalloproteinase expression and matrix degradation,
proliferation and survival, and epithelial-to-mesenchymal transition (EMT).

Importantly, the

activity of basolateral TGFβRI is directly involved with disassembling tight and adherens
junctions by phosphorylating occludin-TGFβR1 bound polarity protein, partitioning-defective
protein-6 (Par6) which recruits an E3 ligase to target cytoskeletal assembling and cell-cell
adhesion stabling protein, RhoA (56).

EGFR, Met, and IGF1R are found among adherens

junctions and bind directly with E-cadherin (54). Activity of these tyrosine kinase receptors is
central to the same signaling events described for TGFβR1 activity.

E-cadherin negatively

regulates EGFR, cMet, and IGF1R activation in an adhesion dependent manner (54). Therefore,
loss of E-cadherin from the basolateral membrane is important for the inappropriate activation of
these adherens junction kinase receptors.
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Regulation of Polarity by Cell-Cell Adhesions
Polarity complex proteins are required to maintain the identity of apical and basolateral
orientation of cells.

Collectively, cell-cell adhesion structures maintain polarity complex

organization, and polarity complexes are required to maintain cell-cell adhesions. Binding of
polarity complex proteins, partitioning-defective protein 3 (Par3) to tight junction protein, JAM1
and partitioning-defective protein 6 (Par6) to the occludin-TGFβRI complex is important for the
assembly and apical-basolateral and basolateral positioning of polarity complexes (73). Polarity
complexes and their members include, Par6, Par3, atypical protein kinase C (aPKC) (Par6-Par3aPKC) complex; crumbs, protein associated with lin seven 1 (PALS1), PALS1-associated TJ
protein (PATJ) (crumbs-PALS1-PATJ) complex; and scribble, discs large (Dlg), lethal giant
larvae (Lgl) (scribble-Dlg-Lgl) complex (reviewed, (74)). The loss of JAM1, occludin, their
peripheral plaque proteins, or the assembly of E-cadherin adherens junctions cause polarity
complex proteins to be dispersed, non-organized or complexed in the cell. This leads to the loss of
key homeostatic features including, positive feedback – location identity of proteins within the
cell, membrane segregation of lipids and proteins, directed vesicle trafficking, and lipid
modification. All of these processes contribute to the progression of carcinoma cells. In addition,
dispersed polarity proteins are freely recruited by TGF-β, phosphoinositide-3-kinase (PI3K), and
Wnt signaling to establish front-rear polarization, an event important for cell migration (reviewed,
(75)). Other contributions include PALS1’s inability to traffic E-cadherin to the membrane and
therefore maintain cell-cell adhesions (76) and the loss of PATJ’s interaction with tuberous
sclerosis complex 2 (TSC2) which allows for mammalian target of rapamycin (mTOR) signaling
(77).
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Regulation of Migration and Invasion by Cell-Cell Adhesions
Carcinoma cells gaining the ability to migrate and invade with the absence of cell-cell
adhesions or their individual proteins is a hallmark of metastasis. This migratory and invasive
behavior of carcinoma cells occurs by 1.) allowing cells to simply dissociate completely or
partially from one another (78, 79); 2.) relieving inhibitory control on basolateral receptor
signaling (80-85); 3.) supporting re-arrangement and altering of the cell’s cytoskeleton; and 4.)
disrupting juxtacrine signaling that establish and maintain neighboring adhesion structures.
Specific cell-cell adhesion proteins that are lost and thereby promote carcinoma cell migration
and invasion include E-cadherin, claudin-1 (86), claudin-16 (87), JAM1 (88), junctional adhesion
molecule 3 (JAM3) (89), and occludin (90). Decreased E-cadherin (91-94) and occludin (95)
expression correlates with increased histological grade, myometrial invasion, and lymph node
metastasis in EC.

Mechanisms of Cell-Cell Adhesion Loss in Carcinomas
Many mechanisms contribute to the loss of cell-cell adhesions, including epithelial-tomesenchymal transition (EMT), mutation, epigenetic silencing, proteolysis, defective membrane
transport, microRNA silencing, and tyrosine phosphorylation.

EMT may be considered the most

central and universal mechanism, as its activation is supported by multiple signaling pathways.
Such pathways include those activated from frizzled, integrin, notch, TGFβ, and/or tyrosine kinase
receptors and/or serine-threonine kinase receptors. More importantly, though EMT activity is
involved in the loss of cell-cell adhesions, EMT also contributes to the expression of metastasispromoting genes (reviewed, (46)). Aside from EMT, mechanisms of cell-cell loss known to be
relative in EC include mutation and epigenetic silencing. In EC, single-base missense mutations
in exon 3 of the β-catenin gene, CTNNB1, is associated with β-catenin nuclear expression and
found in 14-44% of tumors (reviewed, (37)). Mutations in the E-cadherin gene, CDH1, are rare in
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EC (96). Epigenetic silencing has greater significance in the loss of E-cadherin in EC. DNA
hypermethylation of the E-cadherin gene, CDH1 occurs with increasing frequency in ECs that
have extensive myometrial invasion, ~80% (97).

Epithelial-to-Mesenchymal Transition (EMT)
Epithelial-to-mesenchymal transition (EMT) is a genetic re-programming event that
transitions a cell’s lineage from an epithelial-like phenotype to a more mesenchymal-like
phenotype. EMT was first recognized for its central importance in embryonic development,
assisting in neural-crest formation and dorsal closure. In cancer, EMT is widely accepted as being
a hijacked event of carcinoma cells that promotes metastasis by creating a more migratory and
invasive behavior in cells. This is attributed to the mesenchymal-like phenotype and matrix
degradation activities.

EMT hallmarks include cell-cell adhesion down-regulation by

transcriptional suppression of cell-cell adhesion genes, transcriptional up-regulation of matrix
degrading proteases and mesenchymal-related proteins, such as N-cadherin and vimentin, and
Rho-mediated actin cytoskeleton rearrangement (reviewed, (46)). The genetic re-programming of
EMT is mediated by a collection of EMT transcription factors, including snail (SNAI1) (98, 99),
slug (SNAI2) (100, 101), δEF1 (ZEB1) (102), SIP1 (ZEB2) (103), E12/E47 (104), and twist (105).
Cell-cell adhesion proteins directly targeted by EMT transcription factors include E-cadherin,
occludin, claudin-1 and claudin-7 (106, 107).

Transcriptional silencing occurs by EMT

transcription factors binding to E-box consensus sequences, CANNTG, in the promoter of target
cell-cell adhesion proteins. In EC, SNAI1 (108) and ZEB1 (109) are found to correlate with Type
II ECs and membrane-bound loss of E-cadherin expression. In most carcinoma types, EMT is
activated by combined stimulation of frizzled, integrin, notch, TGFβ, tyrosine and/or serinethreonine kinase receptors. Signaling pathways that activate EMT include Ras-Raf-MEK-MAPK,
PI3K-Akt,

TGFβ-Smads,

ILK-Akt,

Wnt-β-catenin,

15

TGFβ-Par6-Smurf

(reviewed,

(46)),

abbreviations: MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein
kinase; integrin-linked kinase (ILK).

Adding to the Collective Effects of the Loss of Cell-Cell Adhesions in Carcinomas –
Therapy Resistance
In the last several years, the effects from the loss of cell-cell adhesions, such as
proliferation and transcriptional control, basolateral receptor activity, polarity, and migration and
invasion, have been expanded to include therapy resistance. In carcinoma cells, including nonsmall cell lung cancer (NSCLC) (110, 111), breast (112), colon (113, 114), pancreatic (114),
urothelial (115), epidermoid (116), and liver (116), sensitivity to chemotherapy agents (cisplatin
and oxaliplatin) and epidermal growth factor (EGFR) inhibitors (gefitinib, erlotinib, and
cetuximab) significantly correlates with the presence of cell-cell adhesion proteins, E-cadherin
(110-115), β-catenin (113, 115), α-catenin (110), γ-catenin (110, 113, 114, 116), and claudin-7
(110). α-catenin is a peripheral plaque protein of adherens junctions. Cisplatin is one of the most
widely used chemotherapy agents and shows efficacy in cancers, such as head and neck, NSCLC,
cervical, bladder, ovarian, and endometrial (reviewed, (117)). Cisplatin acts by cross-linking
DNA (118). EGFR inhibitors (cetuximab, a monoclonal antibody; gefitinib and erlotinib, tyrosine
kinase inhibitors), have shown clinical effectiveness for NSCLC (119, 120), colon (121),
pancreatic (122), and head and neck (123) cancers. EGFR is frequently overactive in many cancer
types, leading to abnormal activation of pro-proliferative and anti-apoptotic responses through
phosphatidylinositol 3-kinase/Akt (PI3K/Akt) and Ras/Raf/Mek signaling (124). The dependence
of cell-cell adhesion proteins on therapy responsiveness has been established in NSCLC (111),
urothelial (115), and breast (112) carcinoma cells. Resistant clones to cisplatin and/or EGFR
inhibitors are re-sensitized to therapy by transfection of E-cadherin. The reverse occurs with
siRNA targeting of E-cadherin, as carcinoma cells once sensitive become resistant. In cisplatin
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resistant clones of epidermoid and liver carcinomas sensitivity to cisplatin is restored by
transfection of γ-catenin (116).

Importantly, clinical relevance of cell-cell adhesion protein

presence and therapy sensitivity has been established. This has been demonstrated in NSCLC
patients receiving the EGFR inhibitor, erlotinib. TRIBUTE, a Phase III randomized, placebocontrolled trial conducted in the United States, enrolled chemotherapy-naϊve patients with
metastatic NSCLC to compare disease progression and survival rates of patients who received
erlotinib combined with cisplatin and paclitaxel to patients who received cisplatin and paclitaxel.
NSCLC patients with E-cadherin positive tumors have significantly longer time to progression
(hazard ratio 0.37; log rank p=0.0028) compared to patients with E-cadherin negative tumors
(110). A trend of longer survival was also found for E-cadherin positive patients (110). Known
mechanisms for cisplatin resistance include changes in cellular uptake and efflux of the agent,
increased detoxification, inhibiting of apoptosis signals, and increase in DNA repair (reviewed,
(118, 125)). Mechanisms relating to how and why loss of cell-cell adhesion proteins lend to
therapy resistance are less known. One assumption, involving cisplatin resistance with γ-catenin
loss, is that dissociation between the actin cytoskeleton and membrane cause altered location of
membrane proteins important for drug uptake (116).

Observations of declined rates of

endocytosis with loss of cell-cell adhesion proteins are also expected to contribute to resistance
(116).
My interest in the regulation of cell-cell adhesions involves the therapeutic potential of reestablishing such contacts to improve drug sensitivity.

In EC, the mainstay therapies for

metastatic disease are combination chemotherapy regimens that involve cisplatin, such as
paclitaxel-cisplatin or doxorubicin-cisplatin (reviewed, (39)).

With all metastatic cancers,

resistance to therapy or acquired resistance is a significant clinical issue. A significant limitation
to targeting cell-cell adhesions and their individual proteins, such as E-cadherin, in a clinical
setting

has

been

the

inability

to

target
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these

structures

and

proteins

by

small

molecules/pharmacological agents, antibodies, or ligand-binding agents. Currently, there are no
known druggable signaling pathways that work to re-establish cell-cell adhesions or their
individual proteins in carcinoma cells.

This important clinical observation has led to our

consideration of the purinergic pathway, a pathway that is drug targeted in a variety of different
diseases. The purinergic pathway’s generation of adenosine and its signaling activity has a history
of providing epithelial cell-cell adhesion in the form of barrier function. Barrier function is a
homeostatic event of endothelial and epithelial cells and its actions are directly related to the
regulation and maintained integrity of cell-cell adhesions and their individual proteins. The
remainder of this introduction will introduce the purinergic pathway and adenosine and
adenosine’s tissue protective effect of barrier function.
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Purinergic Pathway
A great amount of research laboratory-based effort has been devoted to identifying and
understanding the important molecular events that are central to metastasis and therapy resistance,
as these mechanisms are the primary causes of cancer morbidity and mortality. From these efforts
many potential therapeutic targets have been identified. Unfortunately, many of these potential
targets have not progressed beyond pre-clinical testing because currently available
pharmacological agents cannot be directed against them. Examples include the cell-cell adhesion
proteins, E-cadherin and occluding; re-expression of these proteins in cells in vitro reverses
therapeutic resistance and/or phenotypic changes associated with EMT. Additional examples
include EMT transcription factors, which are central to the genetic re-programming of carcinoma
cells. Various pharmacological agents already exist for members of the purinergic pathway
(reviewed, (126)), so this metabolic pathway is targeted in a variety of diseases, such as asthma,
chronic obstructive pulmonary disease, interstitial lung disease, Huntington’s disease, Parkinson’s
disease, and congestive heart failure (reviewed, (126)).

The significance of the purinergic

pathway in cancer has not been studied in great detail, and therefore the potential for available
drugs that target this pathway to provide therapeutic benefit in cancer patients has not been
adequately explored. Our interest in the purinergic pathway and its generation of adenosine in EC
involves its ability to induce barrier function.

Barrier function is directly associated to the

regulation and maintained integrity of cell-cell adhesions and their individual proteins.
The purinergic pathway is a ubiquitously expressed metabolic pathway comprised of
various cell surface and intracellular localized enzymes, membrane-oriented nucleoside
transporters, and G-protein coupled and ligand-gated cation channel receptors that is primarily
recognized for its generation and regulation of purine nucleotides and nucleosides. Adenine
nucleotides, such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine
monophosphate (AMP), and the nucleoside adenosine are the best-described components of this
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pathway. Along with being central to energy metabolism, adenine nucleotides or nucleosides can
exert substantial effects on various tissues and cell types at the extracellular level. Allen Drury
and Albert Szent-Györgyi were the first to show such a response, in 1929, as intravenous injection
of tissue isolated purines, AMP and adenosine, caused arterial dilation, lowering of blood
pressure, and temporary heart block (127). Purine receptors were not recognized until decades
later following an accumulation of studies concerning the differential effects of extracellular
purines. It was Geoffrey Burnstock that defined the basis for distinguishing the two main types of
purine receptors, P1, selective for adenosine and P2, selective for ATP and ADP (128).
Separation was based on relative potencies of ATP, ADP, AMP, and adenosine, selective
antagonistic effects of adenosine by methylxanthines (129), activation of adenylate cyclase by
adensoine, and stimulation of prostaglandin synthesis by ATP and ADP (128). P2 receptors have
since been further classified into two families based on inherent biological properties of the
receptors and are defined as P2X, ligand-gated cation channel receptors (130), and P2Y, G
protein-coupled receptors (131, 132). No studies at this time indicate P1 or P2 receptors to be
responsive to AMP. Likewise, an unknown receptor for AMP has not been identified.
Adenine nucleotides, ATP and ADP, gain access to the extracellular surface of cells by
disrupted membrane integrity, exocytosis, and channel-mediated efflux (133). The release of ATP
and/or ADP is enhanced by cellular stressors, such as hypoxia, ischemia, and cellular stretch and
swelling. Channel-mediated efflux includes the cystic fibrosis transmembrane conductance
regulator (CFTR) (134, 135), multidrug resistance-1 p-glycoprotein (MDR1-Pgp) (136), volumesensitive outwardly rectifying (VSOR) anion channels (137), maxi-anion channels (138), voltagedependent anion channel-1 (VDAC-1) (139), and connexin hemichannels (140-142). The purine
nucleoside adenosine can gain access to the extracellular membrane in a similar manner by
accessing equilibrative nucleoside transporters (ENTs) or sodium-dependent concentrative
nucleoside transporters (CNTs). In basal physiology conditions, extracellular adenosine is largely
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the result of adenosine’s passive transfer through equilibrative nucleoside transporters (143). In
contrast, with cellular stress or disease the main source of extracellular adenosine comes from
phosphohydrolysis of liberated adenine nucleotides (144, 145). Ecto-enzymes responsible for
phosphohydrolysis of ATP, ADP, and AMP include the following:

1.) nucleoside triphosphate diphosphohydrolase (NTPDases), which catalyze adenine nucleotide
phosphohydrolysis ATP  ADP  AMP;
2.) nucleotide pyrophosphatase/phosphodiesterases (NPPs), which catalyze adenine nucleotide
phosphohydrolysis ATP  ADP  AMP;
3.) alkaline phosphatases, which catalyze adenine nucleotide phosphohydrolysis ATP  ADP 
AMP  adenosine;
4.) 5’nucleotidase (CD73), which catalyzes adenine nucleotide phosphohydrolysis AMP 
adenosine.

Activity of the various ecto-enzymes is dependent on cell type, availability and concentration of
co-activators (Ca2+ and Mg2+), individual Michaelis–Menten kinetics (KM), and local
concentrations of ATP, ADP, and AMP (reviewed, (146)). A schematic summary of extracellular
members of the purinergic pathway and phosphohydrolysis of adenine nucleotides at the
extracellular surface is detailed in Figure 2.2.

Purinergic Pathway Ecto-enzyme 5’Nucleotidease (CD73)
5’Nucleotidase (CD73) is a Zn2+ dependent ecto-enzyme that catalyses the
phosphohydrolysis of purine and pyrimidine ribo- and deoxyribonucleoside 5’monophosphates to
their respective nucleosides. 5’AMP is CD73’s preferred substrate with KM values of 3-6μM
(147-149). CD73 is found essentially in all tissue types. However, the distribution of the enzyme
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Figure 2.2 Schematic summary of extracellular purinergic pathway members and adenine
nucleotide phosphohydrolysis.

Adenine nucleotides, ATP and ADP, gain access to the

extracellular surface by disrupted membrane integrity, exocytosis, or channel-mediated efflux.
ATP acting on P2X ligand-gated cation channel receptors or P2Y G protein-coupled receptors can
initiate a diverse array of intracellular signaling networks. P2X and P2Y receptors are nucleotide
specific. Membrane associated ecto-enzymes, such as NTPDases and 5’nucleotidase (CD73),
convert ATP or ADP to AMP and AMP to adenosine by phosphohydrolysis, respectively.
Generated adenosine can initiate equally diverse intracellular signaling networks by acting on P1
G protein-coupled receptors. Adenosine is the primary agonist of P1 receptor subtypes. Modified
and from the DFG Research Group, Neuronal and glial P2 receptors molecular basis and
functional significance, www.uni-leipzig.de/~biochem/for748/index.php.

Image modified

courtesy of Kim Vu, Department of Pathology, the University of Texas MD Anderson Cancer
Center. Image reference: (150).
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Figure 2.2
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is not always homogeneous in a particular tissue, even among cellular residents (151-153). CD73
resides in glycolipid-rich membrane subdomains known as lipid rafts and is anchored by a Cterminal glycosyl phosphatidylinositol (GPI) linkage (154).

The physiological relevance of

CD73’s membrane anchorage by GPI is not understood. CD73 is synthesized in the rough
endoplasmic reticulum as an initial precursor. Co-translational modification, such as N-linked
glycosylation (155, 156), and proteolytic cleavage of the C-terminal hydrophobic domain and
simultaneous GPI replacement forms the mature protein (154). The amount of CD73 at the cell
surface and within intracellular pools varies among cell types and is constantly recycled from the
cell surface to intracellular pools and back. The well-described function for CD73 is catalytic
generation of adenosine (reviewed, (157)). Functions of CD73 that are not related to its catalytic
activity have been described and include co-stimulatory molecule for the CD3/T-cell receptor
(TCR) (158-162) and cell adhesion. Cell adhesion studies are less developed and have included
CD73’s interaction with extracellular matrix (ECM) proteins laminin, fibronectin (163, 164), and
tenascin C (165). CD73 expression can be regulated by retinoic acid, interferon-γ (INF-γ) (166),
interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) (167).

The Fate of Extracellular Adenosine
Once generated by 5’nucleotidase (CD73), adenosine has the following four possible
fates: 1.) internalization through nucleoside transporters, ENTs and CNTs; 2.) deamination to
inosine by the extracellular CD26-bound adenosine deaminanse (ADA); 3.) phosphorylation to
AMP by adenosine kinase (AK); 4.) activation of P1 receptor subtypes. P1 receptor subtypes
include adenosine 1 receptor (A1R), adenosine 2A receptor (A2AR), adenosine 2B receptor
(A2BR), and adenosine 3 receptor (A3R). The fate of adenosine depends upon a combination of
situations including local adenosine concentration, presence and density of P1 receptor subtypes,
individual binding affinities of specific P1 receptors, presence of nucleoside transporters, ENTs
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and CNTs, and presence of ecto-enzymes, CD26-ADA and AK. The fate of adenosine is also
affected by the overall cellular state of a cell. Cellular stressors, such as inflammation, ischemia,
hypoxia, or disease can influence the fate of adenosine.

Increased levels of extracellular

adenosine, such as the 100µM levels seen in asthmatics (168), typically occurs with disease or
cellular stress. Estimated extracellular adenosine concentrations at basal physiology is 40-600nM
(169).

P1 Receptor Subtypes, Adenosine Receptors
The action of extracellular adenosine to activate a receptor was first considered based on
the observation by Taisija De Gubareff and William Sleator, Jr., that adenosine’s action in the
heart could be antagonized by methylxanthines, including caffeine and theophylline (170). Four
G-protein coupled receptors for adenosine have since been described, A1R (171), A2AR (172),
A2BR (173), and A3R (174), and are individually or collectively expressed in all tissue and cell
types (reviewed, (175)).

In this introduction thus far the adenosine receptors have been

collectively referred to by their broad P1 classification. Among scientists studying adenosine,
however, these receptor types are more classically viewed as belonging to one of two categories,
those that stimulate adenylate cyclase and those that inhibit its action. Subtypes A2AR and A2BR
are coupled to adenylate cyclase and stimulate the increase of cyclic adenosine monophosphate
(cAMP), while A1R and A3R subtypes inhibit adenylate cyclase and raise intracellular Ca2+
concentrations.

The G proteins Gi, Go, Gq, and Gs are known to selectively couple to the

adenosine receptor subtypes, thereby controlling the specificity of the signaling network that is
activated by a particular subtype (reviewed, (175)). Further specificity of the activation of a
particular signaling network is achieved by differences in binding affinity for adenosine among
subtypes, tissue or cell type specific expression of a subtype, and tissue or cell type specific
expression of G proteins.

Adenosine’s affinity for adenosine receptor subtypes is
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A1R>A3R>A2AR>A2BR.

Table 2.1 details individual affinities for the adenosine receptor

subtypes.

Adenosine Receptor Subtype, A2BR
The structure of A2BR is typical of G protein–coupled receptors, with seven
transmembrane domains connected by three extracellular and three intracellular loops, and flanked
by an extracellular N-terminus and an intracellular C-terminus. A2BR is considered the low
affinity adenosine receptor and is therefore understood to be activated only at exceptionally high
concentrations of adenosine as those typical of pathological conditions rather than physiological,
~10μM or higher (176). Gene transcript and radioligand studies have identified A2BR to be
expressed in various tissues, including the uterus (177, 178). A2BR is coupled to Gs and Gq
families of G proteins.

Coupled-Gs is associated with adenylate cyclase activity, cAMP

accumulation, and protein kinase A (PKA) activity.

Coupled-Gq is associated with

phosphatidylinositol-phospholipase C (PI-PLC) and increased diacylglycerol (DAG) and protein
kinase C (PKC) accumulation and inositol triphosphate (IP3) and Ca2+ immobilization (reviewed,
(179)). A2BR signaling also converges with the mitogen activated protein kinase (MAPK) and
phosphatidylinositol-3’-kinase (PI3K) pathways in a cAMP-dependent and PKA-dependent or –
independent manner (180).

The Tissue Protective Nature of Adenosine – Barrier Function
The tissue protective nature of adenosine was first recognized by adenosine’s ability to
cause coronary artery vasodilation in response to hypoxia.

Vasodilation allows for more

oxygenated blood to be delivered to hypoxic tissues. Adenosine has since evolved as an important
signaling molecule that provides homeostatic function and tissue protection in normal tissues in
response to cellular stressors, such as inflammation, ischemia, and hypoxia. With all cellular
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Table 2.1. Individual binding affinities for the adenosine receptor subtypes

aReference:

(181)

bReference:

(182)

cReference:

(183)

Adenosine Receptor

Adenosine
Affinity

A1R

a15-100nM

A2AR

a0.5-20μM

A2BR

b>10μM

A3R

c30-300nM

27

stressors the increased production of adenosine at the extracellular surface and/or adenosine’s
release into the microenvironment is the central theme to adenosine’s tissue protective effects.
The outcome of adenosine’s effects therefore depends on the target tissue or cell type and
adenosine receptor subtypes activated.

Tissues protective effects include stimulating

immunosuppressive responses, activation of vasodilation, ischemic pre-conditioning and postconditioning, balancing the oxygen supply/demand ratio, inducing endothelial and epithelial
barrier function, inhibiting superoxide generation, and inhibiting excitatory neurotransmitter
release (reviewed, (184)). Though all have great importance in re-gaining and maintaining the
basal physiology of tissues, adenosine’s tissue protective effect of barrier function will be the
central focus of this dissertation.

Barrier Function
Barrier function is a homeostatic event of endothelial and epithelial cells whose actions
are directly related to the regulation and maintained integrity of cell-cell adhesions and their
individual proteins. Barrier function is a feature specific to cell types that form a biological barrier
between the outside (lumen) and inside (interstitial tissue) environments of a tissue. Endothelial
and epithelial cell types have important barrier functions. The objective of this barrier is to
regulate the movement of ions, solutes, and H2O and prevent the movement of noxious stimuli,
such as pathogens, bacteria, and foreign antigens through the spaces between the cells
(paracellular space). Cell-cell adhesions are the primary basis of barrier function, as 1.) their
integral membrane proteins serve as the physical barrier of the paracellular space and 2.) select
integral proteins actively regulate the permeability state of the cells. Of the latter, the tight
junction proteins occludin and claudins are the main proteins that define selected permeability
(reviewed, (185)). In response to physiological needs or stressors, barrier function activation is an
effort of extracellular factors to communicate with intracellular mediators to make structural
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changes to the actin cytoskeleton and/or cell-cell adhesions in order to respond appropriately. The
response may be a simple change in permeability or an abrupt recovery effort of cell-cell
adhesions following stressor-induced disruption. Extracellular factors that accumulate or are
released with cellular stress and initiate barrier protection include cytokines, such as interleukin-10
(IL-10) (186, 187) and TGF-β (188-193), growth factors, such as epidermal growth factor (EGF)
(194) and hepatocyte growth factor (HGF) (195), and small molecules, such as adenine
nucleotides and adenosine (196).

Barrier Function – CD73-generated Adenosine and Adenosine’s Action on A2BR
Indirect observations provided the first indications that adenosine provided barrier
function. For example, adenosine protected against lung microvascular leakage produced by
phorbol myristate acetate (PMA) (197), adenosine blocked ischemia-reperfusion induced
permeability and damage of endothelial cells (198), and endothelial cells exposed to adenine
nucleotides and adenosine caused intracellular cAMP accumulation (199), a second messenger
known to regulate endothelial permeability (200, 201). The direct association between adenosine
and barrier function was shown by Frederick Haselton in 1993 (202), who demonstrated that
applied adenosine to bovine fetal aortic endothelial cells (BAEC) decreased permeability to
paracellular tracers in a reversible, concentration-dependent manner; through the use of receptor
specific adenosine analogs, this effect was demonstrated to be mediated via A2 receptors subtypes
A2AR or A2BR (202). Adenosine’s relation to cellular stress was discovered in separate studies
by Lois Richard (203) and Paul Lennon (196). Since then, adenosine’s activation of barrier
function has been described in the context of various stressors, cell types, tissue systems, and
diseases. The present understanding of adenosine’s induction of barrier function will be presented
by emphasizing the studies that have advanced this understanding.
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Stressor  AMP  CD73  Adenosine A2BR  Barrier Function
Louis Richard’s work had demonstrated that application of adenosine prevented the
disruption of barrier function in oxidant-injured human umbilical vein endothelial cell (HUVEC)
monolayers (203). However, Paul Lennon was the first to show that adenine nucleotides and
adenosine released from an in vitro stressor, activated polymorphonuclear leukocytes (PMNs),
resulted in barrier function. Prior to these studies, adenosine’s effect on barrier function had only
been demonstrated by physical addition of adenosine to cell monolayers (196). Co-culture studies
showed endothelial expressed CD73 to be responsible for converting PMN-released AMP to
adenosine and adenosine to activate A2BR to induce barrier function (196). Therefore, these
studies were important in defining that 1.) adenosine accumulated at the extracellular surface as a
result of its release and CD73’s conversion of AMP to adenosine, 2.) a stressor, activated PMNs,
physically lead to adenosine’s induction of barrier function, and 3.) CD73-generated adenosine
activated A2BR to induce barrier function.
The first studies showing this same effect, Stressor  AMP  CD73  Adenosine
A2BR  Barrier Function, with hypoxia came from separate studies from Kristin Synnestyedt
(204), and Holger Eltzshing (144). By co-culturing activated PMNs with normoxic or posthypoxic conditioned human microvascular endothelial cells (HMEC-1), post-hypoxic HMEC-1
were had a greater than a 60% increase in barrier function than normoxia conditioned HMEC-1
(144). These studies further demonstrated adenosine’s activation of A2BR to be important for the
increased barrier function (144). Kristin Synnestyedt’s work was the first to show relevance of
hypoxia to induce adenosine’s barrier function in intestinal epithelial cells (204). Mice gavaged
with α,β-methylene diphosphate (AOPCP), a catalytic inhibitor of CD73, had increased epithelial
intestinal permeability, as shown by FITC-tracer leakage from the intestinal lumen into the blood,
when placed in hypoxia (204). Similar studies with endothelial cells in CD73 deficient (CD73-/-)
(205) and A2BR deficient (A2BR-/-) (206) mice have since been completed. The concept that
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adenosine’s promotion of barrier function is most important under conditions of stress is best
highlighted by the work in the CD73-/- and A2BR-/- mice. These mice are both phenotypically
normal under basal conditions. However, both mice suffer extensive vascular leak and pulmonary
edema when placed in hypoxic conditions (205, 206).

Adenosine’s Barrier Function Effect is Supported by Increased Expression of CD73
and A2BR and Down-Regulation of ENT1
From the above studies, two central themes are evident. One, adenosine’s barrier function
is a product of accumulated extracellular adenosine. Two, adenosine’s barrier function is a product
of CD73’s generation of adenosine and its activation of the adenosine receptor subtype, A2BR
(Stressor  AMP  CD73  Adenosine A2BR  Barrier Function). A third central
theme is that adenosine’s barrier function effect is supported by shifts in expression of purinergic
pathway member expression. This third theme is derived from studies demonstrating that with
stress, cytokine release from inflammatory cells or increased steady-state levels of hypoxiainducible factor-1α (HIF-1α) controlled the expression of molecules known to be critical in
adenosine generation and regulation. One of the earliest findings had shown the pro-inflammatory
cytokine tumor necrosis factor-α (TNF-α) (207) and A2BR paracrine signaling (AMP  CD73
 Adenosine  A2BR signaling  CD73 transcript expression) (208) to increase CD73
expression to prepare for resealing disrupted endothelial barriers by extravasated PMNs (207) or
to protect against the disruption of barrier function (208). Though unrelated to barrier function or
endothelial or epithelial cells, studies by Shuichi Kobayshi (209) were among the first to show the
global shifts in purinergic pathway members in response to hypoxia. This shift was supportive of
the extracellular accumulation of adenosine.

Shown in rat adrenal pheochromocytoma cells

(PC12), hypoxia caused significant decreases in adenosine deaminase (ADA), adenosine kinase
(AK), and equilibrative nucleoside transporter (ENT1) expression, while CD73 expression
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significantly increased.

It was concluded that accumulation of extracellular adenosine was

associated with hypoxia, but the authors were unclear of its importance (209).

Kristin

Synnestvedt’s studies in intestinal epithelial cells were the first to show that CD73’s increased
expression in hypoxia was a result of HIF-1 transcriptional induction of CD73 (204). Holger
Eltzshing’s post-hypoxia human microvascular endothelial cells (HMEC-1) studies also indicated
that CD73 and A2BR mRNA was increased by 12- and 5-fold, respectively, over normoxia
conditioned HMEC-1 (144). It has since been found that many members of the purinergic
pathway are up-or down-regulated by HIF-1 in hypoxia to support the accumulation of
extracellular adenosine for barrier function. These include CD73 (up-regulated) (204), A2BR (upregulated) (210), ENT1 (down-regulated) (211), AK (down-regulation) (212).

Intracellular Mediators of Adenosine’s Barrier Function – The Gap in the Knowledge
Adenosine’s generation by CD73 and adenosine’s activation of A2BR have been wellestablished to induce barrier function. However, it remains largely unknown which intracellular
mediators are activated by adenosine’s activation of A2BR.

cAMP, a central secondary

messenger of many G protein-coupled receptors including A2BR, is associated with the activation
of intracellular barrier function mediators, PKA and exchange protein directly activated by cAMP
(Epac).

PKA activation inhibits GTPase, RhoA activation of cell contractility (213).

Cell

contraction, a barrier disruption action, is related to actin/myosin-driven force that pulls adherens
junctions inward, forcing them to dissociate from their adjacent partner (214). Epac1 and Epac2
are cAMP-dependent guanine-nucleotide-exchange factors for the small GTPases Rap1 and Rap2,
and are known to be important mediators of cAMP signaling (215, 216).

Epac increases the

integrity of adherens and tight junctions by enhancing the distribution of member proteins to cellcell adhesion sties (217). Additional mechanisms that are related to the known down-stream
signaling events of A2BR have included activation of PKC (218) and alterations in intracellular
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Ca2+ (219). Though many of these mechanisms are intuitively related to A2BR signaling, these
have yet to be convincingly related to adenosine’s barrier function.

Studies from Donald

Lawrence and Katrina Comerford have provided the most insight into how A2BR activation may
be regulating endothelial (220) and epithelial (221) barrier function. Such studies have described
a PKA-dependent phosphorylation of vasodilator-stimulated phosphoprotein (VASP). VASP is a
protein involved with actin cytoskeleton remodeling (222).

Upon phosphorylation, VASP

localizes to tight junction structures and associates with ZO-1.

This leads to the structural

relaxation of the actin cytoskeleton which is needed to re-form disrupted cell-cell adhesion
structures (220, 221). VASP is a major target for cyclic nucleotide kinases, including PKA.

Concluding Remarks
The dissemination of cancer cells and their propagation in an organ or tissue is the most
life-threatening issue of cancer as there is no definitive cure for metastatic disease. Likewise,
therapy resistance is a significant clinical issue for patients with metastatic disease. Currently,
there are no mechanisms that can re-sensitize cancer cells to a therapy. The work reported in this
dissertation is innovative in that it establishes adenosine’s activation of A2BR to be related to the
reforming of cell-cell adhesions in stressed carcinoma cells. The purinergic pathway is a highly
drug targeted pathway, which raises the possibility that pharmacological agonists of A2BR could
be used to re-establish cell-cell adhesions in carcinoma cells and therefore provide therapeutic
benefit (re-sensitize to therapy) in patients with metastatic disease. Targeting cell-cell adhesions
in vivo has been an area of great interest, but clinically useful strategies have been lacking. The
concept of adenosine-mediated cell-cell adhesion has not been previously reported for carcinomas
of any tissue type. Therefore, the focus of this dissertation was to establish this association in EC.
Defining the basic science behind these cellular events in cancer is valuable, as it will provide the
rationale for proceeding with pre-clinical studies. Such studies are labor-, time-, and resource-
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intensive. With an increased pressure to provide new therapeutic strategies for clinical use, novel
ideas that are applicable and relevant need to be established in the research laboratory.
From the basic science perspective, this dissertation work is exciting as it describes the
very novel discovery that adenosine’s activation of A2BR induces filopodia that have cell-cell
adhesion function. The function of filopodia promoting cell-cell adhesions is well-described in
embryonic development and with wound healing (223-225). Such an event is important for the
proper alignment and development of mature adhesion structures. The gap in knowledge in the
adenosine field concerning adenosine’s barrier function activity has been the mechanism by which
it regulates cell-cell adhesions. Few studies have shed light on this topic (220, 221). Our work
here, describing adenosine’s regulation of cell-cell adhesion functioning filopodia, will hopefully
help to provide a better understanding of adenosine’s role in cell-cell adhesions both in cancer and
in other non-cancer systems, such as trauma and sepsis. This work significantly adds not only to
the understanding of adenosine’s barrier function in the adenosine field, but it introduces a novel
mechanism (adenosine-mediated re-forming cell-cell adhesions) that has to be avoided/downregulated by carcinoma cells attempting to lose attachment with their neighboring cells.
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CHAPTER THREE
Materials and Methods
Normal Tissues and Carcinomas
Endometrial and ovarian normal tissues and carcinomas were received from The
University of Texas MD Anderson Cancer Center Multidisciplinary Gynecological Cancer
Translational Research Tumor Bank (MDA-GCTR-TB). Hematoxylin and eosin stained slides
were microscopically reviewed by a gynecological pathologist, Dr. Russell Broaddus, to confirm
surgical stage, tumor grade, and histotype in accordance to the criteria established by the
International Federation of Gynecology and Obstetrics (FIGO). Colon carcinomas with matched
adjacent normal colon tissue were received from The University of Texas MD Anderson Cancer
Center Tissue Biospecimen and Pathology Resource (TBPR) Institutional Tissue Bank. The
TBPR is a Cancer Center Support Grant (CCGS) supported core facility funded by NCI
#CA16672. Use of human tissues was approved by The University of Texas MD Anderson
Cancer Center Institution Review Board, LAB01-718.

RNA – Human Endometrial Biopsies
RNA was obtained from human endometrial biopsies of premenopausal women who
received depot medroxyprogestrone acetate (MPA) 150mg intramuscular injection.

These

biopsies were part of a clinical trial assessing the effectiveness of hormonal therapy. Baseline
(pre-treatment) and 3 month post-treatment endometrial biopsies were obtained. For baseline and
post-treatment, endometrial biopsies were timed to occur on days 8 or 9 of the menstrual cycle.
These biopsies were timed as such to occur during the proliferative phase of the endometrium.
RNA from these biopsies were kindly provided by Dr. David Loose, Department of Integrative
Biology and Pharmacology, the University of Texas at Houston - Medical School, Houston,
Texas.
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RNA – Platinum Sensitivity
RNA was obtained from platinum sensitive and platinum resistant ovarian high grade
papillary serous carcinomas (HGPSC) (226). Resistance or sensitivity was defined by review of
medical records and resistance criteria set forth by the Gynecological Oncology Group, which
included the following: 1.) disease progression while on a first-line platinum-based regimen; 2.)
disease progression within 6 months of completion of platinum-based therapy; and 3.) persistent
clinically measurable disease with best response as stable disease at the completion of first-line
therapy

Animals
C57BL/6 mice were purchased from Harlan Laboratories (Indianapolis, IN).
5’nucleotidase (CD73) (205) and adenosine receptor 2B deficient mice (227), indicated as CD73-/and A2BR-/-, were provided by Dr. Michael Blackburn, Department of Biochemistry and
Molecular Biology, the University of Texas at Houston - Medical School, Houston, Texas.
Animals were maintained in accordance to the Institutional Animal Care and Use Committee
(IACUC) and the Association for Assessment and Accreditation of Laboratory Care (AAALAC)

Carcinoma Cell Lines
Endometrial
Endometrial carcinoma cell lines HEC-1A, HEC-1B, KLE (228), ECC-1, and AN3CA
were obtained from the American Type Culture Collection (ATCC), Rockville, MD. Ishikawa
cells were kindly provided by Changping Zhou, Ph.D., The University of Connecticut Health
Center, Farmington, CT.

HEC-1A cells were cultured in McCoy’s 5A medium (Cellgro,

Manassas, VA) containing 10% fetal bovine serum (FBS) and 1X penicillin-streptomycin. HEC1B, Ishikawa, and AN3CA cells were cultured in Minimum Essential Medium (MEM) (Cellgro,
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Manassas, VA) with 10% FBS, 1X Na+ pyruvate, 1X non-essential amino acids, and 1X penicillinstreptomycin. ECC-1 and KLE were cultured in DMEM (Cellgro, Manassas, VA) with 10% FBS,
1X Na+ pyruvate, and 1X penicillin-streptomycin.

WISH-HeLa
WISH-HeLa cells were kindly provided by Dr. Daniel Carson, Rice University, Houston,
Texas. WISH-HeLa cells were cultured in DMEM (Cellgro, Manassas, VA) with 10% FBS, 1X
Na+ pyruvate, and 1X penicillin-streptomycin.

RNA Isolation
Normal and Carcinoma Tissues
Total RNA was isolated from colon, endometrial, and ovarian normal tissues and
carcinomas using a phenol-based method. Tissues and carcinomas were homogenized via a
polytron in TRIzol® Reagent (Invitrogen, Carlsbad, CA) and mixed with chloroform. Lysates
were separated into three phases by centrifugation. Total RNA was precipitated from the aqueous
phase with isopropanol, washed with 75% DEPC-ethanol, and re-suspended in DEPC H2O.
Isolated RNA was DNase (Roche, Mannheim, Germany) treated per manufacturer instructions.

Carcinoma Cell Lines
Total RNA from carcinoma cell lines was isolated using Quick-RNA™ MiniPrep (Zymo
Research, Irvine, CA) or miRNeasy® Mini Kit (Qiagen, Valencia, CA) spin columns per
manufacturer instructions. Total RNA was eluted from columns with DEPC H2O. Isolated RNA
was DNase (Roche, Mannheim, Germany) treated per manufacturer instructions.
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Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Probe-based assays for real-time reverse transcription-polymerase chain reaction (RTPCR) were designed using Primer Express software (Life Technologies-Applied Biosystems,
Carlsbad, CA). Primer and probe sequences, accession number, and accompanying information
for all assays are detailed in Table 12.1. Design and development of all quantitative real-time PTPCR assays was achieved by collaboration with Dr. Gregory Shipley, The University of Texas at
Houston - Medical School, Houston, Texas. 100ng RNA aliquots were reverse transcribed in
quadruplicates, including a no reverse transcriptase control, with 300nM assay-specific reverse
primer, 4mM MgCl2, 500µM dNTPs, and 10 units of MMLV Superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA) at 50°C for 30 minutes, followed by 72°C for 5 minutes. 40µl of PCR
mix containing 1X PCR buffer, 300nM specific forward and reverse primers, 4mM MgCl2, Taq
DNA polymerase, and 100nM fluorogenic probe were added to each 10µl RT reaction.
Amplification was performed using the ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA).

Transcript levels were determined through comparison to a

standard curve generated from the PCR amplification of template dilutions covering a 5-log range.
Final transcript values were normalized to 18S ribosomal RNA (rRNA), dilution of 1/500 or 1/200
and

presented

as

mean

transcript

levels

expressed

as

%18SrRNA

(molecules

of

transcript/molecules of 18S rRNA). Primer and probe sequences and accession numbers of assays
developed and used in this dissertation are indicated in Table 3.1.

Immunofluorescence
Normal and Carcinoma Tissues
Cryosections, 4µm in thickness, of normal colon and endometrium and endometrial
carcinomas were sectioned by MDA-GCTR-TB. Room temperature warmed sections were fixed
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Table 3.1. Real-time quantitative RT-PCR assays

Gene
Symbol

Taqman Primers and Probe

Acession Number

5'-Nucleotidase

CD73

FP: 1447+GACAGAGTAGTCAAATTAGATG
RP: 1511-TGAGAGGGTCATAACTGG
P: 1471+TCTTTGCACCAAGTGTCGAGTGC

NM_002526

Adenosine
Deaminase

ADA

FP: 264+CTGCTGAACGTCATTGG
RP: 340-GCAGGCATGTAGTAGTC
P: 281+CATGGACAAGCCGCTCACCC

NM_000022

Adenosine
Receptor 1

A1R

FP: 1147+GCTGGCTGCCTTTGCAC
RP: 1215-GGATGCTGGGCTTGTGG
P: 1165+TCCTCAACTGCATCACCCTCTTCTGC

NM_ 000674

FP: 838+ATGCTGGGTGTCTATTTGCG

NM_000675

Adenosine
Receptor 2A

A2AR

Adenosine
Receptor 2B

A2BR

Adenosine
Receptor 3

RP: 902-TGGCTCTCCATCTGCTTCAG
P: 865+CTGGCGGCGCGACGACA

A3R

FP: 977+CACTGAGCTGATGGACCACTC
RP: 1040-CAGTGACTTGGCTGCATGG
P: 1018-TCCCGCTGGAGGGTGGTCCT

NM_000676

FP: 708+CCCTACAGACGGATCTTGCTG
RP: 777-TGTTGGGCATCTTGCCTTC
P: 734+CCTGTCCCTGTGGAGGTTCCCCT

NM_000677

Equilibrative
Nucleoside
Transporter 1

ENT1

FP: 1413+CCAGCCGTGACTGTTGAG
RP: 1489-CAGGACACAGGAATGAAGTAAC
P: 1438+FAM CCAGCATCGCAGGCAGCAGC

NM_001078177

Osteopontin

SPP1

FP: 619+GGACTGAGGTCAAAATCTAAGAAG
RP: 693-GGTGATGTCCTCGTCTGTAG
P: 646+CGCAGACCTGACATCCAGTACCCT

NM_001040058

Purinergic
Receptor P2Y

P2RY2

FP: 1212+GTGGTGCTGGCTGTCTTC
RP: 1286-CGAGCGGAAGGAGTAGTAG
P: 1232+CCTCTGCTTCCTGCCATTCCACG

Abbreviations: FP, Forward Primer; RP, Reverse Primer; P, Probe
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NM_176072

in 4% paraformaldehyde for 1 hour at 4°C and washed with 1X phosphate buffered saline (PBS).
Tissues sections were blocked with Background Snipper (Biocare Medical, Concord, CA) for 1
hour at room temperature and incubated with anti-human CD73, 1:100 (Hycult Biotech, Plymouth,
PA) and wide spectrum cytokeratin, 1:500 (Abcam, Cambridge, MA) at 4°C overnight. Following
incubation, tissues were washed with 1X PBS and incubated with fluorochrome-conjugated
secondary antibodies, anti-mouse Alexa Fluor® 594 and anti-rabbit Alexa Fluor® 488 (Invitrogen,
Carlsbad, CA) at room temperature for 1 hour. Tissue sections were washed with 1X PBS,
incubated with DAPI Nucleic Acid Stain (Invitrogen, Carlsbad, CA), and mounted with
DakoCytomation Antifade Fluorescent Mounting Medium (DakoCytomation, Carpinteria, CA).
Primary and secondary antibodies were diluted in Background Snipper.

For spectral bleed-

through artifact controls, tissue sections were incubated with each fluorochrome separately.
Autofluorescence of tissue sections was determined by substituting primary antibodies with 1X
PBS.

Images were captured using a IX71 Olympus microscope (Center Valley, PA) and

Image-Pro MC 6.1 imaging software. CD73 fluorescence intensity was measured in four 20X
field images using NIH ImageJ software. Data is represented as mean fold increase of CD73
intensity in epithelial/carcinoma cells relative to surrounding stroma cells/connective tissue.

Carcinoma Cell Lines
Colon and endometrial carcinoma cell lines were grown to 70% confluency on 1- 2- or 4well chamber slides (Lab-Tek™, Nalge Nunc International, Rochester, NY). After fixation with
4% paraformaldehyde for 1 hour at 4°C, cells were washed with 1X PBS, and permeabilized with
0.1% trition X100 (Sigma-Aldrich, St. Louis, MO) for 20 minutes, room temperature. Cells were
blocked with Background Snipper (Biocare Medical, Concord, CA) for 1 hour at room
temperature and incubated with respected primary antibodies at 4°C overnight.

Following

incubation, cells were washed with 1X PBS and incubated with fluorochrome-conjugated
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secondary antibodies, anti-mouse Alexa Fluor® 594 and anti-rabbit Alexa Fluor® 488 (Invitrogen,
Carlsbad, CA) at room temperature for 1 hour. Cells were washed with 1X PBS, incubated with
DAPI Nucleic Acid Stain (Invitrogen, Carlsbad, CA), and mounted with DakoCytomation
Antifade Fluorescent Mounting Medium (DakoCytomation, Carpinteria, CA).

Primary and

secondary antibodies were diluted in Background Snipper. For spectral bleed-through artifact
controls, tissue sections were incubated with each fluorochrome separately. Autofluorescence was
determined by substituting primary antibodies with 1X PBS. Images were captured using a IX71
Olympus microscope (Center Valley, PA) and Image-Pro MC 6.1 imaging software.

Immunofluorescence – Antibodies
Primary antibodies and their working dilutions are as follows. CD73, 1:100, Hycult
Biotech, Plymouth Meeting, PA; E-cadherin, 1:500, BD Biosciences, San Jose, CA; Na+K+
ATPase, 1:200, Epitomics, Burlingame, CA; Pan-cytokeratin, 1:200, Abcam, Cambridge, MA;
VASP, 1:100, Cell Signaling, Danvers, MA; Vimentin, 1:200, Cell Signaling, Danvers, MA.

Immunoblot
Carcinoma cell lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer
(50mM Tris, 150mM NaCl, 1% Triton-X 100, 0.1% SDS, 0.5% Na deoxycholate) (Upstate,
Temecula, CA) supplemented with 1X protease inhibitor cocktail (Roche, Mannheim, Germany).
20µg of isolated protein was combined with 4X loading buffer and β-mercaptoethanol and boiled
for 5 minutes at 95°C. 8% or 10% polyacrylamide gels were used for the protein samples. Protein
samples were transferred onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules,
CA), blocked overnight with 5% blotto-TBS/Tween, and probed with the following antibodies:
Adenosine receptor 2B (A2BR), 1:500, Millipore, Billerica, MA; β-actin, 1:5,000, Sigma, St
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Louis, MO; E-cadherin, 1:1000, BD Biosciences, San Jose, CA; HIF-1α, 1:500, BD Biosciences,
San Jose, CA; phospho-Smad2 (p-Smad2 Ser465/467), 1:500, Cell Signaling, Danvers, MA;
Smad2, 1:500, Cell Signaling, Danvers, MA; vinculin, 1:500, Sigma, St Louis, MO.

In Vivo Ruthenium Red Paracellular Permeability
Vaginal Smears
10-14 week-old C57BL/6, CD73-/-, and A2BR-/- mice were maintained in a dark:light
cycle of 12:12 hours. Phase of estrous was determined daily by vaginal smears. Mice were
anesthetized by isoflurane prior to collecting vaginal smears. Cells were flushed from the vaginal
lining by introducing 20ul of sterile 1X phosphate buffered saline (PBS) into the vaginal opening.
Recovered cell suspensions were smeared on glass microscope slides and fixed with 70% ethanol.
After re-hydrating in absolute alcohol, slides were progressed through an alcohol gradient of 90%
and 70%, rinsed with dH2O, and stained with hematoxylin for 1 minute. Slides were rinsed with
dH20, stained with eosin for 30 seconds, and progressed through an alcohol gradient of 70%, 90%,
and 100%. Cell morphology and phase determination was performed using a BX41 Olympus
microscope (Center Valley, PA). To minimize the incidence of translational or missed stages,
vaginal smears were performed daily at 09:00. Representative images of vaginal smears are
shown in Figure 3.1.

Ruthenium Red Uterine Perfusions
Estrous cycles of 10-14 week-old C57BL/6, CD73-/-, and A2BR-/- mice were synchronized
and stage of cycle determined by vaginal smear. Proestrus staged mice were individually placed
in a modular incubator chamber (Billups-Rothenberg, Delmar, CA) and exposed to room air or
hypoxia (7% O2) for 1, 2, or 4 hours. Following allotted time-of-exposure, mice were anesthetized
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Figure 3.1. Representative images of diestrus, proestrus, estrus, and metestrus vaginal
smears. 10-14 week-old C57BL/6, CD73-/-, and A2BR-/- mice were maintained in a dark:light
cycle of 12:12 hours. Vaginal smears were taken on consecutive days. Diestrus smears consist
mainly of leucocytes with variable numbers of epithelial cells. Proestrus smears are characterized
by rounded, usually nucleated, epithelial cells, generally in low to moderate numbers. Estrus
smears consist entirely of cornified epithelial cells in high numbers, which usually form sheets of
cells. Metestrus smears are characterized by equal numbers of cornified epithelial cells and
leucocytes. Image magnification 20X.
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Figure 3.1
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by tribromoethanol (Avertin) dosed at 0.2ml/10g. With the peritoneal cavity exposed, the left
uterine horn was initially perfused-fixed with 0.2ml 0.2% ruthenium red (Sigma-Aldrich, St Louis,
MO) and 2% glutaraldehyde (Sigma-Aldrich, St Louis, MO) in 0.1M sodium cacodylate buffer.
Following surgical closure of the endocervical region, the uterine horn was filled with 0.1ml 0.2%
ruthenium red and 2% glutaraldehyde in 0.1M sodium cacodylate buffer. Mice exposed to hypoxia
were returned to the modular incubator chambers for 10 minutes. Uteri were then removed and reperfused-fixed, in order, with 0.7ml 0.2% ruthenium red and 2% glutaraldehyde in 0.1M sodium
cacodylate buffer and 0.2ml 0.2% ruthenium red in 2% OSO4 in 0.1M sodium cacodylate buffer. In
additional studies, CD73-/- mice were injected IP with 5'-N-ethylcarboxamidoadenosine (NECA)
0.1mg/kg or 0.9% NaCl- containing an equal volume of NECA vehicle, dimethylsulfoxide
(DMSO) 0.1ml/20g (DMSO content, 0.006%) prior to being exposed to hypoxia for 4 hours. This
protocol was in accordance with the National Institute of Health (NIH) guidelines for use of live
animals and was approved by the Institutional Animal Care and Use Committee at the University
of Texas Health Science Center at Houston. This technique was modified and adapted from
Molitons, BA., Falk, SA., and Dahl, RH., Ischemia-induced loss of epithelial polarity role of the
tight junction, JCI 1989;84:1334-1339 (229).

Ruthenium Red Uterine Perfusions – Transmission Electron Microscopy
Perfused-fixed uteri were longitudinally cut into 1mm sections, washed in 0.1M sodium
cacodylate buffer, dehydrated in graded ethanol solutions, and embedded in LX-112 medium.
Ultrathin sections were obtained, stained with uranyl acetate and lead citrate, and examined by
transmission electron microscopy (model JEM 1010, JEOL Inc., Peabody, MA). Digital images
were acquired using an AMT Imaging System (Advanced Microscopy Techniques Corp.,
Danvers, MA).

Ruthenium red paracellular permeability was quantified by assessing
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approximately 200 consecutive paracellular spaces per uterine section. Percent ruthenium red
permeability was determined by the ratio of dye positive to total paracellular spaces assessed.

Transforming Growth Factor-β (TGF-β) Studies
Tranepithelial Resistance (TER)
HEC-1A cells were plated at a density of 1x105 cells and grown to confluency on
transwell-collagen coated permeable inserts, 0.4μm pore size, 12 well plates (Corning, Corning,
NY). Medium was changed every 24 hours until a stable monolayer was attained. Following 4
days post-confluency, HEC-1A monolayers were serum starved for 24 hours using Opti-MEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). The Opti-MEM® in the
inserts and lower chambers was replaced with Opti-MEM® alone or containing human
recombinant 2.5ng/mLTGF-β1 (R&D Systems, Minneapolis, MN) or equal vehicle, 4mM HCl
with 1mg/mL of bovine serum albumin (BSA) (Sigma, St. Louis, MO). The electrical potential
difference across the monolayer was measured using a two-electrode EVOM voltohmmeter
(World Precision Instruments Inc., New Haven, CT). Resistance measurements were taken every
at 24, 48, 72, 96, and 120 hours following the initial treatment of the cells. Opti-MEM® with or
without TGF-β1 or BSA/HCl, was replaced every 24 hours.

Data is expressed as percent

increased TER from mean baseline.

CD73 Regulation by TGF-β1 – Quantitative RT-PCR Time-Course
Endometrial carcinoma cells, HEC-1A and Ishikawa, were plated in 6-well plates at a
density of 1x105 cells/well in respective base mediums containing 10% FBS. After reaching 70%
confluency, cells were serum starved for 24 hours using Opti-MEM® Reduced Serum Medium,
GlutaMax™ (Invitrogen, Carlsbad, CA).

Cells were treated with human recombinant

2.5ng/mLTGF-β1 (R&D Systems, Minneapolis, MN) or equal vehicle, 4mM HCl with 1mg/mL of
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bovine serum albumin (BSA) (Sigma, St. Louis, MO) in Opti-MEM® for 24, 48, 72, 96, and 120
hours. In separate studies, cells were treated for 12, 24, 48, and 72 hours. RNA was isolated in
experimental replicates of 4 from each time-course.

Isolated RNA was DNase (Roche,

Mannheim, Germany) treated per manufacturer instructions. Real-time quantitative RT-PCR was
performed at The University of Texas Quantitative Genomics Core Laboratory. In separate
studies, cells were co-incubated with 1µM of Smad3 inhibitor, SIS3 (Calbiochem, San Diego,
CA).

CD73 Regulation by TGF-β1 – Immunofluorescence Time-Course
HEC-1A cells were plated at a density of 1x104 cells/well in 2-well chamber slides (LabTek™, Nalge Nunc International, Rochester, NY). After reaching 70% confluency, cells were
serum starved for 24 hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen,
Carlsbad, CA). Cells were treated with human recombinant 2.5ng/mLTGF-β1 (R&D Systems,
Minneapolis, MN) or equal vehicle, 4mM HCl with 1mg/mL of bovine serum albumin (BSA)
(Sigma, St. Louis, MO) in Opti-MEM® for 24, 48, and 72 hours. In separate studies, cells were
co-incubated with 1µM of Smad3 inhibitor, SIS3 (Calbiochem, San Diego, CA).

CD73 Regulation by TGF-β1 – Immunoblot Time-Course
HEC-1A cells were plated in 100mm plates at a density of 1x106 cells/plate in McCoy’s
5A medium or Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS and allowed to
reach 70% confluency. Cells were serum starved for 24 hours using OptiMEM® Reduced Serum
Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). Cells were treated with human recombinant
2.5ng/mLTGF-β1 (R&D Systems, Minneapolis, MN) or equal vehicle, 4mM HCl with 1mg/mL of
bovine serum albumin (BSA) (Sigma, St. Louis, MO) in Opti-MEM® for 24, 48, 72, 96, and 120
hours. Protein lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer (50mM
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Tris, 150mM NaCl, 1% Triton-X 100, 0.1% SDS, 0.5% Na deoxycholate) (Upstate, Temecula,
CA) supplemented with 1X protease inhibitor cocktail (Roche, Mannheim, Germany).
Densitometry was determine from 2 separate studies using NIH ImageJ software.

CD73 and A2BR Induced Expression by Hypoxia
Endometrial carcinoma cells, HEC-1A and HEC-1B, and cervical carcinoma cells, WISHHeLa, were plated in 6-well plates at a density of 1x105 cells/well in respective base mediums
containing 10% FBS. After reaching 90% confluency, cells were serum starved for 24 hours using
Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).

Cells were

placed in normoxic or hypoxic (1% O2, 5% CO2) conditions. RNA was isolated at 4, 6, 12, and 24
hours following hypoxic or normoxic exposure. Isolated RNA was DNase (Roche, Mannheim,
Germany) treated per manufacturer instructions. Real-time quantitative RT-PCR was performed
at The University of Texas Quantitative Genomics Core Laboratory. In separate studies, cells were
co-incubated with 1µM of Smad3 inhibitor, SIS3 (Calbiochem, San Diego, CA).

Increased Steady-State Levels of HIF-1α by Hypoxia
HEC-1A, HEC-1B, and WISH-HeLa cells were plated at a density of 1x106 cells/plate in
respective base mediums containing 10% FBS. After reaching 90% confluency, cells were serum
starved for 24 hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen,
Carlsbad, CA). Cells were placed in normoxic or hypoxic (1% O2, 5% CO2) conditions. Protein
lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer (50mM Tris, 150mM
NaCl, 1% Triton-X 100, 0.1% SDS, 0.5% Na deoxycholate) (Upstate, Temecula, CA)
supplemented with 1X protease inhibitor cocktail (Roche, Mannheim, Germany) at time points of
4, 6, 12, and 24 hours.
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CD73 Catalytic Studies
Reverse Phase High Performance Liquid Chromatography (RP-HPLC)
Protein lysates from normal endometrium, endometrial carcinomas, and endometrial
carcinoma cell lines were freshly prepared using radioimmunoprecipitation assay (RIPA) buffer
(50mM Tris, 150mM NaCl, 1% Triton-X 100, 0.1% SDS, 0.5% Na deoxycholate) (Upstate,
Temecula, CA) supplemented with 1X protease inhibitor cocktail (Roche, Mannheim, Germany).
For determining specific activity for CD73, 10μg of protein lysates were incubated with 400μM
5’AMP (Sigma, St. Louis, MO) for 15 minutes, 37°C in the presence of 10μM deoxyconformycin
in HEPES buffer, with or without 1mM of α, β- methylenediphosphate (AOPCP) (Sigma, St.
Louis, MO). Heat-inactivated protein lysates were used as negative controls. Reactions were
terminated with 5 minute incubation at 95°C. Reactions were analyzed for adenosine production
using reverse-phase (C18) high performance liquid chromatography. CD73 specific activity was
expressed as nmole production per min per mg of protein (nmole/min/mg).

CD73 Enzyme Histochemistry
Normal Colon and Endometrium and Endometrial Carcinomas
Cryosections, 15µm in thickness (230), of normal endometrium and endometrial
carcinomas were sectioned by MDA-GCTR-TB. Room temperature warmed sections were fixed
in 0.05M cacodylate-buffered 4% paraformaldehyde for 15 minutes and washed in 0.05M
cacodylate buffer containing 0.25M sucrose. Sections were incubated for 1.5 hours at room
temperature, in a reaction solution containing 1mM 5’AMP, 2mM Pb(NO3)2, 5mM MnCl2, 0.25M
sucrose, and 50mM tris-malate pH 7.4. 5mM tetramisole hydrochloride (levamisole) was included
to block enzymatic activity of non-specific phosphatases. Further specificity for CD73 activity
was demonstrated in selected sections by including 1mM α,β-methylene diphosphate (AoPCP).
For negative controls, 5’AMP was omitted. Following incubation, sections were washed in dH2O
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and immersed in 2% (NH4)2S for 10 seconds. Sections were mounted with DAPI containing
permount. This technique was modified from Wachstein, M. and Meisel, E., Histochemistry of
hepatic phosphatase at a physiological pH with special reference to the demonstration of bile
canaliculi, Am. J. Clin. Pathol. 1957;27:13-23 (231). Images were captured using a BX41
Olympus microscope (Center Valley, PA) and Image-Pro MC 6.1 imaging software.

Colon and Endometrial Carcinoma Cell Lines
Colon and endometrial carcinoma cell lines were grown to 70% or 90% confluency on 2well chamber slides (Lab-Tek™, Nalge Nunc International, Rochester, NY). Fixation, reaction
solution incubation, and phosphate precipitation methods were identical to those described for the
cryosections.
CD73 Enzyme Histochemistry – Transmission Electron Microscopy
Enzyme histochemistry was performed on HEC-1A cells as described. Cells were fixed in
2% glutaraldehyde (Sigma, St. Louis) for 1 hour at 4°C, washed in 0.1M sodium cacodylate
buffer, dehydrated in graded ethanol solutions, and embedded in LX-112 medium. Ultrathin
sections were obtained, stained with uranyl acetate and lead citrate, and examined by transmission
electron microscopy (model JEM 1010, JEOL Inc., Peabody, MA). Digital images were acquired
using an AMT Imaging System (Advanced Microscopy Techniques Corp., Danvers, MA).

WISH-HeLa Time-Course
WISH-HeLa Time-Course - Histology
WISH-HeLa cells were plated at a density of 1x104 cells/well in 2-well chamber slides
(Lab-Tek™, Nalge Nunc International, Rochester, NY) and observed for cell confluencies of 50%,
70%, 90%, 100% and 2- and 4-day post-confluency. Chamber slides were fixed at 4°C in 4%
paraformaldehyde for 1 hour, re-hydrated in absolute alcohol, moved through an alcohol gradient
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of 90% and 70%, rinsed with dH2O, and stained with hematoxylin for 1 minute. Chamber slides
were rinsed with dH2O, stained with eosin for 30 seconds, and progressed through an alcohol
gradient of 70%, 90%, and 100%. Images were captured using a BX41 Olympus microscope
(Center Valley, PA) and Image-Pro MC 6.1 imaging software.

WISH-HeLa cell area and

perimeter was measured using The National Institute of Health (NIH) analysis software, ImageJ
(NIH, Bethesda, MD, http://rsb.info.nih.gov/nih-image). Eight to ten images of a 40X field were
measured per percent/post-confluency timepoint.
WISH-HeLa Time-Course - Quantitative RT-PCR
WISH-HeLa cells were plated in 6-well plates at a density of 1x105 cells/well and
observed for growth equal to percent cell confluencies of 70%, 90%, 100% and 2- and 4-day postconfluency. RNA was isolated in 4 experimental replicates from each confluency stage. Isolated
RNA was DNase (Roche, Mannheim, Germany) treated per manufacturer instructions. Real-time
quantitative RT-PCR was performed at The University of Texas Quantitative Genomics Core
Laboratory.

WISH-HeLa Time-Course - Immunofluorescence
WISH-HeLa cells were plated at a density of 1x105 cells/chamber in 1-well chamber
slides (Lab-Tek™, Nalge Nunc International, Rochester, NY) and observed for growth equal to
percent cell confluencies of 70%, 90%, 100% and 2- and 4-day post-confluency. Chamber slides
were fixed at 4°C in 4% paraformaldehyde for 1 hour and advanced through immunostaining
methods.
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Small Interfering RNA (siRNA) – CD73 Silencing
CD73 Silencing - Synthetic 21-mer siRNAs
Three individual synthetic 21-mer siRNAs for CD73 were custom designed (SigmaAldrich, St. Louis, MO). siRNA sequences were adapted from Mikhailov et al., CD73 participates
in cellular multiresistance program and protects against TRAIL-induced apoptosis, J Immunol
2008;181:464-475 (232). Individual CD73 siRNA oligonucleotide sequences are detailed in Table
3.2

CD73 Silencing – Optimization
HEC-1A cells were plated in 6-well plates at a density of 1x105 cells/well in McCoy’s 5A
medium containing 10% FBS. After reaching 50% confluency, cells were serum starved for 24
hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). Cells
were transfected with varying concentrations, 10nM, 25nM, and 100nM, of individual CD73
siRNAs or the non-targeting siRNA or transfected with a combination mixture, a 1:1:1 ratio, of
individual CD73 siRNAs. Individual and combination concentrations were 10nM, 25nM, and
100nM. Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) was used as the cationic lipid carrier.
RNA was isolated in experimental replicates of 3 from each group 24 hours after siRNA
transfection. Effectiveness of CD73 silencing was determined by real-time quantitative RT-PCR.
Real-time quantitative RT-PCR was performed at The University of Texas Quantitative Genomics
Core Laboratory (Figure 3.2). For CD73 silencing studies in this dissertation, 25nM of CD73
siRNA 1247 was used.

CD73 Silencing – Quantitative RT-PCR 1247 CD73 siRNA
HEC-1A cells were plated in 6-well plates at a density of 1x105 cells/well in McCoy’s 5A
medium containing 10% FBS. After reaching 50% confluency, cells were serum starved for 24
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Table 3.2. Individual CD73 and non-targeting siRNA oligonucleotide sequences

CD73 siRNA

Oligonucleotide Sequence

978

5'-ACAGCAGCAUUCCUGAAGATT-3'

1162

5'-CCUGAGACACACGGAUGAATT-3'

1247

5'-CGCAACAAUGGCACAAUUATT-3'

Non-Targeting

5'-GAUCAUACGUGCGAUCAGATT-3'
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Figure 3.2. Optimization of CD73 siRNAs. Endometrial carcinoma cells, HEC-1A, were
transiently transfected with individual CD73 siRNAs or the non-targeting siRNA or transfected
with a combination mixture, a 1:1:1 ratio, of individual CD73 siRNAs.

Individual and

combination concentrations used were 10nM, 25nM, 100nM. CD73 expression was determined
24 hours post-transfection by qRT-PCR. (A) 10nM, (B) 25nM, (C), 100nM concentrations of
individual and combined CD73 siRNA oligonucleotides. With 100nM concentrations, a small
change in CD73 expression is additionally found with the non-targeting control, compared to the
lipofectamine control. This suggest that concentrations of 100nM may be leading to off-target
effects. Error bars represent ± 1 SE. (*p<0.05)
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Figure 3.2

A

B
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C
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hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA) and
transfected with 25nM of CD73 siRNA 1247, non-targeting siRNA, or Lipofectamine™ 2000
alone. RNA was isolated in 3 experimental replicates 24 hours post-transfection. CD73 silencing
with transient transfection was determined by quantitative RT-PCR. Real-time quantitative RTPCR was performed at The University of Texas Quantitative Genomics Core Laboratory.

CD73 Silencing - Proliferation
HEC-1A cells were plated in 100mm plates at a density of 1X106 cells/plate in McCoy’s
5A medium containing 10% FBS. After reaching 50% confluency, cells were serum starved for
24 hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA)
and transfected with 25nM of CD73 siRNA 1247, non-targeting siRNA, or Lipofectamine™ 2000
alone. Following 24 hours, cells were trypsinized and re-plated in 12-well plates at a density of
1x105 cells/well (Day 0). Effects of CD73 silencing on HEC-1A proliferation were determined by
manual cell counting for 5 consecutive days. Trypan Blue (Sigma-Aldrich, St. Louis, MO) was
included in counting suspensions to concurrently observe cell viability.

Three experimental

replicates were performed for each group.

CD73 Silencing – Immunofluorescence
HEC-1A cells were plated at a density of 1x104 cells/well in 2-well chamber slides (LabTek™, Nalge Nunc International, Rochester, NY), observed for growth equal to 50%, and serum
starved for 24 hours using OptiMEM® Reduced Serum Medium, GlutaMax™ (Invitrogen,
Carlsbad, CA). Cells were transfected with 25nM of CD73 siRNA 1247, non-targeting siRNA, or
Lipofectatine™ 2000 alone. Medium was replaced 24 hours post-transfection with OptiMEM®
Reduced Serum Medium. Chamber slides of 48 or 72 hours post-transfection were fixed at 4°C in
4% paraformaldehyde for 1 hour and advanced through immunostaining methods.
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Flow cytometry – Annexin V
HEC-1A and HEC-1B cells plated in 100mm plates at a density of 1x106 cells/plate in
McCoy’s 5A medium or Minimum Essential Medium (MEM) containing 10% FBS and allowed
to reach 90% confluency. Cells were serum starved for 24 hours using OptiMEM® Reduced
Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). Cells were incubated at 37°C in
normoxic conditions or 1% O2, 5% CO2 (hypoxia) for 24 hours (migration end-point) or 36 hours
(invasion end-point). Annexin-V staining (Roche, Mannheim, Germany) was performed per
manufacturer instructions. Samples were analysed by flow cytometry at the University of Texas
MD Anderson Cancer Center Flow Cytometry & Cellular Imaging Core.

Modified and Unmodified Boyden Chambers – Migration and Invasion
Migration and invasion studies were performed using the modified, non-coated
membrane, and unmodified, Matrigel™ (BD Bioscience, Bedford, MA) coated membrane, twochamber system described by Albini, A. et al., A rapid in vitro assay for quantitating the invasive
potential of tumor cells, Cancer Res. 1987;47:3239-3245 (233) and Tumor and endothelial cell
invasion of basement membranes: the matrigel chemoinvasion assay as a tool for dissecting
molecular mechanisms, Pathol Oncol Res. 1998;4(3):230-241 (234). Membranes of modified and
unmodified systems consisted of an 8um diameter pore size and 6 pores/cm2 pore density (BD
Bioscience, Bedford, MA). Cells were plated at a density of 3x105 cells/insert in OptiMEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). OptiMEM® containing 5%
FBS was used as a chemoattractant. Chambers were incubated at 37°C in normoxic conditions or
1% O2, 5% CO2 (hypoxia) for 24 hours (migration end-point) or 36 hours (invasion end-point).
Following incubation cells were removed from the upper-chamber, and lower-chamber
membrane-bound cells were fixed with 100% methanol.

Cells were stained by incubating

membranes in eosin, 30 seconds, and hematoxylin, 5 minutes. Six or 9 10X images per membrane
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were captured using a BX41 Olympus microscope (Center Valley, PA) and Image-Pro MC 6.1
imaging software. Quantification was performed by counting the number of cells present in a 10X
field.

Cell counting was assisted by using The National Institute of Health (NIH) analysis

software, ImageJ (NIH, Bethesda, MD, http://rsb.info.nih.gov/nih-image). Data are expressed as
mean number of cells that have migrated or invaded the membrane in a 10X field. Experimental
replicates of 3, 4, or 6 were performed for each group. Results were validated by a second series
of independent experiments.

Migration and Invasion – Normoxia-Hypoxia
HEC-1A and HEC-1B cells were plated in 100mm plates at a density of 1x106 cells/plate
in McCoy’s 5A medium or Minimum Essential Medium (MEM) containing 10% FBS and
allowed to reach 90% confluency. Cells were serum starved for 24 hours using OptiMEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA) and removed from plates using
0.25% tyrpsin (Invitrogen, Carlsbad, CA). Cells were re-suspended in OptiMEM® containing
50uM of 5’adenosine monophosphate (5’AMP) (Sigma-Aldrich, St. Louis, MO) and plated at a
density of 3x105 cells/insert. Inserts were incubated at 37°C in normoxic conditions or 1% O2, 5%
CO2 (hypoxia) for 24 hours (migration end-point) or 36 hours (invasion end-point).

Migration and Invasion – CD73 siRNA
HEC-1A and HEC-1B cells were plated in 100mm plates at a density of 1x106 cells/plate
in McCoy’s 5A medium or Minimum Essential Medium (MEM) containing 10% FBS and
allowed to reach 50% confluency. Cells were serum starved for 24 hours using OptiMEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). Following serum starvation,
cells were transfected with 25nM of CD73 siRNA 1247, non-targeting siRNA, or Lipofectatine™
2000 alone. Medium was replaced 24 hours post-transfection with OptiMEM® Reduced Serum
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Medium.

Cells were removed from plates 55-60 hours post-transfection, re-suspended in

OptiMEM® containing 50uM of 5’adenosine monophosphate (5’AMP) (Sigma-Aldrich, St. Louis,
MO) and plated at a density of 3x105 cells/insert. Inserts were incubated at 37°C 1% O2, 5% CO2
(hypoxia) for 24 hours (migration end-point) or 36 hours (invasion end-point).

Migration and Invasion – CD73 Catalytic Inhibition
HEC-1A and HEC-1B cells were plated in 100mm plates at a density of 1x106 cells/plate
in McCoy’s 5A medium or Minimum Essential Medium (MEM) containing 10% FBS and
allowed to reach 90% confluency. Cells were serum starved for 24 hours using OptiMEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).

Prior to trypsinization,

selected groups were pre-incubated with 10uM or 100uM α,β-methylene diphosphate (AoPCP)
(Sigma-Aldrich, St. Louis, MO) for 1 hour. Cells were re-suspended in OptiMEM® containing
50uM of 5’adenosine monophosphate (5’AMP) (Sigma-Aldrich, St. Louis, MO) with or without
10uM or 100uM AoPCP and plated at a density of 3x105 cells/insert. Inserts were incubated in
normoxic conditions or 1% O2, 5% CO2 (hypoxia) for 24 hours (migration end-point) or 36 hours
(invasion

end-point).

For

determining

receptor-mediated

response,

10μM

5'-N-

ethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO) was included in cell
suspensions of selected 5’AMP/AoPCP groups.

Migration and Invasion – Adenosine Receptor Antagonism
HEC-1A and HEC-1B cells were plated in 100mm plates at a density of 1x106 cells/plate
in McCoy’s 5A medium or Minimum Essential Medium (MEM) containing 10% FBS and
allowed to reach 90% confluency. Cells were serum starved for 24 hours using OptiMEM®
Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).

Prior to trypsinization,

selected groups were pre-incubated with 1uM of 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)
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(Sigma-Aldrich, St. Louis, MO), an adenosine A1 receptor

(A1R) antagonist, or N-(4-

Cyanphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide
(MRS1754) (Tocris Bioscience, Ellisville, MO), an adenosine 2B receptor (A2BR) antagonist for
20 minutes. Cells were re-suspended in OptiMEM® or OptiMEM® containing the following:
dimethylsulfoxide

(DMSO)

(Sigma-Aldrich,

St.

Louis,

MO);

10μM

5'-N-

ethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO); 10μM NECA and 1μM
DPCPX; 10uM NECA and 1uM MRS1754. Cells were plated at a density of 3x105 cells/insert
and inserts incubated at 37°C, 1% O2, 5% CO2 (hypoxia) for 24 hours (migration end-point) or 36
hours (invasion end-point).

Migration and Invasion – Vinculin Neutralization
HEC-1A cells were plated in 100mm plates at a density of 1x106 cells/plate in McCoy’s
5A medium or Minimum Essential Medium (MEM) containing 10% FBS and allowed to reach
90% confluency. Cells were serum starved for 24 hours using OptiMEM® Reduced Serum
Medium, GlutaMax™ (Invitrogen, Carlsbad, CA). Prior to trypsinization, selected groups were
pre-incubated with 10μM rabbit IgG or 10μM vinculin for 20 minutes. Cells were additionally
pre-incubated with 1uM of 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) (Sigma-Aldrich, St.
Louis, MO), an adenosine A1 receptor (A1R) antagonist, or N-(4-Cyanphenyl)-2-[4-(2,3,6,7tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide

(MRS1754)

(Tocris

Bioscience, Ellisville, MO), an adenosine 2B receptor (A2BR) antagonist for 20 minutes. Cells
were re-suspended in OptiMEM® or OptiMEM® containing the following: dimethylsulfoxide
(DMSO) (Sigma-Aldrich, St. Louis, MO); 10μM 5'-N-ethylcarboxamidoadenosine (NECA)
(Tocris Bioscience, Ellisville, MO); 10μM NECA and 1μM DPCPX; 10uM NECA and 1uM
MRS1754. Cells were additionally re-suspended with 10μM rabbit IgG or 10μM vinculin. Cells
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were plated at a density of 3x105 cells/insert and inserts incubated at 37°C, 1% O2, 5% CO2
(hypoxia) for 24 hours (migration end-point).

Adenosine Receptor Antagonism –Macromolecule Paracellular Permeability
HEC-1A cells were grown on polycarbonate permeable inserts (0.4-μm pores, 24-mm
diameter; Costar, Cambridge, MA). At 2 days post-confluency, cells were serum starved for 24
hours using Opti-MEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).
Selected inserts were pre-incubated with 1µM of 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)
(Sigma-Aldrich, St. Louis, MO), an adenosine A1 receptor

(A1R) antagonist, or N-(4-

Cyanphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide
(MRS1754) (Tocris Bioscience, Ellisville, MO), an adenosine 2B receptor (A2BR) antagonist for
20 minutes. Medium was removed and replaced with OptiMEM® or OptiMEM® containing the
following: dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO); 10µM 5'-Nethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO); 10µM NECA and 1µM
DPCPX; 10µM NECA and 1µM MRS1754. Inserts were incubated at 37°C, 1% O2, 5% CO2
(hypoxia) for 36 hours. Inserts were washed with Hank’s balanced salt solution (HBSS). At time
0, 1.5mL of HBSS was added to the lower wells, and 0.5mL of HBSS containing 3.5μM
fluorescein isothiocyanate (FITC)-labeled 40-kDa dextran (NANCOS, New York, NY) was added
to the inserts. At 10, 20, 30, and 40 minutes after addition of FITC-labeled dextran, 100-μl
samples were taken from the lower wells. Sample volumes were replaced with equal volumes of
HBSS. The fluorescence intensity of each sample was measured at an excitation wavelength of
485nm and an emission wavelength of 530nm using a FLUOstar Omega Microplate Reader (BMG
Labtech, Cary, NC).
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Adenosine Receptor Antagonism – Immunofluorescence
HEC-1A cells were plated at a density of 1x104 cells/well in 2 or 4-well chamber slides
(Lab-Tek™, Nalge Nunc International, Rochester, NY). After reaching 90% confluency, cells
were serum starved for 24 hours using Opti-MEM® Reduced Serum Medium, GlutaMax™
(Invitrogen, Carlsbad, CA).

Prior to hypoxia incubation, selected camber slides were pre-

incubated with 1µM of 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) (Sigma-Aldrich, St. Louis,
MO), an adenosine A1 receptor (A1R) antagonist, or N-(4-Cyanphenyl)-2-[4-(2,3,6,7-tetrahydro2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide

(MRS1754)

(Tocris

Bioscience,

Ellisville, MO), an adenosine 2B receptor (A2BR) antagonist for 20 minutes. Medium was
removed

and

replaced

dimethylsulfoxide

with

(DMSO)

OptiMEM®

or

(Sigma-Aldrich,

OptiMEM®
St.

Louis,

containing
MO);

the

following:

10µM

5'-N-

ethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO); 10µM NECA and 1µM
DPCPX; 10µM NECA and 1µM MRS1754. Cells were incubated at 37°C, 1% O2, 5% CO2
(hypoxia) for 36 hours.

Adenosine Receptor Antagonism – Immunoblots
HEC-1A cells were plated in 100mm plates at a density of 1x106 cells/plate in McCoy’s
5A medium containing 10% FBS and allowed to reach 90% confluency. Cells were serum starved
for 24 hours using OptiMEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).
Prior to hypoxia incubation, selected plates were pre-incubated with 1µM of 8-Cyclopentyl-1,3dipropylxanthine (DPCPX) (Sigma-Aldrich, St. Louis, MO), an adenosine A1 receptor (A1R)
antagonist,

or

N-(4-Cyanphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-

yl)phenoxy]-acetamide (MRS1754) (Tocris Bioscience, Ellisville, MO), an adenosine 2B receptor
(A2BR) antagonist for 20 minutes. Medium was removed and replaced with OptiMEM® or
OptiMEM® containing the following: dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
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MO); 10µM 5'-N-ethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO); 10µM
NECA and 1µM DPCPX; 10µM NECA and 1µM MRS1754. Cells were incubated at 37°C, 1%
O2, 5% CO2 (hypoxia) for 36 hours. Protein lysates were prepared using radioimmunoprecipitation
assay (RIPA) buffer (50mM Tris, 150mM NaCl, 1% Triton-X 100, 0.1% SDS, 0.5% Na
deoxycholate) (Upstate, Temecula, CA) supplemented with 1X protease inhibitor cocktail (Roche,
Mannheim, Germany).

Adenosine Receptor Antagonism – Electron Microscopy
HEC-1A cells were plated in 100mm plates at a density of 1x106 cells/plate in McCoy’s
5A medium containing 10% FBS and allowed to reach 90% confluency. Cells were serum starved
for 24 hours using OptiMEM® Reduced Serum Medium, GlutaMax™ (Invitrogen, Carlsbad, CA).
Prior to hypoxia incubation, selected plates were pre-incubated with 1µM of 8-Cyclopentyl-1,3dipropylxanthine (DPCPX) (Sigma-Aldrich, St. Louis, MO), an adenosine A1 receptor (A1R)
antagonist,

or

N-(4-Cyanphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-

yl)phenoxy]-acetamide (MRS1754) (Tocris Bioscience, Ellisville, MO), an adenosine 2B receptor
(A2BR) antagonist for 20 minutes. Medium was removed and replaced with OptiMEM® or
OptiMEM® containing the following: dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO); 10µM 5'-N-ethylcarboxamidoadenosine (NECA) (Tocris Bioscience, Ellisville, MO); 10µM
NECA and 1µM DPCPX; 10µM NECA and 1µM MRS1754. Cells were incubated at 37°C, 1%
O2, 5% CO2 (hypoxia) for 36 hours. Cells were fixed in a solution containing 0.2% ruthenium red
and 2% glutaraldehyde in 0.1M sodium cacodylate buffer and 0.2ml 0.2% ruthenium red in 2%
OSO4 in 0.1M sodium cacodylate buffer. Ultrathin sections were obtained, stained with uranyl
acetate and lead citrate, and examined by transmission electron microscopy (model JEM 1010,
JEOL Inc., Peabody, MA).

Digital images were acquired using an AMT Imaging System

(Advanced Microscopy Techniques Corp., Danvers, MA).
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CHAPTER FOUR
Statement of Objectives
Objective
The preliminary objective of this dissertation was to identify which purinergic members
central to adenosine’s extracellular generation and regulation are dysregulated in EC. Following
the identification of CD73’s down-regulation in moderately- and poorly-differentiated, invasive,
and metastatic EC, the primary objective was to establish the role of CD73-generated adenosine to
induce barrier function in normal epithelial cells of the endometrium, and to identify the cell-cell
adhesion events or proteins that adenosine’s activation of A2BR regulates in carcinoma cells. Our
primary hypothesis is that the purinergic pathway, especially CD73-generated adenosine, is
important for maintaining barrier function in epithelial cells of the endometrium via the regulation
of cell-cell adhesions. In addition, we hypothesize that adenosine’s activation of A2BR inhibits
the invasiveness of EC cells and may be a molecular determinant of therapy sensitivity. To
address these hypotheses, we have used a variety of different experimental approaches including
in vivo functional and structural experiments using knock-out mice, in vitro functional and
structural studies using established cell lines, and expression studies using tissues derived from
normal human endometrium and well-characterized endometrial carcinomas.

The following

specific aims were proposed and completed:

Specific Aim 1. Identify the components of purinergic signaling that are dysregulated in
endometrial carcinoma. Probe-based real-time quantitative RT-PCR assays for high-throughput
analysis were designed for select members of the purinergic pathway and assessed in normal
endometrium and endometrial carcinomas.
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Specific Aim 2.

Demonstrate that CD73-generated adenosine serves a critical barrier

protective role in epithelial cells of the endometrium and that CD73 expression is induced by
known stimuli of barrier function.
Sub-aim 2A. An in vivo ruthenium red paracellular permeability assay was developed to
determine loss of endometrial epithelial barrier function in conditions of hypoxic stress in mice
deficient for CD73 or A2BR. Paracellular flux of the electron dense ruthenium red was quantified
in wild-type mice, CD73 deficient mice, and A2BR deficient mice.
Sub-aim 2B. Investigate the ability of in vitro TGF-β1 and hypoxia’s stabilization of HIF-1α to
induce CD73 and/or A2BR expression.

Specific Aim 3. Demonstrate that CD73’s pattern of expression and catalytic activity are
consistent with the proposed role of CD73 in the maintenance of the epithelial phenotype.
CD73 expression and specific activity were assessed by reverse phase high performance liquid
chromatography (RP-HPLC), immunofluorescence, and enzyme histochemistry. Change in CD73
expression with the transitioning of cellular phenotypes was assessed in WISH-HeLa cells.

Specific Aim 4. Show that CD73-generated adenosine and adenosine’s activation of A2BR
inhibits the migration and invasion of endometrial carcinoma cells.

In vitro migration and

invasion studies were performed using modified and unmodified two-chamber systems. siRNA
and commercially available pharmacological agents were used to manipulate CD73 activity and
A2BR activation.

Specific Aim 5. Identify the events or proteins of cell-cell adhesion that are regulated by
adenosine’s activation of A2BR. This specific aim assesses the events and proteins of cell-cell
adhesions that are affected by the manipulation of A2BR activation.
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CHAPTER FIVE
Results
Specific Aim 1. Identify the components of purinergic signaling that are dysregulated in
endometrial carcinoma.

Introduction
A hallmark of cancer cell biology is the ability of cancer cells to take advantage of normal
normal homeostatic events, such as epithelial-to-mesenchymal transition, or existing cellular
machinery to help promote cancer cell survival and progression. In normal tissues, activation of
the purinergic pathway and, subsequently, barrier function, by hypoxia, inflammation, ischemia,
or acute tissue damage represents a physiological response to maintain cell and tissue homeostasis.
In diseases, including the chronic lung diseases asthma, chronic obstructive pulmonary disease,
and interstitial lung disease (reviewed, (235)); the neurodegenerative diseases Huntington’s
disease (236, 237) and Parkinson’s disease (238); the inflammatory bowl diseases ulcerative
colitis and Crohn’s disease; the cardiovascular diseases, congestive heart failure and
cardiomyopathy; and sickle cell disease (239) and renal disease, the normally pro-homeostasis
function of this pathway is significantly altered to promote disease pathophysiologies.

The

purinergic pathway has not been studied in great detail in cancer. Therefore, it is unclear if the
purinergic pathway members and extracellular adenosine serve to promote the progression of EC
or whether the homeostatic mechanisms of this pathway remain intact in well-differentiated, noninvasive, and non-metastatic ECs. Hypoxia and inflammation have prominent roles in many noncancer diseases, including those indicated above. Interestingly, hypoxia and inflammation have
also been shown in cancers to favor cancer progression, metastasis, and/or therapy resistance
(reviewed (240, 241)). These observations led us to hypothesize that the most central members of
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the purinergic pathway involved in the generation and regulation of extracellular adenosine would
likely be dysregulated in EC.
To accomplish this specific aim, we worked in collaboration with the University of Texas
at Houston Quantitative Genomic Core to design probe-based real-time quantitative assays for
high-throughput analysis of selected purinergic pathway members.

14 samples of normal

endometrium and 49 ECs of varying histotypes were received from the University of Texas MD
Anderson Multidisciplinary Gynecological Cancer Translational Research Tumor Bank (MDAGCTR-TB). Table 5.1 indicates the pathological and clinical characteristics of the ECs. Selected
purinergic pathway members assessed included AMP  adenosine catalyzing ecto-enzyme
5’nucleotidase (CD73); adenosine  inosine deaminating enzyme, adenosine deaminase (ADA);
nucleoside transporter, equilibrative nucleoside transporter 1 (ENT1); adenosine receptor subtypes,
A1R, A2AR, A2BR, and A3R; P2 receptor, purinergic receptor P2Y (P2RY2); and osteopontin
(SPP1). SPP1 is not a member of the purinergic pathway, but it has been described as an indicator
of elevated extracellular adenosine levels in models of chronic lung diseases (242, 243).
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Table 5.1. Pathological and clinical characteristics of endometrial carcinomas

G1 EEC
(n=11)

G2 EEC
(n=17)

G3 EEC
(n=17)

UPSC
(n=4)

Myometrial Invasion, n(%)
Non-Invasive
<50%
= or >50%

3 (27%)
5 (45%)
3 (27%)

2 (12%)
10 (59%)
5 (29%)

0 (0%)
2 (12%)
15 (88%)

0 (0%)
2 (50%)
2 (50%)

FIGO Stage, n(%)
IA
IB
IC
II
III
IV

3 (27%)
5 (45%)
2 (18%)
0 (0%)
1 (9%)
0 (0%)

2 (12%)
7 (41%)
2 (12%)
4 (23%)
2 (12%)
0 (0%)

0 (0%)
2 (12%)
4 (23%)
4 (23%)
4 (23%)
3 (18%)

0 (0%)
1 (25%)
0
0
1 (25%)
2 (50%)

Vascular/Lymphatic
Invasion, n(%)
Positive

2 (18%)

5 (29%)

12 (71%)

3 (75%)

Abbreviations:
G1 EEC, Grade 1 Endometrioid Endometrial Carcinoma
G2 EEC, Grade 2 Endometrioid Endometrial Carcinoma
G3 EEC, Grade 3 Endometrioid Endometrial Carcinoma
UPSC, Uterine Papillary Serous Carcinoma
FIGO, International Federation of Gynecology and Obstetrics
FIGO Stage:
IA, cancer confined to endometrial layer
IB, cancer confined to uterine corpus, but invades less than half the myometrium thickness
IC, cancer confined to uterine corpus, but invades equal to or more than half the myometrium
thickness
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II, cancer spreads to the cervix, but does not extend beyond the uterus
III, local and/or regional spread of the cancer
IV, cancer has spread to distant tissues or organs
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Ecto-enzyme 5’nucleotidase (CD73) is the single purinergic pathway member dysregulated
in endometrial carcinomas
Results from high-throughput qRT-PCR analyses were assessed by comparing transcript
levels to established pathological and surgical parameters for EC, including histological grade,
myometrial invasion, surgical-pathological staging (FIGO), disease type (Type I vs. Type II), and
vascular/lymphatic invasion. This information was derived from review of the pathology reports
for each EC examined.

Type I includes Grade 1 and Grade 2 endometrioid endometrial

carcinomas (G1 EEC and G2 EEC), and Type II included Grade 3 endometrioid endometrial
carcinomas (G3 EEC) and uterine papillary serous carcinomas (UPSC).

Ecto-enzyme

5’nucleotidase (CD73) was found to be the single purinergic pathway member to be consistently
and significantly dysregulated in normal versus EC and among ECs and their different parameters
(Table 5.2 and 5.3). Therefore, for subsequent comparisons to pathological and clinical data
(Figures 5.2-5.5), only CD73 was considered.

Figure 5.1 indicates expression of selected

members of the purinergic pathway in proliferative and secretory endometrium and by endometrial
carcinoma grade.
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Table 5.2.

One-Way ANOVA and independent t-test p values for purinergic pathway

members evaluated by qRT-PCR in normal endometrium and endometrial carcinomas –
Part I

Gene
Symbol

-20

Myometrial
Invasion
ap

FIGO
Stage
ap

0.019

0.037

5'Nucleotidase

CD73

Adenosine Deaminase

ADA

0.733

0.760

0.258

Adenosine Receptor A1
Adenosine Receptor A2A
Adenosine Receptor A2B
Adenosine Receptor A3

A1R
A2AR
A2BR
A3R

0.798
0.886
0.879
0.264

0.672
0.694
0.969
0.253

0.111
0.468
0.099
0.267

Equilibrative Nucleoside Transporter 1

ENT1

0.036

0.043

0.056

Osteopontin

SPP1

0.013

0.324

0.911

P2RY2

0.442

0.906

0.128

Purinergic Receptor P2Y

a

Grade
ap
7.0x10

One-Way ANOVA statistics were used, significance was determined by a p value of p<0.05

Abbreviations:
FIGO, International Federation of Gynecology and Obstetrics
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Table 5.3.

One-Way ANOVA and independent t-test p values for purinergic pathway

members evaluated by qRT-PCR in normal endometrium and endometrial carcinomas –
Part II

Gene
Symbol

Vascular/Lymphatic
Invasion

bp

bp

5'Nucleotidase

CD73

0.001

0.616

Adenosine Deaminase

ADA

0.288

0.146

Adenosine Receptor A1
Adenosine Receptor A2A
Adenosine Receptor A2B
Adenosine Receptor A3

A1R
A2AR
A2BR
A3R

0.466
0.122
0.466
1.000

0.536
0.933
0.083
0.664

Equilibrative Nucleoside Transporter 1

ENT1

0.125

0.072

Osteopontin

SPP1

0.052

0.302

P2RY2

0.177

0.312

Purinergic Receptor P2Y

b

Type I vs
Type II

Independent t-test statistics were used, significance was determined by a p value of p<0.05

Categories:
Type I, Grade 1 and Grade 2 endometrioid endometrial carcinoma
Type II, Grade 3 endometrioid endometrial carcinoma and uterine papillary serous carcinoma
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Figure 5.1. Expression of selected members of the purinergic pathway in proliferative and
secretory endometrium and by endometrial carcinoma grade. Transcript data were plotted
using a box and whisker plots: bottom box, 25th percentile; top box, 75th percentile; black bar, 50th
percentile (median); whiskers, upper and lower adjacent; circles, outside fence; and asterisks,
extreme values. CD73 transcript values were normalized to 18S ribosomal RNA (rRNA) and are
presented as molecules of CD73/molecules of 18S rRNA (%18SrRNA). (A) ADA transcripts, (B)
A1R transcripts, (C) A2AR transcripts, (D) A2BR transcripts, (E) A3R transcripts, (F) ENT1
transcripts, (G) SPP1 transcripts, and (H) P2RY2 transcripts. Error bars represent ± 1 SE. (ns =
non-significant; *, p<0.05)
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Elevated CD73 expression in secretory phase endometrium is not regulated by progesterone.
A unique feature of the normal endometrium is its cyclic regulation by estrogen and
progesterone.

Proliferative phase endometrium is dominated by changes induced by estrogen,

while secretory phase endometrium is dominated by changes induced by progesterone (244).
Prior to performing post-hoc analyses for CD73 transcripts in EC, CD73 expression was assessed
among the two phases of normal endometrium. Interestingly, in normal secretory endometrium
CD73 transcripts were significantly elevated as compared to normal proliferative endometrium
(Figure 5.2). This finding was exciting, as epithelial cells of secretory phase endometrium are the
most differentiated of the two phases and are highly supportive of barrier function and fertility.
With progesterone being the most dominant hormone of the secretory phase and it being
responsible for the regulation of many genes in this phase, the possibility of progesterone inducing
CD73 expression was assessed by using well-differentiated endometrial carcinoma cells, HEC-1A,
manipulated to stably express progesterone receptor β (PRβ) (245).

Somewhat unexpected,

progesterone was found not to induce CD73 transcripts (Figure 5.3 A). In a similar regard, A2BR
transcripts were not induced by progesterone (Figure 5.3 B). Insulin-like growth factor-binding
protein 1 (IGFBP1), a known progesterone regulated gene, was induced in the same experimental
conditions (Figure 5.3 C). CD73 and A2BR induction by progesterone was additionally assessed
in endometrial biopsies from women taking the progestin, depot medroxyprogesterone acetate
(MPA). Patients who took depot MPA were premenopausal and biopsies were timed at days 5-10
in the proliferative phase. Biopsies were taken at baseline (prior to treatment) and 3 months posttreatment. CD73 transcripts were not increased in endometrial biopsies. In most patients, in fact,
CD73 expression was down-regulated (Figure 5.4 A and Table 5.4). A2BR transcripts remained
unchanged or were elevated in a small number of patients at 3 months post-treatment (Figure 5.4
B and Table 5.4).

These studies demonstrate CD73 transcripts to be significantly elevated in

secretory phase endometrium, a phase known to be characterized by enhanced epithelial

79

differentiation and barrier function. However, expression of CD73 and A2BR are not regulated by
the dominant hormone of the secretory phase, progesterone.
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Figure 5.2.

CD73 expression in proliferative and secretory phase endometrium. CD73

transcript data from qRT-PCR studies of proliferative and secretory phase endometrium were
plotted using a box and whisker plot: bottom box, 25th percentile; top box, 75th percentile; black bar,
50th percentile (median); whiskers, upper and lower adjacent; circles, outside fence.

CD73

transcript values were normalized to 18S ribosomal RNA (rRNA) and are presented as molecules of
CD73/molecules of 18S rRNA (%18SrRNA). CD73 transcripts were significantly elevated in
secretory phase endometrium. Error bars represent ± 1 SE. (**p<0.005)
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Figure 5.2
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Figure 5.3. Progesterone treatment in endometrial carcinoma cells, HEC-1A, manipulated
to express progesterone receptor β (PRβ). HEC-1A stably expressing progesterone receptor β
(PRβ) were treated with 400nM of progesterone or vehicle control (0.001%, 100% ethanol
(EtOH)) for 24 hours and transcripts for CD73, A2BR, and insulin-like growth factor-binding
protein 1 (IGFBP1) assessed by qRT-PCR. CD73 (A) and A2BR (B) transcripts were not induced
by progesterone. (C) Known progesterone regulated gene and positive control IGFBPI was
induced by progesterone. Transcript values were normalized to 18S ribosomal RNA (rRNA) and
are presented as molecules of transcript/molecules of 18S rRNA (%18SrRNA).
represent ± 1 SE. (***p<0.0005)
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Figure 5.4. CD73 and A2BR expression in benign endometrium at baseline and 3 months
post-progestin, depot medroxyprogesterone acetate (MPA), treatment. Baseline and 3 month
post-treatment endometrial biopsies were obtained from women taking exogenous progesterone,
depot medroxyprogesterone acetate (MPA). CD73 and A2BR transcripts were assessed by qRTPCR. Transcript values were normalized to 18S ribosomal RNA (rRNA) and are presented as
molecules of CD73/molecules of 18S rRNA (%18SrRNA). Individual lines represent a single
patient. (A) CD73 transcripts remained unchanged or were down-regulated in patients following 3
months post-MPA as compared to baseline. (B) A2BR transcripts remained unchanged or were
increased in patients following 3 months post-MPA as compared to baseline.
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Table 5.4. CD73 and A2BR expression in benign endometrium at baseline and 3 months
post-progestin, depot medroxyprogesterone acetate (MPA), treatment – Data summary from
Figure 5.4

CD73
3 Month
Post-Treatment

Patient

Line

CD73
Baseline

1
2
3
4
5
6
7
8

Purple
Yellow
Teal
Gray
Tan
Red
Green
Blue

0.0825
0.0816
0.0546
0.0533
0.0476
0.0471
0.0395
0.0139

0.0599
0.0341
0.0198
0.0134
0.0636
0.0455
0.0142
0.0139

Patient

Line

A2BR
Baseline

A2BR
3 Month
Post-Treatment

1
2
3
4
5
6
7

Green
Tan
Teal
Purple
Yellow
Red
Blue

0.00032
0.00025
0.00013
0.00041
0.00035
0.00018
0.00015

0.00152
0.00118
0.00097
0.00021
0.00018
0.00023
0.00022

Data are expressed as molecules of CD73/molecules of 18S ribosomal RNA for a single patient
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CD73 expression is down-regulated in moderately- and poorly-differentiated, invasive, and
metastatic endometrial carcinomas
Post-hoc analyses (Tukey) was performed to determine CD73 transcript expression in
relation to EC histotype and grade, invasiveness, and stage. G1 EECs are well-differentiated, G2
EECs are moderately-differentiated, and G3 EEC and UPSC are poorly-differentiated. Compared
to expression in secretory phase endometrium, CD73 transcripts were significantly lower in all the
different grades of EC (Figure 5.5 A). Proliferative endometrium and G1 EECs had similar levels
of CD73 transcripts, but compared to proliferative endometrium, CD73 expression in G2 and G3
EECs and UPSCs was significantly lower. To assess differences in myometrial invasion, ECs
were divided into three categories: non-invasive, less than (<) 50% invasion, and equal to (=) or
greater than (>) 50% invasion (Figure 5.5 B). Non-invasive are ECs confined completely to the
endometrium. ECs with 50% or greater myometrial invasion had significantly lower CD73. In a
similar manner, ECs were divided into surgical staging categories (Figure 5.5 C). FIGO stage IA
ECs are non-invasive, FIGO stage IB & IC ECs invade the myometrium but are confined to the
uterine corpus, and FIGO II, III & IV ECs have extrauterine disease involvement, whether local
(II), regional (III), or distant (IV). CD73 transcripts were lower (p=0.05) for FIGO stage IB & IC
ECs compared to the non-invasive stage IA ECs. CD73 was significantly lower in stage II, III, &
IV ECs compared to the non-invasive stage IA ECs. When ECs are grouped into Type I or Type
II categories, CD73 transcripts were found to be significantly lower in Type II disease (Figure 5.5
D). As previously known from our One-Way ANOVA statistical comparisons, vascular/lymphatic
invasion was not a significant determinant of CD73 expression (Figure 5.5 E). These data indicate
that at the transcript level, CD73 is significantly down-regulated in moderately- and poorlydifferentiated, invasive, and metastatic ECs. CD73 transcripts levels in non-invasive were similar
to those seen with benign proliferative phase endometrium.
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Figure 5.5.

CD73 expression in established pathological and clinical parameters for

endometrial cancer. CD73 transcript data were plotted using a box and whisker plots: bottom
box, 25th percentile; top box, 75th percentile; black bar, 50th percentile (median); whiskers, upper
and lower adjacent; circles, outside fence; and asterisks, extreme values. CD73 transcript values
were normalized to 18S ribosomal RNA (rRNA) and are presented as molecules of
CD73/molecules of 18S rRNA (%18SrRNA). (A) CD73 transcripts in different grades of EC were
significantly different among all groups when compared with secretory phase endometrium.
CD73 transcripts of proliferative and Grade 1 endometrioid endometrial carcinomas (G1 EEC)
were similar. CD73 in Grade 2 and Grade 3 endometrioid endometrial carcinomas (G2 EEC and
G3 EEC) and uterine papillary serous carcinomas (UPSC) were significantly lower. (B) CD73
transcripts were significantly lower in invasive ECs with 50% or more myometrial invasion
compared to non-invasive ECs.

(C) Compared to non-invasive stage IA ECs, CD73 transcripts

were at statistical significance for stage IB and IC ECs (p=0.05) and significantly lower in more
advanced stage ECs (p<0.05). (E) CD73 transcripts were significantly lower in Type II ECs
(p<0.05). (F) Vascular/lymphatic invasion was not a significant determinant of CD73 expression.
Error bars represent ± 1 SE.
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Table 5.5. CD73 expression in established pathological and surgical parameters for EC –
Data summary from Figure 5.5

N

Mean ± SE

Normal Endometrium
N-Endo Proliferative
N-Endo Secretory

9
5

0.0087 ± 0.0015
0.0212 ± 0.0017

Grade
N-Endo Secretory
N-Endo Proliferative
G1 EEC
G2 EEC
G3 EEC
UPSC

5
9
11
17
17
4

0.0212 ± 0.0017
0.0087 ± 0.0015
0.0046 ± 0.0070
0.0037 ± 0.0010
0.0014 ± 0.0005
0.0002 ± 0.0001

Myometrial Invasion
Non-Invasive
<50% Invasion
= or >50% Invasion

5
19
25

0.0064 ± 0.0050
0.0031 ± 0.0010
0.0019 ± 0.0004

c

FIGO
IA
IB & IC
II, III, IV

5
23
21

0.0064 ± 0.0005
0.0026 ± 0.0008
0.0022 ± 0.0006

d

Type I vs Type II
Type I
Type II

28
21

0.0041 ± 0.0007
0.0012 ± 0.0004

e

Vascular & Lymphatic Invasion
Negative
Positive

27
22

0.0033 ± 0.0007
0.0023 ± 0.0006

a

a
a
a,b
a,b
a,b

Data are expressed as mean ± SE molecules of CD73/molecules of 18S ribosomal RNA
aIndicates

significant difference (p<0.05) compared with N-Endo Secretory

bIndicates

significant difference (p<0.05) compared with N-Endo Proliferative

cIndicates

significant difference (p<0.05) compared with Non-Invasive
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d
e

Indicates significant difference (p<0.05) compared with FIGO IA

Indicates significant difference (p<0.05) compared with Type I

Abbreviations and Categories:
G1 EEC, Grade 1 Endometrioid Endometrial Carcinoma
G2 EEC, Grade 2 Endometrioid Endometrial Carcinoma
G3 EEC, Grade 3 Endometrioid Endometrial Carcinoma
UPSC, Uterine Papillary Serous Carcinoma
FIGO, International Federation of Gynecology and Obstetrics
Type I, Grade 1 and Grade 2 endometrioid endometrial carcinoma
Type II, Grade 3 endometrioid endometrial carcinoma and uterine papillary serous carcinoma
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Down-regulation of CD73 is not limited to endometrial cancer
From Figure 5.5 A and Table 5.5, it was observed that uterine papillary serous carcinomas
(UPSC) have very low CD73. This EC histotype is typically very aggressive, associated with
metastatic disease at time of diagnosis, and poor clinical outcome. High grade papillary serous
carcinoma is also a clinically aggressive variant of ovarian carcinoma. Microscopically, ovarian
high grade papillary serous carcinoma (HGPSC) is very similar to uterine papillary serous
carcinoma (UPSC). Therefore, CD73 was also examined in this subtype of ovarian cancer. In
Figure 5.6, HGPSCs have significantly lower CD73, similar to the low values seen in UPSC. This
data highlights that CD73’s importance is not limited to EC.

94

Figure 5.6.

CD73 expression in normal ovary and ovarian high grade papillary serous

carcinoma (HGPSC). CD73 transcript data from qRT-PCR studies of normal ovary and high
grade papillary serous carcinomas (HGPSC) were plotted using a box and whisker plot: bottom
box, 25th percentile; top box, 75th percentile; black bar, 50th percentile (median); whiskers, upper and
lower adjacent; circles, outside fence. CD73 transcript values were normalized to 18S ribosomal
RNA (rRNA) and are presented as molecules of CD73/molecules of 18S rRNA (%18SrRNA).
CD73 transcripts were significantly down-regulated in HGPSC. Error bars represent ± 1 SE.
(*p<0.05)
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Figure 5.6
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Table 5.6.

CD73 expression in normal ovary and ovarian high grade papillary serous

carcinoma (HGPSC) – Data summary from Figure 5.6

N-Ovary
HGPSC

N

Mean ± SE

9
10

0.0146 ± 0.0017
0.0027 ± 0.0005

p value (N-Ovary vs HGPSC)
-0.00006

Data are expressed as mean ± SE molecules of CD73/molecules of 18S ribosomal RNA
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Summary
Generation of extracellular adenosine is important in maintaining homeostasis in normal
epithelial cells. However, this pro-homeostasis function of the purinergic pathway is often times
significantly altered to promote disease pathophysiologies. The purinergic pathway has not been
studied in great detail in cancer. qRT-PCR studies of select members of the purinergic pathway
identified CD73, the primary ecto-enzyme responsible for the generation of extracellular
adenosine, to be the single member significantly dysregulated in EC. CD73 was found to be
significantly down-regulated in moderately- and poorly-differentiated, invasive, and metastatic EC
as compared to normal endometrium, proliferative or secretory, or well-differentiated and noninvasive ECs. CD73 is the primary ecto-enzyme responsible for the generation of extracellular
adenosine. These data suggest that the down-regulation of the homeostatic action of extracellular
adenosine may be important for the progression of this disease. EC is a cancer that arises in the
epithelial cells of the endometrium. The most related pro-homeostasis event of CD73-generated
adenosine to induced barrier function in endothelial cells and intestinal epithelial cells. Barrier
function is a homeostatic event whose actions are directly related to the regulation and maintained
integrity of cell-cell adhesions and their individual proteins. The loss of cell-cell adhesions in
carcinoma cells significantly influences carcinoma cell progression and metastasis. The following
specific aims and their studies address the potential relationship of CD73-generated adenosine is
to induce the homeostatic event of barrier function in epithelial cells of the normal endometrium
and the relatedness of this homeostatic action to inhibit the progression of EC cells, potentially by
regulating cell-cell adhesions.
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CHAPTER SIX
Results
Specific Aim 2.

Demonstrate that CD73-generated adenosine serves a critical barrier

protective role in epithelial cells of the endometrium and that CD73 expression is induced by
known stimuli of barrier function.

Introduction
The barrier function induced by extracellular adenosine is predominantly a response
related to cellular stress. This is best demonstrated by the understanding that mice deficient for
CD73 (205) or A2BR (206) have unremarkable phenotypes at conditions equal to basal
physiology. However, both of these transgenic mice suffer extensive vascular leak and pulmonary
edema when place in hypoxic conditions (205, 206).

Increased production of extracellular

adenosine and its effect on barrier protection is related to the concomitant increase of CD73 and
A2BR by stressors. This increase is related to events such as cytokine release (207), or hypoxiainduced HIF-1 transcriptional activity (204, 210). Studies in specific aim 1 suggest that CD73’s
function in normal endometrium is counterproductive for EC progression, as CD73 transcripts
were found to be significantly down-regulated in moderately- and poorly-differentiated, invasive,
and metastatic ECs as compared to normal endometrium or well-differentiated and/or noninvasive ECs.
Specific aim 2 examines two of the central themes of adenosine’s barrier function: 1.)
adenosine’s barrier function is a product of CD73’s generation of adenosine and its activation of
the adenosine receptor subtype, A2BR; and 2.) adenosine’s barrier function effect is supported by
changes in the expression of purinergic pathway members to support the extracellular
accumulation of adenosine. Sub-aim 2A was intended to establish that CD73-generated adenosine
and A2BR are important to endometrial epithelial barrier function in vivo. To accomplish this
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sub-aim, an in vivo uterine perfusion assay was developed that takes advantage of the electron
dense properties of ruthenium red. Ruthenium red is a low molecular weight dye, 786 daltons,
that binds to cell surface acid polysaccharides (246). With loss of barrier function, ruthenium red
will move into paracellular spaces (229), and this can be visualized using transmission electron
microscopy. This is an established method for measuring the integrity of barrier function of
epithelial cells (229). Mice deficient for CD73 (CD73-/-) or A2BR (A2BR-/-) were used in these
studies alongside with wild-type (C57BL/6) mice. For sub-aim 2B, the ability of the cytokine
transforming growth factor-β1 (TGF-β1) or increased steady-state levels of HIF-1α to increase
CD73 and/or A2BR expression in EC cells was assessed. Sub-aim 2B was intended to investigate
whether EC cells retain the capability to induce CD73 and/or A2BR when stressed and thus
provide the chance to induce barrier function by adenosine. TGF-β1 was used as a way to mimic
the release of cytokines on epithelial cells, as seen in inflammation, and hypoxia was used to
increase the steady-state levels of HIF-1α. HIF-1 is a heterodimer consisting of HIF-1α and HIF1β subunits (247, 248). The biological activity of HIF-1 is determined by the expression and
activity of the HIF-1α subunit (249-251). In response to regain O2 homeostasis in stressed cells,
HIF-1α steady-state levels increase and leads to HIF-1 driven-gene expression (reviewed, (252)).
HIF-1 binding sequences in CD73 and A2BR promoters have been described, and HIF-1 directly
induces CD73 (204) and A2BR (210) expression. TGF-β1 has been established as an inducer of
intestinal epithelial barrier function (188-193). However, TGF-β1’s-mediated barrier function has
not been previously linked to CD73, adenosine, or A2BR expression or activity. This specific aim
is the first to report such findings.
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In vivo CD73 or A2BR deficiency causes loss of barrier function in endometrial epithelial
cells
The results obtained in specific aim 1 suggest that the loss of CD73 function in normal
endometrium and well-differentiated ECs is important for the progression of this disease.
Generation of adenosine at the extracellular surface in normal cell types and tissues is an
important homeostatic response in response to cellular stress. Adenosine’s extracellular activity
induces angiogenesis, vasodilatation, immunosuppression, ischemic pre-conditioning and postconditioning, balancing the oxygen supply/demand ratio, inducing endothelial and epithelial
barrier function, inhibiting superoxide generation, and inhibiting excitatory neurotransmitter
release (reviewed, (184)). We considered that CD73-generated adenosine may be an important
component for barrier function in the normal endometrial epithelium. To determine if CD73 or
A2BR deficiency was associated with the loss of barrier function in endometrial epithelial cells, an
in vivo ruthenium red paracellular permeability assay that takes advantage of the electron density
of ruthenium red was developed. For barrier function stress, 10-14 week old, proestrus phase
mice were maintained in hypoxia conditions (7% O2) for 4 hours. Controls were maintained in
normoxia conditions (room air, 21% O2).

Studies have shown that CD73-/- (205) and A2BR-/-

(206) mice exposed to hypoxia (8% O2) have significant endothelial and intestinal epithelial
barrier disruption within 4 hours. 7% O2 was selected for our studies based on our preliminary
results using varying hypoxic levels (7%, 8%, or 10% O2). Uterine horns were perfused-fixed
with 0.2% ruthenium red and 2% glutaraldehyde. Ruthenium red paracellular permeability was
quantified by assessing approximately 200 consecutive paracellular spaces per uterine section. As
shown in Figure 6.1 and Table 6.1, there were no differences in barrier function in normoxia
conditioned C57BL/6, CD73-/-, and A2BR-/- mice.

In hypoxia, CD73-/- and A2BR-/- mice have

significant increases in ruthenium red paracellular permeability, and thus disrupted barrier
function, compared to their C57BL/6 counterparts. Representative electron photomicrographs
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demonstrating increased ruthenium red paracellular flux in CD73-/- and A2BR-/- mice are shown in
Figure 6.2. As expected, significant increases in paracellular flux were observed in both CD73-/and A2BR-/- mice in the hypoxic conditions compared to normoxia. Depth of ruthenium red
paracellular permeability among groups was not significantly different (Table 6.2).
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Figure 6.1. In vivo ruthenium red paracellular permeability in endometrial epithelial cells of
CD73-/-, A2BR-/- and wild-type (C57BL/6) mice.

10-14

week-old,

proestrus

phase

C57BL/6, CD73-/-, and A2BR-/- mice were placed in normoxia (room air, 21% O2) or hypoxia (7%
O2) conditions for 4 hours. 6-7 mice were studied per group. Uterine horns were perfused-fixed
with 0.2% ruthenium red and 2% glutaraldehyde. Ruthenium red paracellular permeability was
quantified by assessing approximately 200 consecutive paracellular spaces per uterine section.
Percent ruthenium red permeability was determined by the ratio of dye positive to total
paracellular spaces assessed. Individual values are plotted, as well as mean ± 1 SE, for each group.
Barrier function was not significantly different among the normoxia C57BL/6, CD73-/-, and
A2BR-/- mice. However, following exposure to hypoxia, ruthenium red paracellular flux was
significantly increased in CD73-/- and A2BR-/- mice compared to C57BL/6 mice.

This protocol

was modified and adapted from Molitons, BA., Falk, SA., and Dahl, RH., Ischemia-induced loss
of epithelial polarity role of the tight junction, JCI 1989;84:1334-1339 (229) (*p<0.05)
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Figure 6.1
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Table 6.1. In vivo ruthenium red paracellular permeability in endometrial epithelial cells of
CD73-/-, A2BR-/- and wild-type (C57BL/6) mice – Data summary from Figure 6.1

p value (normoxia p value (vs hypoxia
vs hypoxia)
C57BL/6)

Mouse

N

Mean ± SE (%)

a

C57BL/6 normoxia
C57BL/6 hypoxia

6
6

1.82 ± 0.60
7.05 ± 3.36

NS

--

a

CD73-/- normoxia
CD73-/- hypoxia

6
6

9.01 ± 4.36
33.82 ± 7.01

0.01

0.01

a

A2BR-/- normoxia
A2BR-/- hypoxia

7
7

4.7 ± 1.19
22.29 ± 5.60

0.01

0.04

Data are expressed as mean percent ruthenium red paracellular permeability ± SE
aMice

were placed in hypoxia, 7% O2, for 4 hours
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Figure 6.2. Representative electron photomicrographs of in vivo ruthenium red paracellular
permeability in endometrial epithelial cells of CD73-/-, A2BR-/- and wild-type (C57BL/6)
mice. Ruthenium red appears as a black electron dense deposit. Arrows indicate paracellular
space.

No ruthenium red is observed in this paracellular space from a C57BL/6 mouse.

Ruthenium red was frequently observed in the paracellular spaces from both CD73-/- and A2BR-/deficient mice.

Electron photomicrographs magnification, 50,000X.
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Figure 6.2

107

Table 6.2. Depth of ruthenium red paracellular permeability in endometrial epithelial cells
of CD73-/-, A2BR-/-, and C57BL/6 mice

Mouse

N

Mean ± SE

p value
(normoxia vs
hypoxia)

a

C57BL/6 normoxia
C57BL/6 hypoxia

6
6

978.57 ± 212.09
1050.00 ± 215.05

NS

--

a

CD73-/- normoxia
CD73-/- hypoxia

6
6

1126.00 ± 133.35
1522.22 ± 304.62

NS

NS

a

A2BR-/- normoxia
A2BR-/- hypoxia

7
7

1123.07 ± 361.64
1375.00 ± 330.71

NS

NS

p value (vs hypoxia
C57BL/6)

Data are expressed as mean micron depth ± SE of ruthenium red paracellular permeability,
measured from the apical surface to the deepest extent of ruthenium red fluxed down the
paracellular space.
aMice

were placed in hypoxia, 7% O2, for 4 hours
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Barrier function in CD73-/- mice can be rescued by intraperitoneal injection of 5'-Nethylcarboxamidoadenosine (NECA), a stable analog of adenosine
To determine if the barrier protective role in endometrial epithelial cells requires
adenosine generated by CD73, CD73-/- mice were injected intraperitoneally (IP) with 5'-Nethylcarboxamidoadenosine (NECA) 0.1mg/kg or 0.9% NaCl- containing an equal volume of
NECA vehicle, dimethylsulfoxide (DMSO, 0.006%) prior to 4 hour hypoxia exposure. NECA is a
stable analog of adenosine that non-specifically activates adenosine receptor subtypes, including
A2BR. The dosing and administration of NECA to CD73-/- mice was identical to that previously
described (205, 253). A significant reduction of ruthenium red paracellular permeability occurred
with IP NECA injection (Figure 6.3 and Table 6.3).

The ability to rescue barrier disruption in

hypoxia conditioned CD73-/- mice strongly suggest that adenosine is responsible for CD73’s and
A2BR’s observed role in endometrial epithelial barrier function.
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Figure 6.3. Barrier function in CD73-/- mice following intraperitoneal injection of 5'-Nethylcarboxamidoadenosine (NECA). CD73-/- mice were intraperitoneally (IP) injected with 5'N-ethylcarboxamidoadenosine (NECA) 0.1mg/kg or 0.9% NaCl- containing an equal volume of
NECA vehicle, dimethylsulfoxide (DMSO) 0.1ml/20g (DMSO content, 0.006%) prior to being
exposed to hypoxia (7% O2) for 4 hours. IP NECA caused a significant reduction of ruthenium
red paracellular permeability in CD73-/- mice. Error bars represent ± 1 SE. Mice per condition,
n=5. Individual mice are represented by a single triangle. (*p<0.05)

110

Figure 6.3
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Table 6.3. Barrier function in CD73-/- mice can be rescued by intraperitoneal injection of 5'N-ethylcarboxamidoadenosine (NECA) – Data summary from Figure 6.3

a
a

CD73-/-

N

Mean ± SE (%)

p value (saline vs
NECA)

Saline
NECA

5
5

17.6 ± 4.4
4.2 ± 1.4

-0.03

Data are expressed as mean percent ruthenium red paracellular permeability ± SE
aMice

were placed in hypoxia, 7% O2, for 4 hours
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Summary, Sub-aim 2A
In specific aim 1, CD73 was significantly down-regulated in moderately- and poorlydifferentiated, invasive, and metastatic ECs compared to well-differentiated and non-invasive ECs.
This suggested that CD73’s expression in normal endometrium might be related to some important
aspect of normal endometrial epithelial cell function, such as barrier function. It is known that
CD73-generated adenosine and adenosine’s activation of A2BR induces endothelial and epithelial
barrier function in response to cellular stressors. We therefore assessed whether CD73-generated
adenosine may be important for epithelial barrier function in normal endometrium. In mice
deficient for CD73 or A2BR, a significant loss of endometrial epithelial barrier function was
observed when mice were stressed with hypoxia. Barrier function in hypoxia conditioned CD73-/mice was rescued by intraperitoneal injection of NECA, a stable analog for adenosine. These
results suggest that CD73-generated adenosine and adenosine’s activation of A2BR has an
important role in maintaining epithelial barrier function in the normal endometrial epithelium.
This follows the known mechanism of adenosine’s barrier function (Stressor  CD73 
Adenosine  A2BR  Barrier Function).
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Sub-aim 2A examined the central theme that adenosine’s barrier function is a product of
CD73’s generation of adenosine and its activation of the adenosine receptor subtype, A2BR. Subaim 2B examines the central theme that adenosine’s barrier function effect is supported by
changes in the expression of purinergic pathway members to support the extracellular
accumulation of adenosine.

This central theme has been supported by previous studies

demonstrating that cellular stress is associated with cytokine release or increased steady-state
levels of HIF-1α, which lend to the increased expression of members of the purinergic pathway
important for the production (CD39 and CD73) and activity (A2BR) of extracellular adenosine,
while expression of members of the purinergic pathway that are important for the internalization
of extracellular adenosine (ENTs) or its deamination (ADA) are concomitantly down-regulation.
Overall, these events support the accumulation and activity of adenosine at the extracellular
surface.

Transforming growth factor-β1 (TGF-β1) increases transepithelial resistance and CD73
expression in endometrial carcinoma cells, HEC-1A
TGF-βs are ubiquitous cytokines that are multifunctional, and dependent on cell type,
regulate cell proliferation and differentiation, angiogenesis, immune actions, steroidogenesis, and
events central to tissue remodeling and repair (reviewed, (254). TGF-β1 has been established to
increase barrier function in intestinal epithelial cells (188-193). Interestingly, TGF-β1’s barrier
function may be co-dependent on its induction of a cAMP-mediated barrier function (190). cAMP
is a primary secondary messenger of A2BR (179). A direct association of TGF-β1’s barrier
function and adenosine signaling has not been reported, however.

We therefore assessed TGF-

β1’s ability to induce CD73 in an in vitro system. TGF-β1 can induce growth inhibition in
carcinoma cells (tumor suppressor function) or EMT (tumor promotive function). TGF-β1’s
ability to increase barrier function in HEC-1A cells was first assessed.
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TGF-β1 treatment

(2.5ng/ml) significantly increased transepithelial resistance (TER) in HEC-1A monolayers with
increasing time (TGF-β1: 48 Hrs, mean 43.48 ± 10.80%; 72 Hrs, mean 67.40 ± 7.50%; 96 Hrs,
mean 63.03 ± 9.96%; 120 Hrs, mean 58.70 ± 7.50%; 144 Hrs, mean 84.76 ± 13.06%) (Figure 6.4
A). Transepithelial resistance (TER) is an electrophysiological measure of the resistance of the
paracellular pathway within an epithelial monolayer. Increased TER is an indication of increased
barrier function.

These findings suggest that TGF-β1’s activity in HEC-1A cells is tumor

suppressive. This is supported by studies of prolonged TGF-β1 treatment (144 hours), 2.5ng/ml
(255) or 10ng/ml (256), that report TGF-β1 to suppress growth of HEC-1A cells. Likewise,
migration and invasion rates for HEC-1A cells are unaffected following 48 hours of TGF-β1
treatment (255). Similar to TER, with increasing time of TGF-β1 treatment, TGF-β1 significantly
increased CD73 transcripts (Figure 6.4 B). A2BR transcripts were not affected by TGF-β1, and
CD73 transcripts did not increase in a similar fashion (early time points) in TGFβR1 deficient
(222) Ishikawa cells, an endometrial carcinoma cell line (Figure 6.4 C-D). Increased CD73
transcript expression was associated with increased CD73 protein following 72 hours of TGF-β1
treatment (Figure 6.4 E and Table 6.4).
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Figure 6.4. Transforming growth factor-β1’s effects on transepithelial resistance (TER) and
CD73 expression in endometrial carcinoma cells, HEC-1A. (A) Barrier function of HEC-1A
cells treated with 2.5ng/ml of TGF-β1 or an equal volume of the vehicle control, 1mg/ml bovine
serum albumin/4mM hydrochloric acid (BSA/HCl) was determined by measuring transepithelial
resistance (TER).

TGF-β1 significantly increased HEC-1A TER over BSA/HCl treatment at 48,

72, 96, 120, and 144 hours. (B) and (C) qRT-PCR of TGF-β1 (2.5ng/ml) and BSA/HCl treated
HEC-1A cells. (B) CD73 transcripts were significantly increased by TGF-β1 treatment. (C)
A2BR transcripts were not affected by TGF-β1. (D) CD73 transcripts are not induced at the
earlier time points by TGF-β1 (2.5ng/ml) treatment of Ishikawa cells, which are deficient in
TGFβR1. (E) Representative images of CD73 immunofluorescence following 72 hours of TGFβ1 (2.5ng/ml) or BSA/HCl treatment of HEC-1A cells. TGF-β1 or BSA/HCl was added to HEC1A monolayers every 24 hours. Error bars represent ± 1 SE. (*p<0.05, **p<0.005, ***p<0.0005).
Image magnification 20X
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Table 6.4. Relative fluorescence intensity of CD73 in transforming growth factor-β1 (TGFβ1) and vehicle treated endometrial carcinoma cells, HEC-1A

aMean

a

Intensity ± SE
X10,000

p value (BSA/HCl vs
TGF-β1)

Hours

N

0
BSA/HCl
TGF-β1

3
3

350.78 ± 19.92
375.10 ± 22.61

-NS

24
BSA/HCl
TGF-β1

3
3

356.19 ± 21.70
615.02 ± 54.02

-0.0003

48
BSA/HCl
TGF-β1

3
3

321.61 ± 26.01
593.87 ± 46.04

-0.0001

72
BSA/HCl
TGF-β1

3
3

318.19 ± 18.13
715.28 ± 28.31

-0.0000001

Data are expressed as relative mean ± SE fluorescence intensity of CD73 from 3 independent

studies. Relative fluorescence intensity of CD73 was determined by capturing ten 20X images per
treatment group/time interval and assessing integrated density by NIH Image J software.
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TGF-β1’s induction of CD73 occurs through the canonical Smad-mediated signaling
pathway.
TGF-β-induced signaling is mediated by Smad-dependent (canonical) and –independent
(non-canonical) pathways. Non-canonical signaling pathways from TGF-β1’s activation of TGF-β
receptors include Rho-p160Rock, TAK1-p38-MAPK, and Ras-Raf-Mek-Erk-MAPK (reviewed,
(257)). TGF-β1’s induction of barrier function in intestinal epithelial cells is an event that occurs
through TGF-β’s Smad-mediated signaling pathway (192).

To examine whether TGF-β1

treatment of HEC-1A cells was associated with the induction of canonical Smad-mediated
signaling, HEC-1A cells were treated with TGF-β1 (2.5ng/ml) and assessed for Smad2
phosphorylation. With TGF-β1 treatment increased levels of Smad2 phosphorylation at serines
465 and 467 was found, indicating activation of TGFβR1 and Smad-mediated signaling (258-260)
(Figure 6.5). E-cadherin levels did not change with TGF-β1 treatment even at extended time
points, which strongly suggests that HEC-1A cells do not undergo EMT with TGF-β1 treatment.
Similar studies have shown that E-cadherin remains membrane-bound with identical TGF-β1
treatment time points in HEC-1A cells (255).

For TGF-β’s canonical signaling to induce gene

transcription, a heteromeric complex involving phosphorylated Smad2 and Smad3 and a co-Smad
member, Smad4, must assemble (261-263). To determine whether TGF-β canonical signaling
mediates CD73 expression, the cell-permeable pyrrolopyridine compound, SIS3 was used. SIS3
selectively inhibits the phosphorylation of Smad3 to prevent the assembly of the Smad2, 3, and 4
complex which is required for TGF-β-directed gene transcription. Following 12 and 24 hours of
treatment, 1µM SIS3 significantly inhibited the increase of CD73 transcripts typically induced by
TGF-β1 in HEC-1A cells (Figure 6.6 A). SIS3 treatment also led to a decrease in CD73 protein
expression. Representative images following 24 hours of TGF-β1 (2.5ng/ml) and DMSO (SIS3
vehicle) or TGF-β1 (2.5ng/ml) and SIS3 (1µM) treatment are shown in Figure 6.6 B. These
studies indicate that CD73 is induced by TGF-β’s canonical, Smad-mediated signaling pathway.
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Figure 6.5. TGF-β canonical, Smad-mediated signaling in endometrial carcinoma cells,
HEC-1A. HEC-1A cells were treated with 2.5ng/ml of TGF-β1 or an equal volume of the vehicle
control, 1mg/ml bovine serum albumin/4mM hydrochloric acid (BSA/HCl), and assessed by
immunoblotting for TGF-β canonical, Smad-mediated signaling.

TGF-β1 increased Smad2

phosphorylation at serines 465 and 467, indicating TGFβR1 activation and Smad-mediated
signaling. E-cadherin levels did not change, indicating HEC-1A cells do not undergo EMT with
TGF-β1 treatment.
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Figure 6.5
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Figure 6.6.

CD73 expression in endometrial carcinoma cells, HEC-1A, following SIS3

inhibition of TGF-β canonical, Smad-mediated signaling pathway. HEC-1A cells were treated
with 2.5ng/ml of TGF-β1 or an equal volume of the vehicle control, 1mg/ml bovine serum
albumin/4mM hydrochloric acid (BSA/HCl), and 0.001% DMSO or 1μM of the Smad3 inhibitor,
SIS3. (A) Following 12 and 24 hours of treatment, SIS3 significantly inhibits TGF-β1’s increase
of CD73 transcripts measured by qRT-PCR. (B) Representative images of CD73
immunofluorescence following 24 hours of TGF-β1 (2.5ng/ml) and DMSO or TGF-β1 (2.5ng/ml)
and SIS3 (1μM) treatment of HEC-1A cells. Error bars represent ± 1 SE. (*p<0.05, **p<0.005,
***p<0.0005). Image magnification 20X
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Induction of CD73 and A2BR expression by hypoxia in the endometrial carcinoma cells,
HEC-1A and HEC-1B, and cervical carcinoma cells, WISH-HeLa
In hypoxia, CD73 and A2BR expression is induced as much as 6- (204) to 12-fold (210)
and 5-fold (210), respectively, over levels seen during normoxia. Increased steady-state levels of
HIF-1α in conditions of hypoxia are central to the gene expression induced by HIF-1. The
regulation of HIF-1α expression and activity in vivo occurs at multiple levels, including mRNA
expression, protein expression, nuclear localization, and transactivation (reviewed, (252)). Among
these, the most intensively studied has been the regulation of steady-state HIF-1α protein levels.
Under normoxic conditions, HIF-1α is ubiquitinated and subject to proteasomal degradation by
von Hipple-Lindau (VHL), a E3 ubiquitin-protein ligase (264-268). HIF-1 binding sequences in
CD73 and A2BR promoters have been described, and HIF-1 directly induces CD73 (204) and
A2BR (210) expression.

Hypoxia is a characteristic feature of most carcinomas, including

endometrial carcinoma (269-272). HIF-1 targets genes that are particularly relevant to cancer
progression, including those involved in angiogenesis, glucose transport and glycolytic enzymes,
genes involved in survival, and genes important to cancer cell invasion (reviewed, (273)).
Because HIF-1 induces CD73 and A2BR to increase extracellular generation of adenosine and
adenosine’s induction of barrier function in normal tissues stressed by hypoxic, it is possible that
carcinoma cells have selectively lost the ability to induce CD73 and A2BR by HIF-1. This event
would be hypothesized to be important, as maintaining barrier function is counterintuitive to the
progressive of carcinoma cells with hypoxia.

Therefore, we assessed the hypoxia-mediated

induction of CD73 and A2BR in endometrial carcinoma cell lines, HEC-1A and HEC-1B, and in
the cervical carcinoma cell line, WISH-HeLa. Figure 6.7 shows the increased steady-state levels
of HIF-1α in HEC-1A (A), HEC-1B (B), and WISH-HeLa (C) cells with hypoxia (1% O2, 5%
CO2). These data suggest the potential for HIF-1 to induce gene expression in these carcinoma
cells. Using qRT-PCR, CD73 and A2BR expression was measured in HEC-1A, HEC-1B, and
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WISH-HeLa cells exposed to normoxic or hypoxic (1% O2, 5% CO2) conditions for various time
periods. Interestingly, CD73 and A2BR transcripts were unchanged by hypoxia in HEC-1A cells
(Figure 6.8 A-B).

In HEC-1B cells, A2BR transcripts significantly increased at 6, 12, and 24

hours of hypoxia (Figure 6.8 D). CD73 transcripts levels were unchanged with hypoxia in HEC1B cells (Figure 6.8 C).

In WISH-HeLa cells, both CD73 and A2BR transcripts were induced by

hypoxia at 24 hours (CD73) and 4, 6, 12, and 24 hours (A2BR) (Figure 6.8 E-F). These results
indicate that adenosine-induced barrier function in hypoxic endometrial carcinoma cells is
prevented by inhibiting HIF-1’s induction of CD73 and/or A2BR (HEC-1A).
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Figure 6.7. Immunoblots of steady-state HIF-1α in endometrial carcinoma cells, HEC-1A
and HEC-1B, and cervical carcinoma cells, WISH-HeLa, in hypoxia. HEC-1A (A), HEC-1B
(B) and WISH-HeLa (C) cells were exposed to normoxia or hypoxia (1% O2, 5% CO2) for
indicated times and steady-state levels of HIF-1α determined by immunoblots. Expression of
HIF-1α, with hypoxia exposure, was found in HEC-1A, HEC-1B, and WISH-HeLa cells.
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Figure 6.8. CD73 and A2BR expression in endometrial carcinoma cells, HEC-1A and HEC1B, and cervical carcinoma cells, WISH-HeLa, in normoxia and hypoxia. HEC-1A (A-B),
HEC-1B (C-D) and WISH-HeLa (E-F) cells were exposed to normoxia or hypoxia (1% O2, 5%
CO2) for indicated times and CD73 and A2BR expression assessed by qRT-PCR. An increase in
CD73 or A2BR transcripts in HEC-1A cells did not occur with hypoxia (A-B). A2BR transcripts
in hypoxic HEC-1B cells significantly increased at 6, 12, and 24 hours as compared to normoxic
cells at similar time points (D). CD73 transcripts did not increase with hypoxia in HEC-1B cells
(C).

(E) CD73 transcripts in hypoxic WISH-HeLa cells significantly increased at 24 hours

compared to normoxic cells. (F) A2BR transcripts were significantly increase at 4, 6, 12, and 24
hours in hypoxic WISH-HeLa cells. Transcript values were normalized to 18S ribosomal RNA
(rRNA) and are presented as molecules of transcript/molecules of 18S rRNA (%18SrRNA). Error
bars represent ± 1 SE. (*p<0.05)
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Summary – Sub-aim 2B
Sub-aim 2A demonstrated that CD73-generated adenosine and A2BR are important for
endometrial epithelial barrier function. This is consistent with the central theme that stressors,
such as hypoxia, to induce the production of adenosine and adenosine’s barrier function by CD73
activity. Another important role of adenosine mediated barrier function (second central theme)
involves the increased production and activity of adenosine at the extracellular surface of the cell.
This involves the increased expression of members of the purinergic pathway important for the
production (CD39 and CD73) and activity (A2BR) of extracellular adenosine, with concurrent
down-regulation of members of the purinergic pathway that are important for the internalization of
extracellular adenosine (ENTs) or its deamination (ADA). This was the focus of sub-aim 2B and
its studies. Events caused by stressors, such as cytokine release with inflammation and increased
steady-state levels of HIF-1α with hypoxia, are two important events that lend to the increased
expression of CD73 and/or A2BR. Inflammation and hypoxia are persistent stressors of most
carcinoma types, including EC. The cytokine, TGF-β1, was found to induce CD73 by the TGF-β
canonical, Smad-mediated signaling pathway. It was also found that TGF-β1 induced barrier
function in these well-differentiated EC cells.
progression in early stage disease.

TGF-β1 acts as a suppressor of carcinoma

However, becomes a supporting feature for carcinoma

progression in late stage disease. These data raise questions as to whether the barrier function
activities of TGF-β and CD73 are one in the same, and whether TGF-β1’s induction of CD73 and
its adenosine-mediated barrier function is one of the tumor suppressive events of TGF-β signaling
in early disease. These data are the first to describe a relationship between TGF-β1 and CD73 in
non-leukocyte cells. Data involving the increased expression of CD73 and A2BR by hypoxia
suggested that adenosine-induced barrier function in hypoxic endometrial carcinoma cells is
prevented primarily by inhibiting HIF-1’s induction of CD73. Induced expression of A2BR was
significant in HEC-1B and WISH-HeLa cells, however for HEC-1B increased levels of CD73 did
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not occur. This data taken together suggest that inhibiting the induced expression of CD73, which
generally occurs with hypoxia, is sufficient enough to prevent increased adenosine production by
theses carcinoma cells, and thus the induction of barrier function.
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CHAPTER SEVEN
Results
Specific Aim 3. Demonstrate that CD73’s pattern of expression and catalytic activity are
consistent with the proposed role of CD73 in the maintenance of the epithelial phenotype.

Introduction
Adherens junction protein, E-cadherin, is the most recognized cell-cell adhesion protein
that is lost in metastatic carcinomas.

E-cadherin’s ability to induce cell-cell adhesions in

transformed mesenchymal cells and its initiation of cell-cell contacts and adhesion development
has earned E-cadherin the distinction as being the essential caretaker of the epithelial phenotype
(274). However, the formation, establishment, maintenance, and regulation of cell-cell adhesions
are a dynamic process dependent on the presence and coordination of many cell-cell adhesion
proteins and their associated counterparts.

As introduced in this dissertation’s General

Introduction, the aberrant localization or loss of expression of various, non-E-cadherin (“other”)
cell-cell adhesion proteins or their regulators can impact a wide variety of events, including
proliferation and transcriptional control, basolateral receptor activity, polarity, migration and
invasion, and therapeutic sensitivity. These effects indicate that “other” cell-cell adhesion proteins
have significant importance to the epithelial phenotype and carcinoma progression and metastasis.
Therefore, it can be argued that many other proteins, and not just E-cadherin, involved in the
dynamics of cell-cell adhesions are caretakers of the epithelial phenotype.
In vivo studies in specific aim 2 strongly support that CD73-generated adenosine is
important for endometrial epithelial barrier function. Barrier function is a homeostatic event
whose actions are directly related to the regulation and maintained integrity of cell-cell adhesions
and their individual proteins. In the initial steps of the metastatic cascade, carcinoma cells will
shed their prototypical epithelial characteristics, including cell-cell adhesions.
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This action

provides carcinoma cells a phenotype that is more influencing of metastatic behavior. In specific
aim 1, CD73 expression was significantly down-regulated in moderately- and poorlydifferentiated, invasive, and metastatic ECs. The loss of cell-cell adhesion proteins, including Ecadherin (91-94) and occludin (95), is typical among these ECs.

We believe that CD73’s

maintenance of the epithelial barrier and therefore its regulation of cell-cell adhesions is the
contributing reason for CD73’s loss of expression in moderately- and poorly-differentiated,
invasive, and metastatic ECs. For this reason, we considered that if CD73 is central to the
regulation of cell-cell adhesions, and thus a caretaker of the epithelial phenotype, then its
expression in carcinoma cells would likely be lost with the transition from an epithelial to a
mesenchymal phenotype. Such a loss of expression is characteristic of proteins that are involved
in maintaining the epithelial phenotype.
This specific aim was intended to establish the pattern of expression and specific activity
of CD73 in relation to the characteristic change of phenotypes seen in progressive and metastatic
carcinomas. To accomplish this specific aim, cryosections of normal endometrium and ECs of
well- and poorly-differentiated histotypes as well as endometrial carcinoma cell lines that were
representative of varying EMT phenotypes (epithelial-like, epithelial and mesenchymal-like, and
mesenchymal-like) were examined. CD73 expression was also assessed in the cervical carcinoma
cell sub-line, WISH-HeLa, which spontaneously transitions from a mesenchymal to epithelial
phenotype with growth confluency.

137

CD73 expression in proliferative and secretory phase and hormone inactive endometrium is
significantly higher in epithelial cells
Studies in specific aim 2 show that CD73-generated adenosine and A2BR activation are
involved in inducing barrier function in epithelial cells of the endometrium. Studies assessing
CD73’s generation of adenosine and its induction of barrier function in endothelial cells indicate
that endothelial-expressed CD73 is largely responsible for the generation of adenosine that induces
endothelial barrier function (196). We therefore would hypothesize that epithelial cells of the
endometrium would exhibit higher levels of CD73 expression relative to other resident cell types.
CD73’s expression among the cellular components of human endometrium has not been
previously characterized. To investigate the cell type expression pattern of CD73 in the normal
endometrium, cryosections from proliferative and secretory phase and hormone inactive
endometrium were double labeled with CD73 and pan-cytokeratin. Pan-cytokeratin served as an
indicator of epithelial cells. Normal colon was used as a control reference for CD73, as CD73’s
expression pattern in normal colon has been described (275).

CD73 is a glycosyl

phosphatidylinositol (GPI) linked ecto-enzyme that is estimated to be 6-fold higher on the apical
membrane of colonic crypt epithelium, as opposed to the basolateral membrane (275).
Additionally, epithelial expression is higher than that of the surrounding stroma (275). Similar
patterns of expression were observed in our studies when assessing CD73 in normal colon (Figure
7.1 A). These studies validated the CD73 antibody selected and used for the following studies.
In normal endometrium (Figure 7.1 B) a similar pattern of expression for CD73 was seen
that had been described and observed within normal colon. CD73 was highly expressed in
glandular epithelium of proliferative and secretory phase and hormone inactive endometrium.
Stromal cells did express CD73, albeit at a lower intensity. Relative fluorescence intensities for
CD73 in epithelial cells versus that of stromal cells are summarized in Table 7.1, and this data
demonstrates that higher expression of CD73 indeed occurs in glandular epithelial cells. Similar
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to that described and observed within the normal colon, CD73 was found in normal endometrium
to be present at the apical and basolateral membranes, with apical intensity being higher than that
observed for basolateral (Figure 7.1 C). The significant levels of CD73 expression identified in
epithelial cells support the premise that CD73-generated adenosine production mediates barrier
function in epithelial cells of the endometrium.
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Figure 7.1. CD73 and pan-cytokeratin immunofluorescence in proliferative phase, secretory
phase, and hormone inactive endometrium. Cryosections of normal colon and endometrium
were characterized for CD73 expression by immunofluorescence. Normal colon served as a
positive control. Pan-cytokeratin served as a marker of glandular epithelial cells. (A) In normal
colon, membranous CD73 is present in epithelial colonic crypts (arrow). CD73 expression is also
present, at a lower visible intensity, in surrounding stromal cells (asterisk). (B) CD73 was highly
expressed in glandular epithelium (arrows) of proliferative phase, secretory phase, and hormone
inactive endometrium. Stromal cells expressed CD73, but at a lower intensity.

(C) CD73 is

present at the apical and basolateral membranes, with apical intensity of CD73 being visibly
higher than basolateral. Image magnification A and B, 20X; C, 40X.
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CD73’s intensity of expression is retained in well-differentiated endometrial carcinomas,
however lost in poorly-differentiated histotypes
Epithelial-to-mesenchymal transition (EMT) is characterized by the gain of expression of
mesenchymal markers, such as S100A4 and vimentin, and the loss of expression of epithelial
markers, such as E-cadherin and occludin. Well-differentiated ECs, such as Grade 1 endometrioid
endometrial carcinoma (G1 EEC), typically maintain E-cadherin expression and are negative for
S100A4 expression (255, 276).

Poorly-differentiated EC histotypes, Grade 3 endometrioid

endometrial carcinoma (G3 EEC) and uterine papillary serous carcinoma (UPSC), generally
express the mesenchymal marker S100A4 and show absence for E-cadherin expression (255, 276).
To investigate the pattern of CD73 expression in ECs with a phenotype either being more
epithelial-like (well-differentiated, G1 EEC) or more mesenchymal-like (poorly-differentiated, G3
EEC or UPSC), cryosections of differing EC histotypes were double labeled for CD73 and pancytokeratin. Pan-cytokeratin served as an indicator of carcinoma cells. In G1 EEC, CD73 was
expressed in carcinoma cells at a similar intensity to that seen in normal glandular epithelium
(Figure 7.2 and Table 7.1).

In carcinoma cells of poorly-differentiated histotypes, G3 EEC and

UPSC, CD73 expression and intensity of expression was significantly lower than in G1 EEC and
glandular epithelium expression in normal endometrium (Figure 6.2 and Table 6.1). These studies
indicate that CD73’s expression found to be down-regulated in moderately- and poorlydifferentiated, invasive, and metastatic ECs by qRT-PCR is a result of CD73’s down-regulation in
carcinoma cells. These data also support that the hypothesis that the loss of CD73 expression in
poorly-differentiated histotypes is not a product of the overall loss of stromal cells, which occurs
with these EC histotypes. Rather, it is the down-regulation of CD73 in carcinoma cells that
appears to have a significant role in the progression of EC.
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Figure 7.2.

CD73 and pan-cytokeratin immunofluorescence in Grade 1 and Grade 3

endometrioid endometrial carcinoma (G1 EEC and G3 EEC) and uterine papillary serous
carcinoma (UPSC). Cryosections of ECs of differing histotypes were characterized for CD73
expression by immunofluorescence. Pan-cytokeratin served as an indicator of carcinoma cells. In
well-differentiated ECs, G1 EEC, CD73 is expressed in carcinoma cells (arrow) at a similar
intensity to that seen in normal glandular epithelium (Table 7.1). Surrounding stroma was also
positive for CD73 expression (asterisk), but stromal expression was typically weaker.

In

carcinoma cells of poorly-differentiated EC histotypes, G3 EEC and UPSC, CD73 expression and
intensity of expression was significantly lower than that for G1 EEC. Image magnification 20X.
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Table 7.1. Relative fluorescence intensity of CD73 in glandular epithelial cells and stromal
cells in normal endometrium and endometrial carcinoma

a

± SE

p value (epithelial vs
stromal)

p value (N-Endo
epithelial vs
carcinoma)

N

aMean

N-Endo Proliferative
Epithelial
Stromal

2
2

1.68 ± 0.11
1.00

0.02

--

N-Endo Secretory
Epithelial
Stromal

2
2

1.91 ± 0.20
1.00

0.04

--

N-Endo Inactive
Epithelial
Stromal

2
2

1.62 ± 0.08
1.00

0.02

--

G1 EEC
Carcinoma
Stroma/Connective Tissue

2
2

2.03 ± 0.13
1.00

0.001

NS

G3 EEC
Carcinoma
Stroma/Connective Tissue

2
2

1.08 ± 0.05
1.00

NS

0.02

UPSC
Carcinoma
Stroma/Connective Tissue

2
2

1.10 ± 0.19
1.00

NS

0.04

Data are expressed as mean fold fluorescence intensity of CD73 ± SE.

Stromal intensities were set at a baseline of 1.00 and intensity of glandular epithelial cells or
carcinoma cells calculated as fold increase over stromal cells.
Relative fluorescence intensity of CD73 was determined by capturing four 20X images per tissue
sample and assessing integrated density by NIH ImageJ software. A fixed area selection tool was
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used to assess integrated density of glandular epithelial cells or carcinoma cells only and stromal
cells only.
Abbreviations:
G1 EEC, Grade 1 endometrioid endometrial carcinoma; well-differentiated
G3 EEC, Grade 3 endometrioid endometrial carcinoma; poorly-differentiated
UPSC, uterine papillary serous carcinoma; poorly-differentiated
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CD73 expression correlates with an epithelial-like phenotype
Epithelial-to-mesenchymal transition cannot be readily followed in time and space in
human carcinomas. Therefore, much of the work describing the genetic re-programming that
occurs with EMT and the phenotypic changes that are associated with this event have been
characterized with in vitro studies. As previously discussed in the Introduction, loss of proteins
regulating cell-cell adhesions can be associated with EMT. To further characterize whether loss of
CD73 is associated with carcinoma cells shifting from an epithelial-like to a mesenchymal-like
phenotype, as seen with many cell-cell adhesion proteins, CD73 expression was assessed in
endometrial carcinoma cell lines that are representative of differing phases of EMT. These are
indicated as epithelial-like, epithelial and mesenchymal-like, and mesenchymal-like. The term
“like” is used here to emphasize that these carcinoma cell lines do not retain all characteristics
central to an epithelial cell or a mesenchymal cell. Instead, they tend to retain qualities that are
more epithelial (epithelial-like), a combination (epithelial and mesenchymal-like), or more
mesenchymal (mesenchymal-like). These characteristics are represented in Figure 7.3. HEC-1A
cells retain the classic cobblestone morphology of epithelial cells, express membranous Ecadherin, and have no expression of the mesenchymal marker, vimentin. HEC-1A cells are
therefore considered epithelial-like. KLE is considered epithelial and mesenchymal-like for its
cytoplasmic E-cadherin expression and simultaneous vimentin expression. AN3CA is considered
mesenchymal-like with its spindle cell morphology and vimentin expression. AN3CA cells lack
E-cadherin expression. CD73 transcript levels were measured in various endometrial carcinoma
cells that were representative of these three EMT categories. CD73 transcript levels in epitheliallike endometrial carcinoma cells, HEC-1A and HEC-1B, were much higher than those observed in
epithelial and mesenchymal-like endometrial carcinoma cells, KLE, Ishikawa, and ECC-1 (Table
7.2). CD73 transcripts in the mesenchymal-like endometrial carcinoma cells, AN3CA, were
undetectable (Table 7.2).

CD73 protein expression was apparent in the epithelial-like/well-
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differentiated (cobblestone morphology) endometrial carcinoma cells, HEC-1A (Figure 6.4).
CD73 protein expression was found in a few cells of the epithelial and mesenchymal-like EC cells
KLE, and was absent in mesenchymal-like endometrial carcinoma cells, AN3CA. Importantly,
the expression patterns of CD73 in these cell lines mirror that of well-differentiated G1 EEC
(HEC-1A and HEC-1B) and the more poorly differentiated G3 EEC and UPSC (AN3CA), making
these cell lines excellent tools for further in vitro studies.
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Figure 7.3.

Representative endometrial carcinoma cells with epithelial-like, epithelial and

mesenchymal-like, and mesenchymal-like phenotypes. Hematoxylin and eosin stained and Ecadherin and vimentin immunofluorescence of endometrial carcinoma cells, HEC-1A, KLE, and
AN3CA. HEC-1A cells retain characteristics classic of epithelial cells, including cobblestone
morphology and membranous E-cadherin (red) expression. HEC-1A lack expression for the
mesenchymal marker, vimentin (green). KLE cells have an epithelial and mesenchymal-like
phenotype, as they simultaneously express cytoplasmic E-cadherin (red) and vimentin (green).
AN3CA cells are mesenchymal-like, as cells show spindle morphology and express vimentin
(green). AN3CA cells lack E-cadherin (red). Image magnification 40X.
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Figure 7.3
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Table 7.2. CD73 transcripts in endometrial carcinoma cell lines with an epithelial-like,
epithelial and mesenchymal-like, or mesenchymal-like phenotype.

Endometrial Carcinoma
Cells

CD73
Mean ± SE

Phenotype

HEC-1B

0.2664 ± 0.030

Epithelial

HEC-1A

0.1445 ± 0.009

Epithelial

KLE

0.0328 ± 0.004

Epithelial-Mesenchymal

ECC-1

0.0057 ± 0.006

Epithelial-Mesenchymal

Ishikawa

0.0016 ± 0.000

Epithelial-Mesenchymal

AN3CA

0.0000 ± 0.000

Mesenchymal

Data are expressed as mean ± SE molecules of CD73/molecules of 18S ribosomal RNA
Endometrial Carcinoma Cell Origin:
HEC-1B, Grade 2 endometrial endometrioid carcinoma (277)
HEC-1A, Grade 2 endometrial endometrioid carcinoma (277)
KLE, Grade 2, FIGO Stage III endometrial endometrioid carcinoma (228)
ECC-1, passing of a well-differentiated endometrial carcinoma in nude mice (278)
Ishikawa, Grade 1 endometrial endometrioid carcinoma (279)
AN3CA, lymph node metastasis of an undifferentiated endometrial carcinoma (280, 281)
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Figure 7.4. CD73 immunofluorescence in endometrial carcinoma cells with epithelial-like,
epithelial

and

mesenchymal-like,

or

mesenchymal-like

phenotypes.

CD73

immunofluorescence in epithelial-like endometrial carcinoma cells, HEC-1A, epithelial and
mesenchymal-like endometrial carcinoma cells, KLE, and mesenchymal-like endometrial
carcinoma cells, AN3CA. HEC-1A cells express membranous CD73. KLE express CD73 in a
few cells. CD73 expression in AN3CA is absent. Image magnification 20X
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Figure 7.4
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WISH-HeLa, a cervical carcinoma cell sub-line, spontaneously transitions from a
mesenchymal-like phenotype to an epithelial-like phenotype with increasing cell confluency
WISH (Wistar Institute Susan Hayflick) is an epithelial cell line originally derived from
human amnion epithelium (282, 283). However, later it was discovered to be contaminated with
the cervical carcinoma cell line, HeLa (Henrietta Lacks) (284). WISH-HeLa are described to
retain characteristics both of amnion epithelium and that of a transformed state (285). With
changing density of WISH-HeLa cells (as they become increasingly confluent), the phenotype of
the cells transitions from mesenchymal-like (spindle morphology) to epithelial-like (cobblestone
morphology) (Figure 6.5 A) This change was not due to cell crowding effects that occur with
extreme cell density, as this transformation was clearly seen at 90% confluency. In determining
the relative area and perimeter of WISH-HeLa cells at the indicated confluencies, epithelial-like
confluencies (90% and 100% confluency) and mesenchymal-like confluencies (50% and 70%
confluency) are distinct (Figure 6.5 B). Likewise, cell-cell adhesion expression varies between the
mesenchymal-like and epithelial-like confluencies. E-cadherin protein expression was absent at
70% confluence, but was detectable at 100% confluency (Figure 6.5 C). Though collectively
WISH-HeLa cells do not undergo a complete transition from a mesenchymal to an epithelial
phenotype, as can be seen by cytoplasmic displaced E-cadherin and simultaneous expression of
vimentin, a few patches of cells do appear to completely convert phenotypes. This is shown by
representative images of WISH-HeLa cells at 2 day post-confluency (Figure 6.5 C). Membrane
expressed E-cadherin is observed with simultaneous loss of vimentin. In addition, the transcript
levels of tight junction member and mediator of barrier function, claudin-1, increases significantly
at epithelial-like confluencies (Figure 6.5 D). A2BR transcripts remained unchanged with the
changing WISH-HeLa cell confluencies (Figure 6.5 E). This finding highlights that increased
gene expression (CD73 and claudin-1) seen with increasing WISH-HeLa cell confluencies is not a

156

global occurrence. To our knowledge, this is the first study to describe the phenotypic and
genotypic changes associated with WISH-HeLa cell confluency.
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Figure 7.5. Spontaneously transitioning, mesenchymal-to-epithelial, cervical carcinoma cell
sub-line, WISH-HeLa, and cell confluency.

(A) Hematoxylin and eosin staining of WISH-

HeLa cells at varying cell confluencies. A mesenchymal-like phenotype is seen at 50% and 70%
confluencies, as indicated by the spindle morphology of the cells.

At 90% confluency the

transition of phenotypes is apparent by the appearance of cobblestone morphology in selected cells
and retention of the spindle morphology in other cells. Change in phenotypes, mesenchymal-like
to epithelial-like, is not the result of cell crowding. (B) Relative perimeter and area of WISHHeLa cells were measured at indicated confluencies.

Mesenchymal-like (50% and 70%

confluencies) and epithelial-like (90% and 100% confluencies) confluencies are distinct. (C) Ecadherin immunofluorescence is absent from WISH-HeLa cells at 70% confluency. Cytoplasmic
expression of E-cadherin is seen at 100% confluency. A few cells appear to undergo complete
mesenchymal-to-epithelial transition at 2 day post-confluency as indicated by membrane
expressed E-cadherin (inset) and concurrent loss of vimentin (inset, asterisk). (D) qRT-PCR of
WISH-HeLa cell confluencies show transcript levels for tight junction member and barrier
function mediator, claudin-1, to increase significantly in the confluencies that are most epitheliallike. (E) A2BR transcripts remained unchanged among the WISH-HeLa cell confluencies. Error
bars represent ± 1 SE. Image magnification 20X
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CD73 is highly expressed in the epithelial-like phenotype of WISH-HeLa
The studies of this specific aim thus far have demonstrated an apparent correlation
between CD73 expression and the epithelial phenotype of carcinoma cells. To establish this direct
association, we took advantage of the mesenchymal and epithelial growth patterns of WISH-HeLa
and evaluated CD73. Similar to claudin-1, CD73 transcripts increased significantly at epitheliallike confluencies, 100%, 2 day post-confluency, and 4 day post-confluency (Figure 7.6 A). CD73
transcripts were highly and positively correlated with those of claudin-1 transcripts (Figure 7.6 B
and Table 7.3). CD73’s protein expression was also apparent in the regions of WISH-HeLa cells
with the epithelial-like phenotype (90% confluency) (Figure 7.6 C). These studies suggest that
epithelial CD73 expression is involved in regulating essential features of the epithelial phenotype,
such as cell-cell adhesions.
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Figure 7.6. CD73 expression in spontaneously transitioning cervical carcinoma cell sub-line,
WISH-HeLa. (A) CD73 and (B) A2BR transcript levels were assessed by qRT-PCR in WISHHeLa at increasing confluencies. (A) CD73 transcripts significantly increased at epithelial-like
confluencies, 100%, 2 Day Post-Confluency, and 4 Day Post-Confluency. (B) CD73 protein
expression is apparent in the regions of WISH-HeLa cells with the epithelial-like phenotype (90%
confluency). 90% confluency image, mesenchymal-like cells are located above the dashed line.
Error bars represent ± 1 SE. Image magnification 20X.
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Table 7.3. Correlation coefficient for CD73 and Claudin-1 in spontaneously transitioning
cervical carcinoma cell sub-line, WISH-HeLa

WISH-HeLa

Pearson's
Correlation Coefficient

p

0.796

0.00003

CD73 vs Claudin-1
Transcripts
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Endometrial expressed CD73 is catalytically active and its specific activity is highly
correlated to its level of expression
It is generally accepted that CD73’s catalytic activity, the production of adenosine, is its
primary function and is central to adenosine-mediated barrier function. Non-catalytic activities,
including mediating cell-extracellular matrix (EMC) adhesions (163, 164), have only been briefly
described. This specific aim has shown thus far that epithelial cells of normal endometrium and
carcinoma cells of well-differentiated ECs maintain relatively similar levels (high intensity) of
CD73 expression. This suggests that CD73-generated adenosine and adenosine’s barrier function
may be functioning to inhibit the progression of these well-differentiated ECs to more poorlydifferentiated and invasive ECs that are more aggressive (metastatic in nature). The primary
mechanism in which CD73 contributes to epithelial barrier function is through the catalytic
production of adenosine from the phosphohydrolysis of AMP. Studies in this dissertation thus far
have demonstrated that CD73-generated adenosine induces barrier function in epithelial cells of
the endometrium (in vivo model) and that CD73 is primarily expressed in epithelial cells of the
normal endometrium.

Our data suggest that CD73 plays a major role in the generation of

adenosine and that adenosine mediates increased barrier function, which functions to inhibit EC
progression, so it is relevant to demonstrate that normal endometrium and EC expressed CD73 is
catalytically active. To determine this, the specific activity of CD73 was assessed in normal
endometrium, well- and poorly-differentiated ECs, and endometrial carcinoma cells, HEC-1A,
KLE, and AN3CA by reverse phase high performance liquid chromatography (RP-HPLC). CD73
specific activity was determined by incubating samples with AMP or AMP and CD73 catalytic
inhibitor, α, β-methylene diphosphate (AoPCP), or by heat inactivation of CD73. A representative
chromatogram (Figure 7.7 A) shows the retention times and peaks for AMP and adenosine which
are typical of a nucleotidase (CD73) assay.

Similar to the patterns of qRT-PCR and

immunofluorescent expression for CD73, CD73’s specific activity was the highest in normal
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endometrium (N-Endo) and Grade 1 endometrioid endometrial carcinomas (G1 EEC) and
significantly lower in Grade 3 endometrioid endometrial carcinomas (G3 EEC) (Figure 7.7 C and
Table 7.4). A representative modified chromatogram demonstrates the adenosine peaks of a single
sample each of N-Endo, G1 EEC, and G3 EEC samples following incubations of AMP (green)
AMP and AoPCP (black) or heat inactivation (blue) (Figure 7.7 B). Importantly, the data clearly
show that expressed CD73 in N-Endo, G1 EEC, and G3 EEC can function catalytically to produce
adenosine. Amongst endometrial carcinoma cells, representative of epithelial-like (HEC-1A),
epithelial and mesenchymal-like (KLE), and mesenchymal-like (AN3CA), the catalytic activity of
CD73 was associated with levels of protein expression (Figure 7.8 and Table 7.5). For ECs and
endometrial carcinoma cells, a significant correlation was observed between CD73 transcript
levels and CD73 enzymatic activity (Figure 7.9 and Table 7.6).
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Figure 7.7. CD73 specific activity in normal endometrium and endometrial carcinomas.
CD73 specific activity was determined by reverse phase high performance liquid chromatography
(RP-HPLC) in normal endometrium and endometrial carcinomas, G1 EEC and G3 EEC.
Adenosine production was measured at an absorbance of 260nm.
chromatogram with peaks typical of a nucleotidase assay.

(A) Representative

Retention times for AMP and

adenosine are 8 minutes and 13 minutes, respectively. CD73 specific activity was determined by
using heat inactivation (blue line, chromatogram) and a catalytic inhibitor, α,β-methylene
diphosphate (AoPCP) (black line, chromatogram) (B) Modified chromatograms representing
adenosine peaks of a representative sample of N-Endo, G1 EEC, and G3 EEC following
incubation with AMP, AMP and AoPCP, or undergoing heat inactivation. CD73 specific activity
was calculated by subtracting heat inactivated and AMP and AoPCP values from AMP samples.
Y axis is relative. An adenosine standard was run prior to this study and used to obtain plotted
values shown in (C). (C) Data were plotted using box and whisker plots (bottom box, 25th
percentile; top box, 75th percentile; black bar, 50th percentile (median)).

Specific activity for

CD73 was significantly lower in G3 EECs. Error bars represent ± 1 SE. (*p<0.05)

169

Figure 7.7
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Table 7.4. CD73 specific activity in normal endometrium and endometrial carcinomas –
Data summary from Figure 7.7 C

N

a

aMean

± SE

p value (vs
N-Endo)

N-Endo

2

44.38 ± 21.18

--

G1 EEC

3

20.01 ± 8.44

NS

G3 EEC

3

4.07 ± 1.47

0.02

Data are expressed as mean pmol Adenosine / min / mg

Abbreviations:
N-Endo, histologically normal endometrium
G1 EEC, Grade 1 endometrioid endometrial carcinoma; well-differentiated
G3 EEC, Grade 3 endometrioid endometrial carcinoma; poorly-differentiated
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Figure 7.8.

CD73 specific activity in endometrial carcinoma cells, HEC-1A, KLE, and

AN3CA. CD73 specific activity was determined by reverse phase high performance liquid
chromatography (RP-HPLC) in endometrial carcinoma cells with an epithelial-like (HEC-1A),
epithelial and mesenchymal-like (KLE), and mesenchymal-like (AN3CA) phenotype. (A) Data
were plotted using a box and whisker plots: bottom box, 25th percentile; top box, 75th percentile;
black bar, 50th percentile (median); whiskers, upper and lower adjacent. Specific activity for
CD73 was significantly lower in KLE and AN3CA cells compared to HEC-1A. Error bars
represent ± 1 SE. (*p<0.05)
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Figure 7.8
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Table 7.5.

CD73 specific activity in endometrial carcinoma cells, HEC-1A, KLE, and

AN3CA – Data summary from Figure 7.8

a

± SE

p value (vs
HEC-1A)

N

aMean

HEC-1A

3

18.62 ± 0.89

--

KLE

3

4.67 ± 0.33

0.000005

AN3CA

3

0.06 ± 0.01

0.000001

Data are expressed as mean pmol Adenosine / min / mg

Phenotype:
HEC-1A, epithelial-like
KLE, epithelial-mesenchymal-like
AN3CA, mesenchymal-like
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Figure 7.9. CD73 transcripts and specific activity correlations in normal endometrium,
endometrial carcinomas, and endometrial carcinoma cells. CD73 transcript levels and CD73
specific activity were simultaneously graphed and assessed for linear (R2) values. (A) CD73
transcript levels and CD73 specific activity of normal endometrium (N-Endo) and well- and
poorly-differentiated ECs, Grade 1 and 3 endometrioid endometrial carcinoma (G1 EEC and G3
EEC). Linear values show a high correlation, Pearson’s correlation coefficient, 0.968; p=0.00008.
(B) CD73 transcript levels and CD73 specific activity of epithelial-like endometrial carcinoma
cells,

HEC-1A,

epithelial-mesenchymal-like

endometrial

carcinoma

cells,

KLE,

and

mesenchymal-like endometrial carcinoma cells, AN3CA. Linear values show a high correlation,
Pearson’s correlation coefficient, 0.991; p=0.0000002.
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Table 7.6.

CD73 transcripts and specific activity correlations in normal endometrium,

endometrial carcinomas, and endometrial carcinoma cells – Data summary from Figure 7.9

Pearson's
Correlation Coefficient

p

N-Endo, G1 EEC, G3 EEC

0.968

0.00008

HEC-1A, KLE, AN3CA

0.991

0.0000002

Abbreviations:
N-Endo, histologically normal endometrium
G1 EEC, Grade 1 endometrioid endometrial carcinoma; well-differentiated
G3 EEC, Grade 3 endometrioid endometrial carcinoma; poorly-differentiated
Phenotype:
HEC-1A, epithelial-like
KLE, epithelial-mesenchymal-like
AN3CA, mesenchymal-like
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CD73’s catalytic activity is localized primarily to normal epithelial and well-differentiated
carcinoma cells, however it is lost in carcinoma cells of poorly-differentiated histotypes
To determine the localization of CD73’s catalytic activity the normal endometrium and
endometrial carcinomas, a lead sulfide method was used to observed the precipitated byproduct
(hydrolyzed phosphate) of CD73’s phosphohydrolysis of AMP (231). A detailed schematic of this
enzyme histochemistry method is shown in Figure 7.10. Similar to the protein expression pattern
seen for CD73 in normal endometrium, glandular epithelium exhibited the most apparent catalytic
activity for CD73 (Figure 7.11). Strong catalytic activity was also found in carcinoma cells of
Grade 1 endometrioid endometrial carcinomas (G1 EEC), which is similar to that seen for its
protein expression. CD73 catalytic activity in Grade 3 endometrioid endometrial carcinomas (G3
EEC) and uterine papillary serous carcinomas (UPSC) was lower than that of N-Endo or G1 EEC.
Most of the catalytic activity for CD73 in G3 EEC and UPSC is found in the surrounding
stroma/connective tissue. As was expected, endometrial carcinoma cells showed CD73 catalytic
activity (relatively high or low) that was comparative to CD73’s protein expression seen within
these cells (Figure 7.12). Higher CD73 catalytic activity was found in epithelial-like endometrial
carcinoma cells (HEC-1A and HEC-1B), as compared to endometrial carcinoma cells that were
epithelial-mesenchymal-like (KLE) or mesenchymal-like (AN3CA). Importantly, CD73 activity
is greatly apparent at the membrane of the epithelial-like (well-differentiated) carcinoma cells.
These data taken together support that normal epithelial cell or well-differentiated carcinoma cellexpressed CD73 functions to produce adenosine, which mostly likely induces barrier function. In
well-differentiated ECs this may be a feature that restricts the migration and invasiveness of the
carcinoma cells. The following specific aim (Specific Aim 4) addresses this potential.
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Figure 7.10. Enzyme histochemistry reaction for CD73. Tissue or carcinoma cell expressed
CD73’s phosphohydrolysis of AMP can be visibly viewed and cellular localization determined by
precipitation of the hydrolyzed phosphate from AMP by a lead sulfide method. This technique
was modified from Wachstein, M. and Meisel, E., Histochemistry of hepatic phosphatase at a
physiological pH with special reference to the demonstration of bile canaliculi, Am. J. Clin.
Pathol. 1957;27:13-23 (231).
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Figure 7.10
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Figure 7.11. CD73 enzyme histochemistry in normal endometrium, well-differentiated and
poorly-differentiated endometrial carcinomas. (A) Cryosections of normal endometrium and
endometrial carcinomas were microscopically examined for localization of CD73’s catalytic
activity using enzyme histochemistry.

Catalytic activity of CD73 is highest in glandular

epithelium of normal endometrium (N-Endo). Relatively high catalytic activity also occurs in G1
EEC, with lower activity in G3 EEC and UPSC.

Much of the CD73 activity seen in G3 EEC and

UPSC is present in surrounding stromal cells/connective tissue.

Image magnification 20X.

Arrows indicate glandular epithelial cells (N-Endo) or carcinoma cells (G1 EEC, G3 EEC, UPSC)
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Figure 7.11
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Figure 7.12. CD73 enzyme histochemistry in endometrial carcinoma cells. CD73’s catalytic
activity was assessed in endometrial carcinoma cells with an epithelial-like (HEC-1B and HEC1A), epithelial-mesenchymal-like (KLE and ECC-1), and mesenchymal-like (AN3CA) phenotype.
(A) CD73 catalytic activity is higher in HEC-1B and HEC-1A, than in KLE. CD73’s catalytic
activity is primarily localized to the membrane in these cells. (B) CD73 catalytic activity in
epithelial-mesenchymal-like (ECC-1) and mesenchymal-like (AN3CA) endometrial carcinoma
cell lines.

CD73 catalytic activity is low to absent in ECC-1 and AN3CA cells.

magnification 10X.
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Image

Figure 7.12
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Summary
Characterizing the expression pattern of CD73 in resident cells of the normal
endometrium and endometrial carcinomas is important to establishing the significance of CD73
down-regulation in EC. Specific aim 1 studies have shown that CD73 is down-regulated in
moderately- and poorly-differentiated, invasive, and metastatic ECs compared to normal
endometrium and well-differentiated ECs. Data from this specific aim has established that the
primary expression of CD73 is within epithelial cells of the normal endometrium. This high
expression seen in epithelial cells of the normal endometrium was similar to levels seen among
carcinoma cells of well-differentiated ECs

Published studies have demonstrated that well-

differentiated ECs typically retain expression of cell-cell adhesion proteins, such as E-cadherin,
and are generally non-invasive ECs. Most importantly, data shown herein demonstrate that the
loss of CD73 expression in poorly-differentiated histotypes occurs within the carcinoma cells. In
vitro data has clearly established that CD73 expression is related and highly correlated to an
epithelial phenotype of endometrial and cervical carcinoma cells. Epithelial- and carcinomaexpressed CD73 appears to be a caretaker of the epithelial phenotype.

This caretaker

responsibility is likely related to the impact CD73-generated adenosine elicits upon cell-cell
adhesions and their individual proteins. The generation of adenosine by CD73 is the primary
feature of adenosine-mediated barrier function. Results obtained using RP-HPLC and enzyme
histochemistry have confirmed that CD73 expressed in normal endometrium and ECs is
catalytically active.
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CHAPTER EIGHT
Results
Specific Aim 4. Show that CD73-generated adenosine and adenosine’s activation of A2BR
inhibit the migration and invasion of endometrial carcinoma cells.

Introduction
Of the many effects the loss of cell-cell adhesions have on carcinoma cells, the increased
potential for carcinoma cells to migrate and invasive may be among the most concerning. Of all
cancer related mortalities, 90% are related to the dissemination of cancer cells. The process of
carcinoma cell migration and invasion is understood as the movement of individual cancer cells or
groups of cancer cells from the primary site of origin to entering into lymphatic vessels or the
bloodstream, ultimately seeding in a distant tissue or organ (286). Carcinoma cell migration and
invasion are regulated by a broad spectrum of activated proteins and motility-impacting events
including the expression and outside-in signaling of integrins, activation of matrix-degrading
proteinases, such as members of the matrix metalloproteinase family, (MMPs), cell-cell
communication, and loss of cell-cell adhesions (reviewed, (287)). The loss of cell-cell adhesions
in carcinoma cells has a great impact on the expression and activity of many of these migration
and invasion-promoting events and proteins. As for example, loss of cell-cell adhesion proteins
cause polarity proteins to be displaced within the cell, which are freely recruited by TGF-β, PI3K,
and Wnt signaling to establish front-rear polarization, an event important for cell migration
(reviewed, (75)). Loss of the cell-cell adhesion protein, E-cadherin, and its adhesion dependent
suppression of EGFR results in the up-regulation of integrins, including as α5β1-integrin, via the
EGFR/focal adhesion kinase (FAK) MAPK-dependent signaling pathway (288) and expression of
matrix metalloproteinases, including MMP-9 (289-291), which are proteins important in
carcinoma cell migration (focal adhesion formation) and disruption of the surrounding
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extracellular matrix. The loss of cell-cell adhesions therefore contributes significantly to creating
the ideal molecular and environmental conditions needed for carcinoma cells migration and
invasion.
Specific aim 1 and specific aim 2 demonstrated that CD73-generated adenosine is
important to maintaining endometrial barrier function (specific aim 2) and that CD73 is
significantly down-regulated in moderately- and poorly-differentiated, invasive, and metastatic
ECs (specific aim 1). Importantly, specific aim 3 demonstrated that epithelial cell/carcinoma cell
expressed CD73 is catalytically active, and that such catalytically active CD73 is preferentially
expressed in epithelial cells compared to adjacent stromal cells. These data support the theory that
CD73-generated adenosine and adenosine’s activation of A2BR function to inhibit the
progression of ECs, potentially by influencing cell-cell adhesions and their individual proteins.
An interesting point to consider is that adenosine-mediated induction of barrier function occurs
most generally as a response to cellular stress. Cellular stressors are common among all cancers.
Carcinoma cells are known to constantly experience hypoxia regardless of stage of disease.
Likewise, hypoxia is a known promoter of molecular and cellular events that promote
aggressiveness and invasiveness of carcinoma cells. This is particularly true for EC (269, 270,
292, 293). Maintaining barrier function in hypoxic stressed carcinoma cells is counteractive to the
hypoxia-induced progression of EC. Therefore, we hypothesized that hypoxia-induced tissue
protective events, such as CD73-generated adenosine’s barrier function, which in normal tissues
are necessary to maintain homeostasis, would need to be down-regulated in EC for the carcinoma
cells to progress (migration and invasion). This specific aim examines the potential of CD73,
CD73’s generation of adenosine, and adenosine’s activation of A2BR to inhibit the migration and
invasion of well-differentiated EC cells. To accomplish this specific aim, the established in vitro
modified and unmodified two-chamber migration and invasion assay system was used (233).
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These are well-documented in vitro assays for quantitating the migratory or invasive potential of
tumor cells.
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Hypoxia significantly inhibits the migration and invasion of endometrial carcinoma cells,
HEC-1A and HEC-1B
Carcinoma cells are consistently subjected to varying levels of hypoxia in vivo. Such
hypoxic conditions contrast greatly with the culture conditions routinely used for carcinoma cell
experiments in vitro.

Hypoxia impacts various aspects of carcinoma cell progression and

metastasis, including immortalization, transformation, genetic instability, angiogenesis, invasion,
metastasis, and therapy resistance. In EC, the relevance of hypoxia in both well-differentiated
(Grade 1 endometrioid endometrial carcinomas) and poorly-differentiated (Grade 3 endometrioid
endometrial carcinomas) ECs has been established (269, 270, 292, 293). Since CD73-generated
adenosine and adenosine’s barrier function effect is related to hypoxic stress, the relative
migration and invasion of CD73 expressing endometrial carcinoma cells, HEC-1A and HEC-1B,
were assessed under normoxic and hypoxic (1% O2, 5% CO2) conditions. Recall that in specific
aim 2, Figure 6.7., we showed that hypoxia increases steady-state levels of HIF-1α in these cells.
Hypoxic conditions significantly inhibited the migration of HEC-1A cells (Figure 8.1 A and Table
8.1) and migration and invasion of HEC-1B cells (Figure 8.1 A-B and Table 8.1). HEC-1A cells
were not studied for invasion due to the too few numbers of cells that would invade to accurately
quantify. As shown by Annexin V studies in Figure 8.2 and Table 8.2, the decrease in HEC-1A
(A) migration and HEC-1B (B) migration and invasion was not attributed to increased cell death
from hypoxia. No statistical differences in cell death between normoxic and hypoxic conditions
were observed for either migration (24 hours) or invasion (36 hours) endpoints. These data
suggest the potential of CD73’s generation of adenosine to be inhibiting EC cell migration and
invasion.
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Figure 8.1.

HEC-1A migration and HEC-1B migration and invasion in normoxic and

hypoxic conditions. CD73 expressing endometrial carcinoma cells, HEC-1A (A) and HEC-1B
(B,C), were placed in normoxic or hypoxic (1% O2, 5% CO2) conditions along with 50µM of
5’AMP. Hypoxia significantly inhibited HEC-1A migration and HEC-1B migration and invasion.
Representative photomicrographs from each experiment are shown alongside graphs. Error bars
represent ± 1 SE. Image magnification 10X. (*p<0.05)
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Table 8.1.

HEC-1A migration and HEC-1B migration and invasion in normoxic and

hypoxic conditions – Data summary from Figure 8.1

bN

aMean

± SE

p value (vs
normoxia)

HEC-1A - Migration

a

Normoxia
Hypoxia

3
3

43.17 ± 3.41
9.92 ± 1.92

-0.00000002

HEC-1B - Migration
Normoxia
Hypoxia

3
3

249.67 ± 8.91
156.33 ± 4.25

-0.00000000002

HEC-1B - Invasion
Normoxia
Hypoxia

3
3

146.93 ± 10.68
69.73 ± 8.07

-0.00000005

Data are expressed as mean cell number of migrated or invaded cells in a 10X field ± SE

b

N represents the number of migration or invasion inserts per condition
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Figure 8.2. Representative histograms of Annexin V at migration and invasion endpoints in
normoxic and hypoxic endometrial carcinoma cells, HEC-1A and HEC-1B. Cell death was
determined by Annexin V flow cytometry at migration and invasion endpoints in normoxic and
hypoxic (1% O2, 5% CO2) endometrial carcinoma cells, HEC-1A (A) and HEC-1B (B). Endpoints
for migration and invasion were 24 and 36 hours, respectively.

No significant differences in cell

death between normoxia and hypoxia for HEC-1A or HEC-1B were detected.
summarized from triplicate experiments in Table 8.2.
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Data are

Figure 8.2 A
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Figure 8.2 B
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Table 8.2.

Representative histograms of Annexin V studies at migration and invasion

endpoints in normoxic and hypoxic endometrial carcinoma cells, HEC-1A and HEC-1B –
Data summary from Figure 8.2

Normoxia
bN

a

aMean

± SE

Hypoxia
aMean

± SE

p value (vs
normoxia)

HEC-1A - 24 Hours
Live Cells
Dead Cells

3
3

71.90 ± 0.87
28.16 ± 1.80

71.37 ± 0.70
28.67 ± 1.62

NS
NS

HEC-1A - 36 Hours
Live Cells
Dead Cells

3
3

75.07 ± 2.08
24.96 ± 2.22

72.60 ± 3.06
27.41 ± 3.73

NS
NS

HEC-1B - 24 Hours
Live Cells
Dead Cells

3
3

65.07 ± 5.26
34.94 ± 3.32

63.11 ± 5.26
36.90 ± 1.82

NS
NS

HEC-1B - 36 Hours
Live Cells
Dead Cells

3
3

74.90 ± 8.21
25.11 ± 1.21

68.55 ± 6.14
31.46 ± 2.12

NS
NS

Data are expressed as mean live cells or dead cells in normoxia or hypoxia ± SE

b

N represents the number of samples per condition
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Silencing CD73 by siRNA significantly increases the migration and invasion of hypoxic
endometrial carcinoma cells, HEC-1A and HEC-1B
Hypoxia significantly inhibits the migration and invasion of CD73 expressing endometrial
carcinoma cells. To determine if CD73 was responsible for the inhibiting effects we observed,
CD73 expression was inhibited in the endometrial carcinoma cell lines HEC-1A and HEC-1B by
siRNA transfection. siRNA silencing of HEC-1A cells significantly decreased CD73 transcript
levels, at 24 hours post-transcription, to roughly 10% of that of the non-targeting siRNA control
(Figure 8.3 A). Proliferation of HEC-1A cells was unaffected by silencing CD73 (Figure 8.4 B).
Similar to CD73 transcript levels, CD73’s protein expression was significantly lower, by 72 hours
post-transfection, in HEC-1A cells treated with siRNA compared to the non-targeting siRNA
control (Figure 8.3 C). In the two-chamber migration and invasion studies, CD73 silencing
significantly affected the migration and invasion of the endometrial carcinoma cells. As shown in
Figure 8.4 A, HEC-1A cells targeted with CD73 siRNA exhibited increased cell migration as
compared to non-targeting siRNA control treated cells. Following CD73 silencing by siRNA, an
increase in cell migration (Figure 8.4 B) and invasion (Figure 8.4 C) was observed in HEC-1B
cells, as compared to non-targeting siRNA control treatments. Data for Figure 8.4 are summarized
in Table 8.3. These data suggest that the cell migration and invasion inhibitory effects initially
observed with hypoxia are due, at least in part, to CD73.
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Figure 8.3. Effects of CD73 silencing by siRNA in endometrial carcinoma cells, HEC-1A.
(A) CD73 transcript expression in HEC-1A cells was assessed by qRT-PCR following incubation
with non-targeting siRNA or 1247 CD73 siRNA. CD73 transcript levels were significantly
suppressed by 24 hours compared to the control groups. (B) HEC-1A cell proliferation following
incubation with non-targeting siRNA or 1247 CD73 siRNA. Proliferation remained unchanged
with CD73 silencing. (D) CD73 immunofluorescence in HEC-1A cells following incubation with
non-targeting siRNA or 1247 CD73 siRNA. CD73 protein was reduced in the CD73 siRNA
treated cells. Error bars represent ± 1 SE. Image magnification 10X . (*p<0.05)
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Figure 8.4. HEC-1A migration and HEC-1B migration and invasion in hypoxia following
CD73 silencing by siRNA. CD73 was silenced by transfection of CD73 siRNA in endometrial
carcinoma cells, HEC-1A and HEC-1B. Following manipulation, cells were placed in hypoxic
(1% O2, 5% CO2) conditions along with 50µM of 5’AMP. Migration and invasion was then
studied in vitro. (A) HEC-1A migration. Silencing of CD73 by siRNA significantly increased
HEC-1A migration. (B) HEC-1B migration and (C) invasion. Silencing of CD73 by siRNA
significantly increased HEC-1B migration and invasion. Representative images of cell migration
and invasion are shown alongside graphs. Error bars represent ± 1 SE. Image magnification 10X.
(*p<0.05)

203

Figure 8.4

A

204

B

205

C

206

Table 8.3. HEC-1A migration and HEC-1B migration and invasion in hypoxia following
CD73 silencing by siRNA – Data summary from Figure 8.4

bN

a

aMean

± SE

p value (vs non-targeting
siRNA)

HEC-1A - Migration
Parental
Non-Targeting siRNA
CD73 siRNA

3
3
3

34.37 ± 2.35
41.52 ± 7.93
68.56 ± 3.30

NS
-0.001

HEC-1B - Migration
Parental
Non-Targeting siRNA
CD73 siRNA

3
3
3

162.19 ± 6.35
144.19 ± 9.89
262.67 ± 4.77

NS
-0.000000005

HEC-1B - Invasion
Parental
Non-Targeting siRNA
CD73 siRNA

3
3
3

97.31 ± 6.64
103.13 ± 9.96
182.15 ± 6.66

NS
-0.0000007

Data are expressed as mean cell number of migrated or invaded cells in a 10X field ± SE

b

N represents the number of migration or invasion inserts per condition
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Pharmacological blockade of CD73’s catalytic activity increases migration and invasion of
endometrial carcinoma cells, HEC-1A and HEC-1B
CD73 has been described to have catalytic (reviewed, (157)) and non-catalytic functions.
Non-catalytic functions include serving as a co-receptor for T-cell activation (158-162) and a
binding partner for ECM proteins (163-165). Targeting CD73 by siRNA (Figure 8.4) does not
indicate whether the catalytic function of CD73 is important in inhibiting EC cell migration and
invasion or whether it involves a non-catalytic function.

Therefore, HEC-1A and HEC-1B

migration and invasion were assessed in the presence of a specific catalytic inhibitor for CD73,
α,β-methylene diphosphate (AoPCP) (147, 294, 295).

AoPCP is a widely used competitive

inhibitor for CD73 and has been demonstrated to be very powerful, with a Ki = 2nM (294); in the
present study 100μM AoPCP efficiently eliminated CD73’s catalytic activity. Inhibition of CD73
by AoPCP can be demonstrated by enzyme histochemistry. Representative images are shown in
Figure 8.5 A (HEC-1A) and C (HEC-1B). Inhibiting CD73’s catalytic activity significantly
increased HEC-1A migration (Figure 8.5 B) and HEC-1B migration (Figure 8.5 D) and invasion
(Figure 8.5 E). These important experiments demonstrate that CD73’s effects on inhibiting EC
cell migration and invasion are due to its catalytic production of adenosine. CD73-generated
adenosine has several possible fates.

In addition to activating adenosine receptor subtypes,

adenosine can be involved in metabolic activities of the cell. To determine if CD73’s generation
of adenosine is inhibiting EC cell migration and invasion by activation of adenosine receptor
subtypes, the stable adenosine analog and adenosine receptor subtype agonist 5'-Nethylcarboxamidoadenosine (NECA) was employed. The addition of 10µM NECA reversed the
effect of AoPCP on endometrial carcinoma cells. HEC-1A (Figure 8.5 B) and HEC-1B (Figure
8.5 D) cell migration significantly decreased, approximately by 50%, compared to AoPCP treated
cells. HEC-1B cell invasion was completely reduced back to the invasion levels seen in 5’AMP
treated cells (Figure 8.5 E). A data summary of HEC-1A and HEC-1B migration and invasion
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studies with 5’AMP, 5’AMP and AoPCP, and 5’AMP and AoPCP and NECA is provided in Table
8.4. Importantly, these studies have used physiologically relevant concentrations for 5’AMP
(50μM), AoPCP (100µM), and NECA (10μM). Collectively, these data suggest that CD73’s
inhibitory effect on EC cell migration and invasion occurs via activation of an adenosine receptor
subtype.
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Figure 8.5. HEC-1A migration and HEC-1B migration and invasion in hypoxia following
catalytic inhibition of CD73 and application of an adenosine analog, NECA.

Endometrial

carcinoma cells, HEC-1A and HEC-1B, were treated with 50µM 5’AMP or 50μM 5’AMP and
100µM of the CD73 catalytic inhibitor, α, β-methylene diphosphate (AoPCP). 10μM of the stable
adenosine analog, 5'-N-ethylcarboxamidoadenosine (NECA), were added to 50μM 5’AMP and
100µM AoPCP samples to determine if adenosine activation of adenosine receptors inhibited
HEC-1A and HEC-1B migration and invasion. Migration and invasion were assessed in hypoxic
(1% O2, 5% CO2) conditions. (A)

Catalytic inhibition of CD73 with AoPCP significantly

increased HEC-1A migration. With addition of NECA, the migration of HEC-1A was partially
inhibited.

AoPCP significantly increased HEC-1B migration (B) and invasion (C). With

addition of NECA, the migration and invasion of HEC-1B were partially (migration) or
completely (invasion) restored to that seen with 5’AMP. Representative photomicrographs of cell
migration and invasion are shown alongside graphs.
magnification 10X. (*p<0.05)
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Error bars represent ± 1 SE.
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Table 8.4. HEC-1A migration and HEC-1B migration and invasion in hypoxia following
catalytic inhibition of CD73 and application of an adenosine analog, NECA – Data summary
from Figure 8.5

bN

a

aMean

± SE

p value (vs 5'AMP)

p value (vs 5'AMP +
AoPCP)

HEC-1A - Migration
5'AMP
5'AMP + AoPCP
5'AMP + AoPCP + NECA

3
3
3

40.22 ± 1.86
92.74 ± 2.46
72.32 ± 3.71

-0.000000005
0.000000005

0.000000005
-0.000008

HEC-1B - Migration
5'AMP
5'AMP + AoPCP
5'AMP + AoPCP + NECA

3
3
3

156.33 ± 4.25
271.30 ± 5.61
219.96 ± 4.64

-0.000000005
0.000000005

0.000000005
-0.000000005

HEC-1B - Invasion
5'AMP
5'AMP + AoPCP
5'AMP + AoPCP + NECA

3
3
3

69.73 ± 8.07
134.80 ± 20.75
75.93 ± 5.00

-0.002
NS

0.002
-0.005

Data are expressed as mean cell number of migrated or invaded cells in a 10X field ± SE

b

N represents the number of migration or invasion inserts per condition
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Antagonism of the adenosine receptor subtype, A2BR, increases the migration and invasion
of endometrial carcinoma cells, HEC-1A and HEC-1B
NECA is a non-selective adenosine receptor agonist, so it is unknown which adenosine
receptor subtype(s) adenosine is activating in order to inhibit EC cell migration and invasion
(Figure 8.5). Fortunately, a variety of selective pharmacological agonists and antagonists to the
adenosine receptor subtypes are commercially available.

These agents have proven to be

important tools in detailing the function of a certain adenosine receptor subtype (179). We first
were interested in determining which adenosine receptor subtypes were expressed in our
endometrial carcinoma cells. Figure 8.6 (A) shows the entire panel of endometrial carcinoma cells
we assessed by qRT-PCR for transcripts levels of the four adenosine receptor subtypes, A1R,
A2AR, A2BR, and A3R.

A1R and A2BR are the prominent adenosine receptor subtypes

expressed in all endometrial carcinoma cells, including HEC-1A and HEC-1B. Detection of the
adenosine receptor subtypes by immunoblot has been a challenge due to the lack of antibodies that
recognize specific adenosine receptor subtypes. An immunoblot for A2BR is shown in Figure 8.6
B. The dual band at approximately 50kDa is consistent with data reported in the literature (296).
We next chose to evaluate the migration and invasion of HEC-1A and HEC-1B in response to
treatment with NECA and a selective A1R or A2BR antagonist. The utility of combining the nonselective agonist NECA along with highly selective antagonists has been demonstrated (reviewed,
(179)). DPCPX was utilized to antagonize A1R. DPCPX is 20-fold more selective for A1R than
A2BR (297). For A2BR antagonism, MRS1754 was employed. MRS1754 is 400-fold more
selective for A2BR than A1R (298). As anticipated, for HEC-1A (Figure 8.6 C) and HEC-1B
(Figure 8.6 D) migration assays NECA significantly reduced the migration of the cells compared
to the vehicle treated control, DMSO. Antagonism of the A1R by DPCPX had no great effect on
the migration of HEC-1A or HEC-1B cells compared to NECA. However, A2BR antagonism
significantly increased HEC-1A and HEC-1B migration. Similar effects were found for HEC-1B
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invasion (Figure 8.6 E).

These studies indicate that adenosine generation by CD73 and

adenosine’s activation of A2BR are the mechanisms involved in inhibiting EC cell migration and
invasion. It is important to emphasize that this mechanism of Stressor  CD73  Adenosine 
A2BR is the same as that used for adenosine’s mediation of barrier function. It is therefore likely
that activation of A2BR by CD73-generated adenosine is inhibiting cell migration and invasion by
inducing cell-cell adhesion function.
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Figure 8.6. HEC-1A migration and HEC-1B migration and invasion in hypoxia following
adenosine receptor antagonism.

Endometrial carcinoma cells, HEC-1A and HEC-1B, were

treated with vehicle control, DMSO, 10µM NECA, 10µM NECA + 1µM adenosine receptor
subtype A1R antagonist, DPCPX, or 10μM NECA + 1μM adenosine receptor subtype A2BR
antagonist, MRS1754. Migration and invasion were assessed in hypoxic (1% O2, 5% CO2)
conditions. (A) qRT-PCR detection of adenosine receptor subtype expression, A1R and A2BR, in
HEC-1A and HEC-1B. (B) Immunoblot demonstrating A2BR protein expression. (C) NECA
significantly inhibits HEC-1A migration. Antagonism of A1R by DPCPX did not increase HEC1A migration. A2BR antagonism caused a significant increase in HEC-1A migration. NECA
significantly reduced HEC-1B migration (D) and invasion (E). A1R antagonism by DPCPX did
not increase HEC-1B migration and invasion. A2BR antagonism caused a significant increase.
Representative photomicrographs of cell migration and invasion are shown alongside graphs.
Error bars represent ± 1 SE. Image magnification 10X. (*p<0.05)
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Summary
The increased ability to migrate and invade are beneficial features to carcinoma cells,
especially under the circumstances of unfavorable conditions, such as hypoxia. Generation of
adenosine by CD73-expressed carcinoma cells in hypoxic conditions would appear to be a
counteractive event in the progression of these EC cells. Such an event would be predicted to
result in the induction of barrier function. These data present within this specific aim show
CD73’s generation of adenosine, and adenosine’s activation of A2BR to be functionally
responsible for inhibiting the migration and invasion of well-differentiated EC cells.
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CHAPTER NINE
Results
Specific Aim 5. Identify the events or proteins of cell-cell adhesion that are regulated by
adenosine’s activation of A2BR.

Introduction
The gap in knowledge in the adenosine field concerning adenosine’s barrier function
activity has been the molecular mechanisms by which it regulates cell-cell adhesions. Few studies
have examined this topic (220, 221). Maintaining or regaining barrier function is a dynamic event
that involves not only the stabilization or membrane-trafficking of integral membrane and
peripheral plaque proteins to adhesion structures, but includes actin cytoskeleton remodeling,
relaxation of the contracting perijunctional actin-myosin II ring, activation of GTPases, and
phosphorylation of tight junction proteins. cAMP, the primary secondary messenger of many G
protein-coupled receptors, including A2BR, is central to the activation of many of these
intracellular mediators and barrier function events. Previous studies that have provided the most
insight into adenosine’s activation of A2BR have described a cAMP driven, PKA-dependent
phosphorylation of VASP (220, 221). VASP is a member of the enabled/vasodilator-stimulated
phosphoprotein (Ena/VASP) protein family that is involved in regulating actin dynamics (299,
300). VASP is a dual resident of both focal adhesions and cell-cell adhesions. Importantly, as
will be introduce in this specific aim, VASP is a key resident of filopodia that drive the
development of focal adhesions and cell-cell adhesions.
In previous specific aims, CD73 generated adenosine and A2BR increased endometrial
epithelial barrier function, and CD73 was significantly down-regulated in ECs that are
moderately- or poorly-differentiated, invasive, and metastatic. Loss of CD73 expression was
associated with the loss of the epithelial phenotype of carcinoma cells and gain of cell motility and
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invasiveness. Importantly, the mechanism by which adenosine induces barrier function (Stressor
 CD73  Adenosine  A2BR  Barrier Function) is identical to the mechanism that inhibits
the migration and invasion of EC cells. Collectively, these results suggest a connection between
CD73, adenosine, A2BR, and cell-cell adhesions in endometrial carcinoma cells. This specific
aim is particularly important, as we are ultimately interested in the future therapeutic use of
targeting the purinergic pathway as a way of restoring cell-cell adhesions in carcinoma cells. To
move towards accomplishing this goal, it is important that the we first define what cell-cell
adhesion events or specific individual proteins comprising cell-cell adhesions are regulated by
adenosine’s activation of A2BR.
This specific aim introduces the involvement of filopodia in the formation of cell-cell
adhesions and identifies a mechanism by which cell-cell adhesive filopodia are regulated by
adenosine. Currently, adenosine’s induction of filopodia has not been described in any tissue or
disease type. Therefore, these experiments elucidate a novel mechanism associating cell-cell
adhesions and adenosine’s barrier function. The findings described within this specific aim have
potential relevance for understanding adenosine’s barrier function role in tissues other than the
endometrium and diseases other than EC.
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CD73 expression in HEC-1A and HEC-1B endometrial carcinoma cells is predominantly
confined to membranes that are in direct contact with a neighboring cell
CD73 resides in glycolipid-rich membrane subdomains known as lipid rafts and is
anchored by a C-terminal glycosyl phosphatidylinositol (GPI) linkage (154). CD73 has been
determined to be localized to both the apical and basolateral membranes of cells with its intensity
of expression being higher on the apical membrane (275). In the well-differentiated, epitheliallike endometrial carcinoma cells HEC-1A and HEC-1B, membranous CD73 expression was
confined to membranes that were in direct contact with a neighboring cell. A trivial explanation
for this is that this is an artifact of 2-D culture techniques. However, when HEC-1A cells were
grown on a collagen matrix, this same expression pattern for CD73 was maintained (Figure 9.1
A).

CD73’s catalytic activity followed this same membrane expression pattern, as catalytic

activity was found only on the membranes that were in direct contact with a neighboring cell
(Figure 9.2 A); this was not affected by cell confluency (Figure 9.2 A-C). This CD73 expression
pattern and catalytic activity localization is interesting because though HEC-1A and HEC-1B
cells do not have well-defined apical or basolateral membrane distinctions in standard culture
conditions, studies of protein trafficking in non-polarized cells indicate that apical proteins are
distributed uniformly on the membrane (301).
To more precisely define the location of CD73’s catalytic activity, we took advantage of
the electron density nature of the lead precipitate product of the CD73 enzyme histochemistry
assays (Figure 6.12, Specific Aim 3).

The enzyme histochemistry assay was modified to

accommodate examination by transmission electron microscopy. Inspection of images obtained
by transmission electron microscopy revealed that the lead precipitate was clearly visible and
restricted to membranes that were in direct contact with a neighboring cell (Figure 9.2 D).
Importantly, CD73’s catalytic activity was found to be on the extracellular surface of the
membrane, which is typical of this ecto-enzyme. At lower magnifications (5,000X), it appeared
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that the paracellular space had a non-specific accumulation of lead precipitate. However, after
inspecting higher magnification images (25,000X and 50,000X) (Figure 9.2 E-F), CD73 catalytic
activity was pronounced on finger-like extensions that extended from the cell membrane (Figure
9.2 E). These finger-like extensions appeared to be imbedding themselves into the neighboring
cell (Figure 9.2 F). In HEC-1B cells these finger-like extensions, which have characteristics of
filopodia, extended between membranes of neighboring cells (Figure 9.3).

Filopodia were

numerous between cells, and all were found only protruding from cells that had a neighboring cell.
These characteristics suggest a “zippering” cell-cell adhesion function for these filopodia. The
“zippering” function is important, as it leads to the formation of mature adhesion junctions.
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Figure 9.1. CD73 membrane expression in endometrial carcinoma cells, HEC-1A, grown on
a collagen matrix.

CD73 immunofluorescence in endometrial carcinoma cells, HEC-1A, grown

on a collagen matrix. CD73’s expression is absent from cell membranes that are not in contact
with a neighboring cell (arrow). Na+K+ ATPase is used as a marker of basolateral membranes.
Image magnification 20X.
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Figure 9.2. Membrane location of CD73’s catalytic activity in endometrial carcinoma cells,
HEC-1A.

(A) CD73 enzyme histochemistry in endometrial carcinoma cells, HEC-1A. (B)

Electron photomicrographs of CD73 enzyme histochemistry in HEC-1A.

At 50% and 90%

confluency, CD73’s catalytic activity (brown precipitate) is absent from cell membranes that are
not in contact with a neighboring cell (arrow). A higher magnification (40X) of the 50% image is
shown.

Relative location of the higher magnification is indicated by the inset.

(B) Lead

precipitate (black) is seen by transmission electron microscopy and is present in the paracellular
space of cells. CD73 catalytic activity is low-absent from membranes that are not immediately
adjacent to a neighboring cell (arrow). Higher magnification images (25,000X and 50,000X) are
shown of the paracellular space. Relative location of the higher magnification is indicated by the
inset. Finger-like extensions are found within the paracellular space of HEC-1A cells and show
the presence of lead precipitate (black). In the 50,000X magnification, finger-like extensions
appear to be imbedding themselves into the neighboring cell (arrow). Image magnification,
enzyme histochemistry 20X; enzyme histochemistry magnified image, 40X; electron
photomicrographs of enzyme histochemistry, 5,000X, 25,000X, and 50,000X, respectively.
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Figure 9.3. CD73 expressing filopodia in endometrial carcinoma cells, HEC-1B. CD73
immunofluorescence in endometrial carcinoma cells, HEC-1B. CD73’s intensity is highest in the
filopodia extensions between cells (arrows). Filopodia are most numerous between immediately
adjacent cells al, suggesting a “zippering” cell-cell adhesion function.

Filopodia were not

observed from membranes not in contact with a neighboring cell. Image magnification 40X.
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Filopodia that function in cell-cell adhesions are distinct from those that function as focal
adhesions.
Filopodia are thin, actin-rich membrane protrusions that have a diverse array of functions,
including cell migration (focal adhesions), neurite outgrowth, wound healing, guidance towards
chemoattractants, embryonic development, and formation of cell-cell adhesions (reviewed, (302)).
The establishment of filopodia in the formation of cell-cell adhesions is well documented in
studies of epithelial sheet fusion during embryonic development and wound healing (223-225).
Individual cell-cell adhesion formation has been established in cultured keratinocytes (299). The
function of filopodia is dependent on one or a combination of events that include the presence of
specific proteins in the shafts or tips of filopodia, including E-cadherin (cell-cell adhesions) or
integrins (focal adhesions); the presence of structural and signaling proteins in filopodia which
respond to external signals (chemoattractant); and the presence of proteins that alter the
biochemical and biophysical properties of filopodia (reviewed, (302)).

Our observation that

CD73’s expression and catalytic activity were specific for membranes associated with cell-cell
adhesions and that CD73 expressing finger-like extensions (filopodia) were protruding from these
cells led us to hypothesize that adenosine and adenosine’s activation of A2BR might be involved
in filopodia-directed cell-cell adhesion. To first establish that CD73 expressing filopodia were
indeed cell-cell adhesive as opposed to those involved in focal adhesions, HEC-1A cells were
fluorescently immunostained with the non-specific filopodia marker, VASP, and E-cadherin.
VASP is known to localize to regions of dynamic actin reorganization, including the tips of
filopodia. VASP promotes actin polymerization by an anti-capping mechanism. As demonstrated
in cultured keratinocytes, filopodia with cell-cell adhesion function can be distinguished by their
expression of E-cadherin. HEC-1A cells with focal adhesions (Figure 9.4 A) lacked E-cadherin
expression. However, newly forming cell-cell adhesions in HEC-1A cells were found to express
both VASP and E-cadherin (Figure 9.4 B).
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Figure 9.4.

Filopodia of focal adhesions and newly forming cell-cell adhesions in

endometrial carcinoma cells, HEC-1A.

Vascular-stimulated phosphoprotein (VASP) is a

marker for filopodia of focal adhesions and newly forming cell-cell adhesions. (A) E-cadherin is
absent from VASP positive (arrow) focal adhesion filopodia. (B) E-cadherin and VASP are both
localized in the filopodia associated with early cell-cell adhesion formation (arrow).
magnification (A) 20X and (B) 40X.
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CD73 expression is present in filopodia of newly forming cell-cell adhesions in endometrial
carcinoma cells, HEC-1A and HEC-1B
Extensive finger-like extensions extending from membranes of neighboring cells in low to
subconfluent conditions were observed.

Interestingly, filopodia were not identified in cells

lacking direct contact with a neighboring cell. To determine if CD73 was expressed exclusively in
filopodia of newly forming cell-cell adhesions (similar to the expression pattern of E-cadherin)
HEC-1A and HEC-1B were dual labeled with VASP and CD73. CD73 was absent in VASP
positive focal adhesions (Figure 9.5 A). Similar to E-cadherin expression (Figure 9.4 B), CD73
and VASP were localized to the filopodia of newly forming cell-cell adhesions (Figure 9.5 B).
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Figure 9.5.

CD73’s expression in filopodia of newly forming cell-cell adhesions in

endometrial carcinoma cells, HEC-1A and HEC-1B. (A) E-cadherin and vascular-stimulated
phosphoprotein (VASP) immunofluorescence in endometrial carcinoma cells, HEC-1A and HEC1B. VASP is a marker for filopodia of focal adhesions and newly forming cell-cell adhesions. (A)
E-cadherin is absent from VASP positive (arrow) focal adhesion filopodia. (B) CD73 and
vascular-stimulated phosphoprotein (VASP) immunofluorescence in endometrial carcinoma cells,
HEC-1A and HEC-1B. CD73 and VASP are detected in the filopodia associated with early cellcell adhesion formation (arrow). (C) Representative histogram of relative fluorescence intensity
of VASP (green) and CD73 (red) in filopodia at cell-cell adhesions. Individual peaks indicate a
single filopodium.

With each VASP peak a corresponding CD73 peaks is seen.

magnification (A) 20X; (B) 40X; (C) 60X
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Filopodia and barrier function are increased in HEC-1A endometrial carcinoma cells by
adenosine’s activation of A2BR
The establishment of cell-cell adhesions between epithelial cells involves the process of
actin polymerization and cytoskeleton remodeling. This event is common in many processes
requiring cell-cell adhesion, such as embryonic development, wound healing, and steady-state
dynamics of cell-cell adhesion remodeling. In embryonic development and wound healing direct
actin polymerization and its process of forming cell-to-cell extending filopodia is the driving force
for the formation of cell-cell adhesions. Interdigitating filopodia are necessary to properly align
and establish initial cell-cell adhesions (223-225). This event, known as adhesion “zippering”,
also occurs in cultured keratinocytes (299). Previous observations of CD73’s high membrane
expression in well-differentiated endometrial carcinoma cells, HEC-1A, however absent in poorlydifferentiated (AN3CA) endometrial cancer cell lines (Figure 7.4, Specific Aim 3) suggested the
possibility that adenosine’s activity is an important regulator of cell-cell adhesions. Studies in this
specific aim provide further evidence to support this assumption and include the following: 1.)
CD73 is expressed only on cell membranes involved in cell-to-cell contact; 2.) CD73’s expression
and catalytic activity localized to filopodia that extend from cell-to-cell; 3.) in subconfluent
cultures distinct CD73 expressing filopodia can be seen extending from cell-to-cell; and 4.) CD73
expression is limited to filopodia involved in cell-cell adhesion function. Barrier disruption is
associated with the loss of cell-cell adhesions and the necessity of having to re-establish these
adhesions to maintain homeostasis. We therefore hypothesized that adenosine directs a filopodiadriven cell-cell adhesion event that helps to re-establish cell–cell adhesions in barrier disrupted
epithelial cells. To test this hypothesis, HEC-1A monolayers were treated with the adenosine
analog, NECA, NECA and the A2BR antagonist, MRS1754, or vehicle control, DMSO. Cell-cell
adhesion filopodia were examined using images obtained by transmission electron microscopy.
To induce the disruption of cell-cell adhesions, the HEC-1A monolayers were placed in hypoxia
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(1% O2, 5% CO2) for 36 hours. In vehicle control treated cells (DMSO), a limited number of
filopodia were seen among cells (Figure 9.6 A). However, with NECA treatment we found the
presence of filopodia to be noticeably higher among cells (Figure 9.6 A). Antagonism of the
A2BR blocked the NECA-induced increase in filopodia (Figure 9.6 A). These results suggest that
adenosine activation of A2BR is important for the increased formation of filopodia between cells
following a hypoxic insult. Interestingly, filopodia length increased when the neighboring cell
was farther away (Figure 9.6 B). Also, from these images, filopodia were observed to interdigitate
among each other, suggesting an adhesion “zippering” action (Figure 9.6 B). Moreover, filopodia
extending from cell-to-cell also appeared to be imbedding themselves into the cytoplasm of the
neighboring cell (Figure 9.6 B). To demonstrate that functionally these HEC-1A monolayers are
indeed more adhesive and are attempting to preserve barrier function via adenosine signaling
through A2BR, paracellular macromolecule permeability studies were performed (Figure 9.7).
A2BR antagonism resulted in a significant loss of barrier function (increased macromolecule flex)
compared to treatment with DMSO vehicle, NECA, and NECA combined with A1R antagonism
(DPCPX). These results suggest that adenosines activation of A2BR induces filopodia that are
functioning in cell-cell adhesions.
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Figure 9.6. Electron photomicrographs of filopodia in HEC-1A endometrial carcinoma cells
following NECA treatment and A2BR antagonism. HEC-1A cells were treated with 10μM
NECA, 10µM NECA and 1µM MRS1754, or vehicle control (DMSO) and placed in hypoxia (1%
O2, 5% CO2) for 36 hours.

Changes in filopodia were assessed by transmission electron

microscopy. (A) Representative electron photomicrographs of DMSO, NECA, and NECA and
MRS1754 treated groups. Filopodia number increase with NECA treatment compared to DMSO.
A2BR antagonism reduces the number of filopodia. Filopodia induced by NECA have variable
length, which seems to be dependent, at least in part, on the distance to the nearest cell. (B)
Representative electron photomicrograph of NECA treated cells and a higher magnification image
showing interdigitating filopodia. Filopodia appear to be imbedding into the cytoplasm of a
neighboring cell.

Electron photomicrograph magnification (A) 5,000X and (B) 5,000X and

25,000X (magnified image)

244

Figure 9.6
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Figure 9.7.

Macromolecule paracellular permeability in HEC-1A endometrial carcinoma

cells following antagonism of A2BR and A1R. FITC-dextran (40kDa) paracellular permeability
was measured following 36 hours of hypoxia (1% O2, 5% CO2).

HEC-1A were treated with

10μM NECA, 10µM NECA and 1µM DPCPX 10µM NECA and 1μM MRS1754, or vehicle
control (DMSO). Data are presented as percent paracellular permeability relative to DMSO.
Values represent the mean ± SE of triplicate measurements from 3 different experiments. A2BR
antagonism (MRS1754) results in significantly increased FITC-dextran paracellular permeability
compared to treatment with NECA or NECA and DPCPX. (*p<0.05).
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Figure 9.7
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Adenosine’s activation of A2BR increases the expression of membrane VASP in endometrial
carcinoma cells, HEC-1A
Studies by Donald Lawrence and Katrina Comerford have described a NECA-induced,
PKA-dependent, phosphorylation of VASP to be involved in moving VASP to tight junctions
along with ZO-1 to provide adenosine-related barrier function in HMVEC and colon carcinoma
cells, T84 (220, 221). VASP is known for its role in the formation of filopodia, but is also known
to dually function in the stabilization of tight junction adhesions and assembly of the perijunctional actin-myosin II ring (220, 221, 303). The perijunctional ring is a thick circumferential
belt composed of actin filaments. This ring is oriented parallel to the plasma membrane at the level
of adherens junctions and is physically associated with this cell-cell adhesion structure. We
hypothesized that increased expression of membrane VASP seen in these studies likely occurs in
endometrial carcinoma cells via adenosine’s activation of A2BR. In hypoxic (1% O2, 5% CO2)
HEC-1A monolayers addition of NECA increased the membrane expression of VASP (Figure
9.7).

However, antagonism of A1R (DPCPX) with NECA treatment greatly increased the

membrane expression of VASP as compared to NECA alone. This is expected as NECA is a nonspecific adenosine receptor agonist and activation of A1R negatively inhibits cAMP accumulation
by A2BR. The increased expression membrane VASP is attributed to A2BR activation, as A2BR
antagonism (MRS1754) resulted in decreased membrane VASP expression which is similar to that
seen with the vehicle treated control, DMSO.

248

Figure 9.8. VASP expression in HEC-1A endometrial carcinoma cells following adenosine
receptor antagonism.

HEC-1A cells were treated with 10μM NECA, 10µM NECA and 1µM

DPCPC, 10µM NECA and 1µM MRS1754, or vehicle control (DMSO) and placed in hypoxia
(1% O2, 5% CO2) for 36 hours. An increased intensity in VASP membrane expression is seen
with NECA treatment. With A1R antagonism (DPCPX) VASP membrane expression is increased
beyond that of NECA. A2BR antagonism (MRS1754) results in decreased membrane VASP.
Image magnification 20X.
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Figure 9.8
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Adenosine’s activation of A2BR results in the cleavage of full-length vinculin to ~90kDa
fragments in HEC -1A endometrial carcinoma cells.
Similar to VASP, vinculin is a dual resident of cell-matrix adhesions (focal adhesions) and
cell-cell adhesions. At sites of cell-cell adhesion, vinculin functions to bind α-actinin (304), αcatenin (305, 306) or β-catenin (307) to provide increased stabilization of adherens structures to
the actin cytoskeleton.

Full-length vinculin exists in two conformations, a closed inactive

conformation whereby its head domain interacts with its tail and an open active conformation
(reviewed, (308)). Vinculin’s active conformation is dependent on the binding of two different
ligands (309, 310).

Studies have recently suggested, however, that proteolytic cleavage of

vinculin by calcium-dependent protease, calpain, may also function to activate vinculin (311). In
these studies, vinculin fragments of ~95kDa and ~90kDa were found in the cortical cytoskeleton
fraction of aggregating platelets and assumed to be important in actin remodeling (311).
Interestingly, with platelet aggregation, platelets lose their characteristic shape and acquire
extensive filopodia that function to help in the “clumping” (cell-cell contact) of platelets. Given
our previous findings that adenosine activation of A2BR induces filopodia (actin remodeling) and
is associated with membrane VASP expression and barrier function, we considered that vinculin
could also be activated by adenosine’s activation of A2BR. Vinculin expression was assessed in
HEC-1A cells that were treated with the adenosine analog, NECA, NECA and the A2BR
antagonist, MRS1754, or vehicle control, DMSO. NECA treatment caused full-length vinculin to
be cleaved into a ~90kDa and ~95kDa fragment (Figure 9.9). As expected, the cleavage of fulllength vinculin was more apparent in HEC-1A cells treated with NECA and the A1R antagonist
(DPCPX) due to the non-specific agonist function of NECA. The ~90kDa fragment is related to
A2BR activity, as indicated by its disappearance with antagonism of A2BR. These experiments
show that adenosine’s activation of A2BR results in the cleavage of full-length vinculin to a
~90kDa fragment. Studies indicate that proteolytic cleaved vinculin fragments interact more
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efficiently with their protein binding partners than does full-length vinculin (reviewed, (308)). We
therefore believe that the ~90kDa fragment may be acting one of two ways. First, it may be
functioning to stabilize cell-cell adhesions to the actin cytoskeleton by binding with actin binding
proteins, α-actinin and/or α-catenin. Second, it may be functioning to in the formation of cell-cell
adhesion filopodia by its involvement in actin remodeling, as suggested in studies of aggregating
platelets (311). To demonstrate that cleaved vinculin fragments are functioning either to increase
cell-cell adhesion stabilization or the formation of cell-cell adhesion filopodia or both, HEC-1A
cell migration following treatment with adenosine receptor antagonists in the presence or absence
of anti-vinculin antibody was assessed. The anti-vinculin antibody used recognizes amino acid
residues in the head region of vinculin, which involves regions within the ~95kDa and ~90kDa
cleaved fragment. NECA and NECA and A1R antagonist (DPCPX) treatment significantly inhibit
HEC-1A migration (Figure 9.10)

Vinculin neutralization negated this effect, indicating that

vinculin fragmentation is necessary for NECA-mediated inhibition of cell migration. In these
experimental conditions, it is likely that adenosine activation of A2BR causes fragmentation of
vinculin, and then vinculin’s cleaved fragment either stabilizes newly formed or existing cell-cell
adhesions and/or increases the induction of cell-cell adhesion filopodia.

Further studies are

needed to detail this association. However, regardless of function, both events are negative
contributing effects to EC cell migration.
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Figure 9.9.

Vinculin immunoblot in HEC-1A endometrial carcinoma cells following

treatment with NECA and adenosine receptor antagonists.

HEC-1A cells were treated with

10μM NECA, 10µM NECA and 1µM DPCPC, 10µM NECA and 1µM MRS1754, or vehicle
control (DMSO) and placed in hypoxia (1% O2, 5% CO2) for 36 hours. Full-length vinculin is
130kDa. Prominent ~90kDa (asterisk) and ~95kDa fragments of vinculin are seen with NECA
treatment. With A1R antagonism a near complete loss of full-length vinculin along with the
increased presence of the ~90kDa is found. The ~90kDa fragment is related to A2BR activity, as
indicated by its disappearance with antagonism of A2BR.
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Figure 9.9
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Figure 9.10.

Representative images of HEC-1A endometrial carcinoma cell migration

following adenosine receptor antagonism and anti-vinculin antibody treatment.

HEC-1A

cells were pre-treated with (E-H) or without (A-D) 10μm/ml anti-vinculin antibody and then
treated with 10μM NECA, 10µM NECA + 1µM DPCPC, 10µM NECA + 1µM MRS1754, or
vehicle control (DMSO). HEC-1A cells were subjected to hypoxia (1% O2, 5% CO2) for 24 hours.
HEC-1A migration is reduced by (B) NECA and (C) NECA and DPCPX (A1R antagonism)
compared to DMSO or NECA and MRS1754 (A2BR antagonism). The inhibitory effects of
NECA and NECA and DPCPX are lost with pre-treatment with anti-vinculin antibody (F and G).
Image magnification 10X.
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Figure 9.10
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Summary
The work presented within this specific aim has described a very novel discovery that
adenosine’s activation of A2BR induces filopodia that have cell-cell adhesion function. The
function of cell-cell adhesion filopodia is well-described in embryonic development and with
wound healing (223-225). Such an event is important for the proper alignment and development
of mature adhesion structures.

Importantly, we have functionally shown that adenosine’s

activation of A2BR increases barrier function under the identical conditions in which the filopodia
induced by A2BR were described. Data here has shown A2BR to induce the expression of
filopodia protein VASP and also demonstrated a novel relationship between A2BR activity and
full-length vinculin cleavage. The ~90kDa fragment of vinculin has recently been suggested to a
central protein involved in rescuing cell-cell adhesions by stabilizing membrane bound E-cadherin
(312). Our migration studies involving the neutralization of vinculin functionally support that the
~90kDa fragment in inhibiting the progression of carcinoma cells.
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CHAPTER TEN
Discussion
Specific Aims Overview
In the first specific aim, the initial findings of the purinergic pathway in relation to EC
were introduced. These findings established the rationale for studying CD73 and adenosine’s
barrier function. In specific aim 2 the involvement of CD73-generated adenosine and A2BR in
endometrial epithelial barrier function was mechanistically established. In specific aim 3, the
expression of CD73 in normal and EC was characterized in detail. This specific aim also
established that CD73 expression in carcinoma cells is significantly correlated to the epithelial
phenotype. With specific aim 4, it was demonstrated that the mechanism of adenosine’s barrier
function, Stressor  CD73  Adenosine  A2BR  Barrier Function, is the same mechanism
that inhibits EC cell migration and invasion. Finally, in specific aim 5, a detailed molecular
mechanism for adenosine regulation of cell-cell adhesion filopodia is provided.

CD73 is significantly down-regulated in moderately- and poorly-differentiated, invasive, and
metastatic endometrial carcinomas
Previous studies of CD73’s expression in human cancers has not been conclusive and has
not provided consistent results (breast (152, 313, 314); gastric (315); bladder (315); kidney, (316);
glioblastoma (317); colon (314, 318, 319); thyroid (320); larynx (321)). Even among studies of a
single cancer type, such as breast, there is much disagreement as to whether CD73 is downregulated or over-expressed (breast (152, 313, 314). A consensus of all studies would tend to
suggest an over-expression of CD73 in cancer. However, data from this dissertation support the
assumption that CD73 is down-regulated in a number of different carcinomas. This assumption is
based on the following: 1.) our observations that CD73’s expression is down-regulated not only in
higher grade EC but also in ovarian high grade papillary serous carcinoma (HGPSC); 2.) banked
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microarray data from publicly accessible databases, such as NextBio, demonstrate that CD73 is
significantly down-regulated in higher grade and/or advanced stages of endometrial, breast,
prostate, ovarian, colon, adrenal, and kidney carcinomas; and 3.) previous studies present data
using low sample numbers (n=15 or less (313-315, 320, 321) and/or do not take into account
differences in expression by cancer grade or stage (314, 319). This third issue is especially
important, as this has posed a great problem in trying to draw conclusions and understanding from
the current literature. Established histological grading and staging parameters for EC, as with
many cancer types, has shown to have prognostic importance (322). Importantly, when assessing
expression of genes, these differences in grade and stage need to be accounted for, as they define
distinct tumor biologies which occur with disease progression.
The need for separation by grade and stage is supported by the significant differences in
CD73 expression we observed in different EC grades and stages. This work has clearly shown
that CD73 is significantly down-regulated in moderately- and poorly-differentiated, invasive, and
metastatic ECs.

In specific aim 3, these findings were validated by double-labeling

immunofluorescence, HPLC, and enzyme histochemistry.

Specific localization of CD73

expression and enzyme activity is especially important in cancer tissues, which are a complex
mixture of carcinoma cells, desmoplastic stromal cells, inflammatory cells, and vasculature. From
specific aim 3, double-labeling immunofluorescence and enzyme histochemistry showed CD73 to
be low to absent in carcinoma cells of poorly-differentiated ECs, but retained in carcinoma cells of
well-differentiated ECs. Importantly, the primary source of CD73 in poorly-differentiated ECs is
the remaining surrounding stromal cells and connective tissue. In a large histochemistry study
assessing CD73 expression in 102 breast carcinomas of various disease stages, only 9 contained
CD73-positive carcinoma cells (152). Close examination of this study reveals that the stromal
cells are the primary cell type strongly positive for CD73 (152). Prior studies using whole tissue
homogenized assays of breast cancer have shown CD73 to be over-expressed in carcinomas (313).
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In aggregate, these data suggest that there is a stromal cell carryover effect that is explaining the
high CD73 expression in whole breast cancer tissues.

Such an effect of stromal cells is a

significant problem of gene expression studies in breast cancer, as stromal cells are often the
predominant cell type in a given unit area of a breast cancer. A unique feature of EC is that as the
disease progresses, the stromal cells in the endometrium disappear (323). Therefore, the carryover
gene expression from stromal cells is low which makes our observations more centered on the
effects of CD73 in carcinoma cells rather than the surrounding stromal cells of the
microenvironment.
CD73 expression being down-regulated in EC compared to normal endometrium is
interesting when considering what is known about the purinergic pathway, its generation of
adenosine, and disease. CD73 is the primary ecto-enzyme responsible for the generation of
extracellular adenosine (157, 324). A consistent theme when considering adenosine’s role in
disease is that dysregulated expression of members of the purinergic pathway, including CD73
over-expression, serves to increase extracellular adenosine levels and therefore contributes to the
adverse effects of the disease (236-239) (reviewed, (235)). Much of this understanding has been
established in chronic lung diseases, including asthma, chronic obstructive pulmonary disease, and
interstitial lung disease (reviewed, (235)). Elevated levels of adenosine in these diseases leads to
tissue destructive inflammation, interstitial fibrosis, airway remodeling and hyperactivity, and
mucus metaplasia (145, 168, 325-328) (reviewed, (235)). Importantly, these events occur because
of the overactive and out-of-control production of adenosine.

This increased production of

adenosine initially is a protective response of damaged cells attempting to regain hometostasis.
However, with time and with chronic stimuli, this tissue protective role of adenosine becomes
tissue destructive. Given these well-established findings in chronic lung diseases, the question
arises to why CD73-generated adenosine is down-regulated in EC. Aside from the reason that EC
and chronic lung diseases are two very different diseases, a second more important reason of cell-
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type specific biologies is likely the attributed cause. Extracellular adenosine has varying functions
which are dependent on cell-type.

In platelets adenosine is known to inhibit aggregation (329),

but in endothelial cells it promotes both barrier function (202) and angiogenesis (330). In
epithelial cells adenosine promotes barrier function (204), and in immune cells it can have both
pro-inflammatory and anti-inflammatory effects (reviewed, (235)). The needs of carcinoma cells
compared to other cells of the tumor microenvironment differ. It is very possible that while CD73
may be down-regulated in EC carcinoma cells, other cellular components of the microenvironment
may retain CD73 expression, such as endothelial cells for the induction and support of
angiogenesis. It is important to emphasize that while extracellular adenosine levels in mouse
models of cancer have been measured at 0.2-2.4µM, mean 0.5µM (331) these levels are nowhere
close to those seen in chronic diseases such as arthritis (332), asthma, and chronic obstructive
pulmonary disease (168), which can typically have mean levels of extracellular adenosine of
approximately 100μM. Basal extracellular adenosine levels in normal, non-diseased tissues has
been estimated at 40-600nM (169). It has yet to be shown that extracellular adenosine levels in
cancer patients or human carcinomas are at levels consistent with those considered to be chronic.
It is possible that adenosine generated by the tumor microenvironment, including residential
(stromal) or infiltrating (leukocytes) cells likely produces basal levels of adenosine that are
sufficient to activate high affinity adenosine receptor subtypes (A1R, A2A, and A3R) that are
over-expressed on carcinoma cells to provide to the progression of carcinoma.

In colon

carcinomas A3R over-expression has been indicated and shown to function to promote carcinoma
cell proliferation (333). More studies are needed among all cancer types to really understand the
significance of adenosine in cancer.
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CD73-generated adenosine and A2BR induce endometrial epithelial barrier function: the
three central themes to adenosine’s barrier function effect.
As presented within the General Introduction, there are three events that can be
emphasized as being central themes to adenosine’s barrier function effect. One, adenosine’s
barrier function is a product of accumulated extracellular adenosine. Two, adenosine’s barrier
function is a product of CD73’s generation of adenosine and its activation of A2BR (Stressor 
AMP  CD73  Adenosine  A2BR  Barrier Function). Three, adenosine’s barrier function
effect is supported by shifts in expression of purinergic pathway member.

Central Theme One and Two
Using previously characterized CD73-/- mice (205) or A2BR-/- mice (206) and by
intraperitoneal injection of an adenosine analog, NECA into CD73-/- mice we showed the relation
of the first two themes to be relevant to inducing barrier function in endometrial epithelial cells.
Importantly, as found in studies by Kristen Synnestyedt in intestinal epithelial cells (204) the
barrier function induced by adenosine in normal epithelial endometrial cells was also found as a
response to cellular stress. Barrier function among epithelial cells of the endometrium is the
highest during the secretory phase of the endometrium. Estradiol significantly disrupts barrier
function (334). Interestingly, in study that isolated normal epithelial cells of the endometrium
from C57BL/6 mice, progesterone treatment of these endometrial epithelial cells did not increase
transelectrical resistance – barrier function (334). This would suggest that genes induced by
progesterone may not be involved with directly inducing barrier function.

Our results

demonstrated that CD73 is highly expressed in the secretory phase of the endometrium. However,
progesterone was not found to induce CD73 expression.
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Central Theme Three
Adenosine’s barrier function effect is supported by changes in the expression of purinergic
pathway members to support the extracellular accumulation of adenosine. This third central theme
has been supported by previous studies demonstrating that cellular stress is associated with
cytokine release or increased steady-state levels of HIF-1α, which lend to the increased expression
of members of the purinergic pathway important for the production (CD39 and CD73) and activity
(A2BR) of extracellular adenosine, while expression of members of the purinergic pathway that are
important for the internalization of extracellular adenosine (ENTs) or its deamination (ADA) are
concomitantly down-regulation. Overall, these events support the accumulation and activity of
adenosine at the extracellular surface.

TGF-β1
TGF-β1 significantly induced CD73 expression in EC cells via its Smad-mediated
signaling pathway. CD73 has only recently been described to be induced by TGF-β1 in CD4+ and
CD8+ T-cells, dendritic cells, and macrophages (335). These data reported here are the first to
demonstrate a relationship between TGF-β1 and CD73 in non-immune cells.

In intestinal

epithelial cells, TGF-β1 has been demonstrated to induce barrier function (188-193).

It is

interesting that a recent study has suggested the possibility of TGF-β1’s barrier function
potentially being co-dependent on its induction of a cAMP-mediated barrier function (190). cAMP
is a well-known second messenger of A2BR. The induction of CD73 shown in specific aim 2 was
associated with TGF-β1’s induction of barrier function in the EC cells. In our studies, we did not
directly investigate whether the barrier function of TGF-β1 and CD73 are one in the same or two
completely separate events. These issues can be addressed by pharmacological inhibitors of CD73
and siRNA approaches, which were summarized in other parts of this dissertation. These studies
are currently underway. An association between TGF-β and barrier function in the endometrium
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has not been established at this time. An additional interesting consideration is whether TGF-β1’s
induction of CD73 expression and barrier function may be one of the important, previously
undescribed tumor suppressor functions of TGF-β in the early stages of carcinoma progression.
To speculate further on TGF-β’s involvement in the regulation of CD73 in the
endometrium, it is interesting to emphasize the known expression of pattern of the TGF-β
isoforms in the hormone active endometrium. Isoforms are increased in luminal and glandular
epithelial cells during late proliferative phase and peak at early to mid secretory phase (336).
CD73’s expression has not been detailed for the entire menstrual cycle, but our work has clearly
shown a significant difference, 2-fold increase, of CD73 expression in secretory endometrium. An
important event has been TGF-β’s involvement with endometrial epithelial cell differentiation
(reviewed, (337)).

Data shown here has demonstrated that progesterone is not involved in

increasing CD73 expression in the endometrium.

The induction of CD73 in secretory

endometrium may therefore be related to other secretory phase components, which may likely
include TGF-β.

Increased Steady-State Levels of HIF-1α
In hypoxia CD73 and A2BR expression levels are significantly up-regulated, CD73 6- and
20-fold (144, 204) and A2BR 12-fold (144). In EC cells, hypoxia did not increase CD73’s
(Specific Aim 2, Figure 6.7) expression with hypoxia despite HIF-1α stability. Moreover, the
induction of A2BR by hypoxia was significant however much lower, 1- and 2-fold, than expected.
A few possible reasons may explain these results. First, these EC cells may have lost the cellular
machinery necessary to mount a compensatory response to the induction of CD73 in hypoxia.
Second, these EC cells may have a peak tolerance for how much CD73 they are willing to express.
The compensatory response or mechanisms can be supported based on studies by Kristen
Synnestyedt, which assessed HIF-1’s induced expression of CD73 by using luciferase reporter
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promoter constructs of different lengths (204). Studies showed CD73’s full-length promoter to be
partially repressed in hypoxia as compared to its half-length promoter (204). Transcription factors
GATA-1(338) and GATA-2 (339) have been implied to repress genes in hypoxia, and have
consensus sites in the distal full-length promoter of CD73 (340). Thus, despite HIF-1α’s presence
CD73’s expression could be negatively regulated by GATAs. Hypoxia is a characteristic feature
of most carcinomas, including EC (269-272). Transcriptional events induced by HIF-1 increase
the expression of genes that provide to carcinoma cell migration and invasion (341).

It is

reasonable that EC cells would induce mechanisms that would prevent HIF-1’s induction of CD73
given that increased expression of CD73 induces barrier function. A2BR expression was also not
robustly induced by hypoxia as expected in EC cells. This indicated that repressors of A2BR
could also be involved in preventing a barrier function response. In Appendix B, we show that de
novo methylation of CpG dinucleotides in CD73’s promoter does not appear to be involved in this
situation. However, this epigenetic event may be partially involved with A2BR’s ability to be
induced by HIF-1. Using Methylator SVM based software for DNA methylation prediction,
courtesy of Harvard Bioinformatics, we identified two predicted methylated cytosines of CpG
dinucleotides to fall directly within two HIF-1 binding motifs (5'-A/GCGTG-3') of A2BR’s
promoter. Treatment of HEC-1A cells and WISH-HeLa cells with DNA demethylating agent 5Aza-2'-deoxycytidine increased A2BR transcripts in hypoxia by 3-fold (HEC-1A) and 8-fold
(WISH-HeLa) (Appendix, Figure 14.2).

Further studies are needed to specifically define if

methylation of A2BR’s promoter at HIF-1 binding motifs is a direct effect.

Functional Studies: Stressor  AMP  CD73  Adenosine  A2BR  Inhibits
Endometrial Carcinoma Migration and Invasion
Very few studies have addressed CD73 and/or adenosine in relation to carcinoma cell
migration and invasion (breast (342-344)). Functional studies concerning CD73, adenosine, and
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its receptor subtypes, such as A2AR and A3R, has involved assessing carcinoma cell proliferation
((thyroid (345) and colon (333, 346, 347)) or carcinoma cell avoidance of immunosurveillance
(331, 348, 349). With all these studies, the use of in vivo and/or in vitro models that closely mimic
the conditions that are seen in the primary cancer or in vivo microenvironment is of great
importance. Previous migration and invasion studies assessing CD73 in breast carcinoma cells
have not taken this into consideration. Studies have involved exogenously over-expressing CD73
or used supra-physiological concentrations (100μM) of adenosine (306, 308). These experimental
conditions do not mirror the known in vivo expression for CD73 in breast carcinomas, as CD73 is
reported to be nearly entirely absent from carcinoma cells in this cancer type (152). Therefore, it
is difficult to draw hypotheses or conclusions from this work. The study design and EC cells used
in our migration and invasion studies were characterized and selected based on our in vivo
observations (CD73’s induction of barrier function and CD73’s down-regulation in carcinoma
cells). It was also taken into consideration that standard tissue culture conditions, ambient oxygen
content, are distinct from the conditions experienced by carcinoma cells in vivo. In fact, it is
established that ECs are hypoxic in vivo (269-272). From our data, it was concluded that CD73,
its generation of adenosine, and adenosine’s activation of A2BR inhibit EC cell migration and
invasion in a similar manner (Stressor  CD73  Adenosine  A2BR) to that seen with
adenosine’s induction of barrier function.

Barrier function and migration and invasion are

mutually exclusive cellular events. Importantly, our results clearly show that down-regulation of
CD73 in EC cells is not a passive event.
CD73 is best known and characterized for its function to produce adenosine from the
phosphohydrolysis of 5’AMP (157). Studies in this dissertation focused on the catalytic activity
of CD73 in normal endometrium and ECs. CD73 functions that are non-related to its catalytic
activity include its cell-matrix interaction with ECM proteins, laminin, fibronectin (163, 164), and
tenascin C (165).

These functions have not been well-established and/or demonstrated in
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mammalian cells. We can not discount the potential of CD73 having non-catalytic function in
epithelial cells of the endometrium.

Adenosine’s Activation of A2BR Induces Filopodia Zippering
Membrane Expression
A gap in knowledge in the adenosine field concerning adenosine’s barrier function has
been the lack of understanding of the events or proteins which A2BR regulates. A very unique
observation was made in specific aim 5 concerning the restricted expression of CD73 to
membranes of cell-cell contact. CD73 is a GPI-linked ecto-enzyme. GPI linked proteins are
typically known to be targeted to the apical membrane of cells, while small amounts may localize
to the basolateral membrane (350). The GPI linkage functions as an apical targeting signal (351353) Our studies cryosections of normal endometrium demonstrated a greater level of expression
of CD73 on the apical membrane of glandular epithelial cells with a lower level of expression
found on the basolateral membrane (Specific Aim 3, Figure 7.1 C). These results are consistent to
those described fro colonic crypt epithelial cells (275). Studies assessing CD73 trafficking in
polarized versus non-polarized hepatoma cells have shown that regardless of the 2D or 3D
cultured state of cells, CD73’s expression was dispersed among all membrane surfaces (301).
Basolateral membrane localized CD73 has been demonstrated to be GPI-linked, as basolateral
expressed CD73 was released from the membrane by phosphatidylinositol-specific phospholipase
C (PI-PLC) (275). It is assumed that EC cell expressed CD73 is GPI linked. GPI-linked proteins
are localized in specialized membrane domains known as lipid rafts (reviewed, (350)).
Characteristics of lipid rafts, such as sphingolipid, ceramide, and/or cholesterol composition, are
known to change in carcinoma cells, which provides benefit to the progression of the cells
(reviewed, (354). For example, cholesterol depletion causes the loss of EGFR in lipid rafts, which
promotes its binding to EGF and phosphorylation (355). It is unknown if changes in lipid raft
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dynamics are involved in the loss of CD73 expression on membranes not involved in cell-cell
contacts. Lipid raft composition is different among lipid rafts that are at the apical membrane
versus those that are basolateral and involved in cell-cell adhesions (reviewed, (354).
Immunofluorescence studies involving newly forming cell-cell adhesions have described Ecadherin, β-catenin, and α-catenin to be located in lipid rafts.

Filopodia
Electron photomicrographs of EC cells showed finger-like projections (filopodia) among
the paracellular spaces. These filopodia expressed CD73 and was catalytically active. Filopodia
have a diverse array of functions, including participating in wound healing, adhesion to the
extracellular matrix (focal adhesion), guidance towards chemoattractants, neuronal growth-cone
pathfinding, and embryonic development (reviewed, (302)). For determining specific functions of
filopodia, certain characteristics of the filopodia have to be taken into consideration. These
characteristics include the following: 1.) the presence of a particular cell-matrix or cell-cell
adhesion protein within the filopodia (focal adhesions - integrins; cell-cell adhesions - Ecadherin); 2.) the presence of certain structural or signaling proteins within the filopodia; and 3.)
the presence of proteins that alter both the filopodia biochemical and biophysical features. In
addition, the function of filopodia is dependent on cell type (reviewed, (298)). In EC cells
filopodia extending between cells had the characteristic cell-cell adhesion feature of expressing Ecadherin along with filopodia protein VASP. Similar co-expression of E-cadherin and VASP are
seen in the cell-cell adhesion filopodia seen in keratinocytes. (299). An important feature found in
EC cells was the presence of inter-digitating filopodia, known a important feature found in EC
cells was the presence of inter-digitating filopodia, known as adhesion zippers. Inter-digitation is
a signature characteristic of cell-cell adhesion filopodia. Inter-digitation of filopodia was first
identified to be important to dorsal closure and epithelial sheet sealing in Drosophila
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melanogaster and Caenorhabditis elegans embryos (223-225, 299).

The evolutionary

conservation of this process highlights its importance in establishing and maintaining cell-cell
adhesions. As seen with E-cadherin, CD73 was expressed in filopodia functioning to initiate cellcell adhesions. It is unknown if CD73’s presence in filopodia is essential for the direct formation
of filopodia or if it is involved with latter events, such as adhesion zippering. The reduction in
numbers of filopodia with A2BR antagonism strongly supports that adenosine activity is an
important regulator of these filopodia. Filopodia that fail to form adhesion zippering will retract.
When viewing filopodia among treatment groups it cannot be ruled out that lower numbers of
filopodia in A2BR antagonized EC cells are due to a deficiency in adhesion zippering. Therefore,
it is difficult to decipher at this time if adenosine induces filopodia or is directly involved in the
adhesion zippering process. cAMP (356-358) and Ca2+ (299, 359) are both ubiquitous second
messengers for many G protein-coupled receptors, including A2BR, and have been shown to
induce filopodia.

Formation of Cell-Cell Adhesions
The overall importance of adenosine to induce cell-cell adhesion filopodia may be
emphasized by the interesting epithelial-like phenotype of the EC cells, HEC-1B. In the initial
formation of cell-cell adhesions, E-cadherin acts as the initiating event for cell-cell adhesion
formation. By forming homotypic interactions with a neighboring cell’s-expressed E-cadherin
initiates the further development of the adherens junction and initiates cell polarization and tight
junction formation (reviewed, (360)). It has been shown that in the event of E-cadherin deficiency
or inactivation, the entire process of forming cell-cell adhesions can continue if cells are
stimulated by cAMP, PKA, or, PKC (218, 361). cAMP, PKA and PKC are known to be important
primary down-stream components of A2BR signaling (179).

Moreover, stimulation of cells by

PKA prevents the disassembly of tight junction structures in the presence of E-cadherin
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inactivation (361, 362). HEC-1B cells, which have classic epithelial-like characteristics, lack Ecadherin expression, but they express twice the amount of CD73 than other epithelial-like EC
cells, such as HEC-1A (Specific Aim 3, Table 7.2). Additionally, HEC-1B cells display very
prominent cell-cell adhesion filopodia, as shown by immunofluorescence (Specific Aim 5, Figure
8.3). Taken together, these results suggest that CD73-generated adenosine activating A2BR is at
least comparable in importance as E-cadherin is in maintaining and forming cell-cell adhesions.
Importantly, this would also suggest that carcinoma cells that have lost E-cadherin expression and
have thus become resistant to therapies may be successfully targeted to re-establish cell-cell
adhesions by pharmacological agonists to A2BR.

Adenosine  A2BR  Filopodia  Vinculin  Adhesion Formation and
Stabilization
cAMP induces filopodia formation on neurite shafts in a PKA-VASP phosphorylation
dependent manner (356). Our studies here have utilized VASP for its nature of being restricted to
certain types of filopodia, such as cell-cell adhesions versus focal adhesions. However, VASP is
also a protein found among cell-cell adhesion structures. A PKA-dependent VASP
phosphorylation event has been described for adenosine-mediated barrier function (endothelial
cells (220)) (epithelial (221)). In these studies, VASP phosphorylation at the membrane (tight
junction region) of HUVEC (220) and T84 (221) cells leads to the structural relaxation of the
actin cytoskeleton. Our VASP immunofluorescence studies found increased total VASP at the
membrane with adenosine treatment. However, from this work, it is difficult to define how much
VASP may be related to filopodia and how much VASP is related to tight junction stabilization. It
is unknown whether both events occur simultaneously or whether the amount of VASP for either
function is dependent on the severity of the loss of cell-cell adhesions. Much work is needed in
this area to further understand the biology of adenosine-induced VASP.
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As with VASP, vinculin is expressed in both filopodia and cell-cell adhesions (307).
Vinculin is as an important stabilizer of E-cadherin and β-catenin adhesions (307). Vinculin is
divided into a head-domain (residues 1-835) and a tail-domain (residues 836-896). Vinculin has
binding sites for many interacting proteins, including talin, α-actinin, α-catenin and β-catenin,
Arp2/3, VASP, and actin (reviewed, (363))

Vinculin is commonly found in its inactive

conformation, where it inhibits itself by binding its head-domain with its tail-domain (364, 365).
It has generally been accepted that vinculin is activated by conformational change. This change
occurs by the binding or actin to the tail-domain and talin to the head-domain (310).

An

additional mechanism of activation has included the interaction of phosphatidylinositol-4,5bisphosphate (PIP2) to the tail-domain (366, 367). It has recently been challenged that protease
cleavage of vinculin may be an alternative activation event of vinculin (311). In platelets
stimulated to aggregate, cleavage of ~90 and ~95kDa head-domain fragments from full-length
vinculin occurs by calpain, a Ca2+ protease (311). An interesting event is that with platelet
aggregation, platelets lose their characteristic disc shape and acquire extensive filopodia that
function to “clump” the platelets together (cell-cell contact). Studies of recombinant vinculin or
protease cleaved vinculin show vinculin to bind with higher efficiency to its binding partners than
seen with full-length vinculin (304). The controversy with vinculin fragmentation has been the
general concept that fragmentation results in the loss of the actin binding site of vinculin. For
vinculin to function in stabilization of E-cadherin, it is thought that it must bind with α-catenin
(head-domain) and actin (tail-domain) simultaneously. This currently accepted model is being
challenged.

In studies conducted by Madhavi Maddugoda, a recombinant head-domain of

vinculin fused with α-catenin was shown to rescue the disruption of cell-cell adhesions by
stabilizing membrane bound E-cadherin. Recombinant proteins of α-catenin alone or α-catenin
fused with vinculin’s tail-domain were unable to rescue the loss of cell-cell adhesions (312). This
work argues that fragmented vinculin functionally serves a role in the stabilization of cell-cell
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adhesions (312). Concerning our work, it is unclear if the cleaved head-domain fragments of
vinculin function in stabilization of cell-cell adhesions by binding α- and/or β-catenin with greater
affinity, or if the vinculin fragments are functioning to induce filopodia.

Currently, co-

immunoprecipitation studies are underway to determine whether the cleaved ~90kDa fragment of
vinculin has a great amount of bound α- and/or β-catenin. Our work has shown that the A2BR
inhibited migration of EC cells is lost with neutralization of vinculin. With the cleavage of
vinculin and its fragments having functional activity not being an event that is widely known and
accepted at this time, additional studies will be needed to confirm the functionality of the ~90kDa
fragment in EC cells.
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CHAPTER ELEVEN
Conclusion
The work in this dissertation has established the basic science and clear mechanistic
association between adenosine and its regulation of cell-cell adhesions in carcinoma cells. CD73
was shown to be significantly down-regulated in carcinoma cells of moderately- and poorlydifferentiated, invasive, and metastatic ECs, and that the primary down-regulation of CD73 in ECs
were in the carcinoma cells. Importantly, we showed that CD73-generated adenosine and its
activation of A2BR was involved in inducing barrier function, a homeostatic response, in normal
epithelial cells of the endometrium. In EC carcinoma cells, the loss of CD73 in well-differentiated
EC cells increased migration and invasion via Stressor  CD73  Adenosine  A2BR. This is
the identical cascade of CD73’s induction of barrier function. Moreover, adenosine-induced
filopodia by A2BR activity was found to be involved in reforming cell-cell adhesions in EC
carcinoma cells. From this work, we conclude that it is necessary for EC cells to down-regulate
CD73 in order to avoid the barrier function effects from adenosine’s activation of A2BR. More
importantly, the down-regulation of CD73 and therefore generation of extracellular adenosine is
important to preventing the reformation of cell-cell adhesions by adenosine-induced filopodia.
Loss of cell-cell adhesions provide not only to carcinoma cell migration and invasion, but also
provide to carcinoma cell proliferation and basolateral receptor activity. These two events are
important for the early progression of carcinomas. Mechanisms involved in the loss of cell-cell
adhesions have been well-described. What remains understudied and something that is not readily
considered are the mechanisms and molecular components responsible for reforming cell-cell
adhesions once they have been weakened or lost in carcinoma cells. Importantly, it is known that
carcinoma cells of early stage cancers are not too far separated from the genetic and molecular
profile of normal epithelial cells. Epithelial cells have an inherent nature to maintain contact with
neighboring cells. This would suggest that molecular mechanisms that regulate the recognition
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and maintenance of cell-cell contact would be important targets to be down-regulated in
carcinoma cells, especially in early stage disease. In this work, CD73 was found to be downregulated relatively early in EC.

Therefore, it is quite possible that CD73-generated adenosine

and adenosine’s induction of cell-cell adhesion filopodia-induced zippering is one of the
homeostatic mechanisms that responds to reforming cell-cell adhesions under cellular stress. This
is truly a novel finding that has potential for providing therapeutic benefit. The therapeutic
potential of this work is discussed in Chapter 13. A schematic that highlights the central data
presented in this dissertation and the conclusions that have been made are detailed in Figure 11.1.
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Figure 11.1. Summary schematic. (A) CD73 expressed in normal endometrial epithelial cells
generates adenosine in response to cellular stress. This extracellular generated adenosine activates
A2BR to induce barrier function. In well-differentiated EC cells that retain CD73 expression,
adenosine generated by CD73 activates A2BR and induces filopodia formation. Proteins that
support the formation and function of filopodia, such as VASP, are induced by A2BR activity.
Filopodia of these well-differentiated EC cells function to reform cell-cell adhesions by
interdigitating among one another. Activity of A2BR also results in the cleavage of full-length
vinculin, producing a ~90kDa fragment. The combination of filopodia inducing the reforming of
cell-cell adhesions and ~90kDa vinculin acting to rescue cell-cell adhesions significantly inhibits
carcinoma cells from de-attaching from their neighbors. Therefore, the homeostatic event, barrier
function, remains intact in these carcinoma cells, which significantly inhibits the progression of
these carcinoma cells. (B) In poorly-differentiated ECs, CD73’s down-regulation in carcinoma
cells significantly promotes the migration and invasion of these carcinoma cells, as the carcinoma
cells are unable to produce extracellular adenosine.
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CHAPTER TWELVE
Future Directions
Development of Mouse Models of Invasive Endometrial Cancer
The PTEN+/- mouse model typically develops endometrial hyperplasia and, in a smaller
subset of mice, endometrial carcinoma. Onset of hyperplasia is much delayed, reliably appearing
when the mice are 6 months of age. Cancers take longer to develop (368). It would be interesting
to cross the PTEN+/- mice with A2BR-/- and CD73-/- mice. Given the important role of CD73
activation of A2BR in forming cell-cell contacts, we would hypothesize that the resulting mice
might have more invasive cancers at a younger age (acceleration of the phenotype). Recently,
homozygous PTEN deletion has been successfully targeted to the uterus.

These mice all develop

EC within 1 month of age with myometrial invasion by 3 months of age (369). This would be an
ideal model to try therapeutic approaches, such as use of an A2BR agonist, that would promote
adenosine-signaling and promotion of cell-cell contacts.

Adenosine’s Association with PTEN via Vinculin
PTEN is one of the most frequently inactivated tumor suppressors in cancer (370). PTEN
loss is especially important in EC, as approximately 80% of endometrioid ECs and 55% of
premalignant endometrial lesions have loss of PTEN (18). PTEN loss is functionally important, as
PTEN+/- mice develop endometrial hyperplasia with high penetrance (approximately 100%) and
endometrial carcinoma (approximately 25% (371)).

PTEN acts as a tumor suppressor by

negatively controlling the PI3K/Akt signaling pathway, an important pathway for cancer cell
proliferation and survival. Inactivation of PTEN in EC occurs either by mutation, deletions,
promoter hypermethylation, or loss of protein function (370). Recently, vinculin has been shown
to control PTEN protein levels by maintaining the interaction of β-catenin with the membrane
scaffolding protein, membrane-associated guanylate-kinase inverted 2 (MAGI-2).
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In this

dissertation, it was shown that adenosine’s activation of A2BR regulates the cleavage of vinculin
(Specific Aim 5, Figure 9.9). These fragments are currently being assessed for increased binding
efficiencies to α-catenin and β-catenin. Future studies will evaluate the hypothesis that adenosine
activation of A2BR stabilizes PTEN protein via cleavage and activation of vinculin.
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CHAPTER THIRTEEN
Translational
Once a cancer has metastasized there is no definitive cure, and in many cases clinical
focus shifts from cure to slowing the spread of the disease. Unfortunately, many individuals
diagnosed with cancer have dissemination of the disease at the initial time of its discovery.
Therapy resistance remains a significant clinical issue with metastatic disease. Currently, there are
no mechanisms that can re-sensitize cancer cells to therapy. Sensitivity to chemotherapy agents is
associated with the presence of individual cell-cell adhesion proteins in carcinoma cells. These
proteins include E-cadherin (110-115), β-catenin (113, 115), α-catenin (110), γ-catenin (110, 113,
114, 116), and claudin-7 (110). Importantly, these laboratory-based observations are clinically
relevant (110), as re-expression of cell-cell adhesion proteins in carcinoma cells in the
experimental setting has the potential to improve or re-sensitize these cells to therapeutic agents.
A great challenge, however, has been the current inability of these proteins to be drug targeted in
the clinical setting. Our interests with this dissertation work has included the relevance of
adenosine’s ability to induce cell-cell adhesions and this potential scheme being of clinical
usefulness in improving sensitivity or re-sensitizing carcinoma cells to current therapy. As shown
in this dissertation, adenosine’s activation of A2BR induces filopodia-driven cell-cell adhesions in
EC cells. A2BR activity is closely associated to the secondary messenger cAMP, and cAMP has
been indicated in many studies to be involved in filopodia formation. The relevance of cAMP
activation is important as it is shown that cell-cell adhesion formation can proceed even in the
presence of E-cadherin deficiency (218, 361).
In this chapter, a clinical introduction of EC is given. This includes information on the
current standard of care for EC, clinical trials that are on-going in this disease, and a brief
overview of some of the current areas of clinical and translational interest in the management of
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EC. The remainder of the chapter will discuss the potential applications of this dissertation’s work
to the clinic.

Clinical Introduction to Endometrial Cancer
Endometrial cancer (EC) is the fourth most common cancer diagnosis among women in
the United States. In 2011, 46,470 women are expected to be newly diagnosed with EC. With an
estimated mortality of 8,120 women for 2011, EC ranks eighth for cancer-related deaths (1). The
incidence of EC over the past 10 years has continued to increase at a concerning rate which is
attributed to increased life expectancy and obesity (3, 4).
Most ECs are of the endometrioid histology, followed by uterine papillary serous and
clear cell carcinomas (6). EC is a disease that is divided into two distinct categories, Type I and
Type II, based on clinicopathologic and molecular data. Type I ECs (approximately 80% of EC
diagnoses) comprise the endometrioid carcinomas that are often preceded by atypical hyperplasia
and express the estrogen receptor (ER) and progesterone receptor (PR) (372). Type I ECs are low
grade and rarely metastasize (373). If diagnosed at an early stage, the prognosis of Type I ECs is
favorable, with 5-year survival rates of 97% for FIGO, stage I and 80% for FIGO stage II (373).
Type II ECs (approximately 20% of EC diagnoses) comprise non-endometrioid subtypes,
including uterine papillary serous and clear cell carcinoma. Type II ECs are high grade and arise
in the background of an atrophic endometrium and appear to be un-related to high estrogen levels
(7, 374). Type II ECs are highly aggressive clinically and, despite their lower prevelance, account
for a large proportion of EC-related mortalities (45-50%) (375). More than 60% of women
diagnosed with Type II EC with have metastasis at the time of diagnosis (7). The 5-year survival
rates for FIGO stage III disease (regional metastasis) and stage IV disease (distant metastasis) is
43% and 3%, respectfully (376). When combined as a whole (Type I and Type II), the majority of
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ECs (72%) are diagnosed in early stages, FIGO stage I or II, whereas 20% will have regional
metastasis (FIGO stage III) and 8% distant metastasis (FIGO stage IV) (38).
The epidemiology of endometrial cancer is multifactorial. Most cases are sporadic and
develop in postmenopausal women. The median age of diagnosis is 61 years (6). Common risk
factors associated with Type I ECs include unopposed estrogen exposure and obesity (377).
Unopposed estrogen is most related to estrogen replacement therapy or tamoxifen use,
reproductive issues causing anovulation, and obesity. (6, 378). Smaller subsets of sporadic ECs,
those that are related to Type II disease, are associated with aging and the unique genetic and
molecular changes that occur with these more aggressive variants (39). Approximately 2-5% of
ECs are associated with a hereditary syndrome, hereditary nonpolyposis colorectal cancer
syndrome (HNPCC), also known as Lynch syndrome. HNPCC is caused by germline mutations
in DNA mismatch repair genes, MLH1, MSH2, MSH6, and PMS2 (379).
Unlike many cancers, EC presents with a distinct symptom, abnormal uterine bleeding,
which occurs in 90% of patients.
postmenopausal bleeding (PMB).

An EC diagnosis occurs in ~10% of patients with
In 20-40% of patients, PMB is caused by endometrial

hyperplasia, endometrial polyps, or a miscellaneous benign pathology of the endometrium. In the
remaining 50-70% of patients, PMB is often attributed to endometrial or vaginal atrophy (380).
Screening methods are not typically implemented for EC. Papanicolaou (Pap) smears are a very
poor screening test for EC (381), and screening for EC using transvaginal ultrasonography in
asymptomatic postmenopausal women has a poor positive predictive value (9%) and is not
recommended (382).

Management of Endometrial Cancer – Standard of Care
For EC, the mainstay therapy is surgery and includes a total hysterectomy (removal of
uterus and cervix), bilateral salphingo-oophorectomy (removal of ovaries), and assessment of
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peritoneal cytology. For women with non-endometrioid carcinomas, deeply invasive low grade
endometrioid carcinomas, and many grade 3 endometrioid endometrial carcinomas, additional
procedures are added to this surgical approach, including removal of the omentum, bilateral pelvic
lymphadenectomy, para-aortic lymphadenectomy, and peritoneal biopsies, including biopsies of
the bladder, diaphragm, right/left colic gutters, right/left pelvic sidewalls, small- and large-bowel
serosa and mesentery, and other suspicious tissues (383). Survival and the use of adjuvant
therapies are greatly dependent on surgical stage.
Adjuvant therapies for EC include radiation, anti-hormone therapy, and single-agent and
combination chemotherapy.

External pelvic radiotherapy and/or vaginal brachytherapy is used

postoperatively for patients at high risk for local recurrence, such as those having a grade 3
endometrioid carcinoma or a stage IC tumor and those with poor prognosis (384). External beam
radiotherapy and/or intrauterine brachytherapy is also used as a primary therapy for medically
inoperable patients (385, 386). Historically, chemotherapy was reserved to treat patients with
metastatic or recurrent disease following failure of hormone therapy (39). As a result of recent
Phase II and III clinical trials, chemotherapy is now standard of care for patients with locally
advanced or metastatic disease.

Doxorubicin, paclitaxel, and platinum agents (cisplatin and

carboplatin) are the most active chemotherapy agents in EC. In chemotherapy-naïve EC patients,
single-agent response rates are 17-37% for doxorubicin, 36% for paclitaxel, 20-42% for cisplatin,
and 24-33% for carboplatin (reviewed, (39, 387). Phase III clinical trials have subsequently
compared the efficacy of combination chemotherapy in EC, including the comparison of
doxorubicin-cisplatin versus doxorubicin-paclitaxel-cisplatin (388). Combination chemotherapy
regimens, including the three agent combination of doxorubicin-paclitaxel-cisplatin, have shown
significantly greater response rate (RR), progression free survival (PFS), and overall survival
(OS).

Interestingly, these increases have only been incremental (approximately 2 months).

Current standard of care for EC generally includes combination chemotherapy regimens versus
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that of a single-agent alone. Though combination regimens are the most active, responses are
observed in only 50% of patients, and a complete response is infrequently observed. PFS and OS
have improved, but the 5-year survival rate for patients with advanced or recurrent EC has
remained unchanged (reviewed, (39)). Promising second-lines of treatment are limited. Secondline chemotherapy is limited to response rates of 4% for, cisplatin, 7.7% for docetaxel, 12% for
ixabepilone, 13.5% for oxaliplatin, 15% for ifosfamide, and 27.3% for paclitaxel (reviewed, (39))
(389). Hormonal therapy, primarily progestins, is less toxic than chemotherapy, and has a 20%
RR in patients with PR+ EC. Hormone therapy use is also common in elderly patients because of
its low toxicity level, in younger women wishing to maintain fertility, and medically inoperable
patients (reviewed, (3)).

Targeted therapies have yet to be introduced into routine clinical

practice, although many are the subject of early phase clinical trials (reviewed, (390)).

Targeted Therapy
A major advance in the treatment of cancer over the past decade has been the introduction
of agents that target specific molecular abnormalities in cancer cells. Common examples include
trastuzumab, a monoclonal antibody against Her2/neu used in Her2/neu-positive breast cancer;
rituximab, an anti-CD20 monoclonal antibody used in non-Hodgkin's lymphoma; imatinib, a
tyrosine kinase inhibitor used in KIT-positive gastrointestinal sarcomas; and sunitinib, a tyrosine
kinase inhibitor used in renal cell cancer. The attractiveness of targeted agents is their advantage
of being more selective against cancer cells than healthy cells. Conventional chemotherapy is
non-selective in that it targets fast growing/dividing cells, which may or may not be cancer cells.
Because of this, toxicity is a significant issue with chemotherapy.

Along with being more

specific, targeted agents have proven to be less toxic and, in some cases, have improved efficacy
over conventional chemotherapy. Phase III clinical trials combining the use of targeted agents
along with chemotherapy regimens have shown added benefit of combining such therapeutic
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schemes. As a result, many standard protocols for various cancers include the combination of a
targeted agent along with conventional chemotherapy. As example, the anti-angiogenic agent,
bevacizumab is combined with first-line and second-line chemotherapy (oxaliplatin, 5fluorouracil, leucovorin (FOLFOX4) in the treatment of metastatic colon cancers. Bevacizumab,
along with carboplatin and paclitaxel, is use in the treatment ofnon-small cell lung cancer
(NSCLC). Bevacizumab (Avastin) is a monoclonal antibody that inhibits vascular endothelial
growth factor A’s (VEGF-A) activation of its target receptors. Though targeted agents have
shown great benefit in many cancer types, for EC the use of targeted therapy is absent from
standard of care protocols. However, recent advances in the understanding of the signaling
pathways that are dysregulated in EC have led to the initiation of several clinical trials that are
aimed at evaluating the therapeutic effectiveness of targeted agents in this disease. With the
following, we will introduce what is most recently known for targeted agents in Phase II and III
clinical trials for recurrent or metastatic EC.

Clinical Trials for Targeted Therapies in Endometrial Cancer
At the molecular level, Type I and Type II ECs are distinct diseases. The most frequently
altered signaling pathway in Type I ECs is the PI3K/PTEN/AKT/mTOR pathway, which is
dysregulated by oncogenic mutations, PTEN loss of function, and/or overexpression of tyrosine
kinase receptors (TKR)s. Type II ECs tend to have inactivation of p53 and/or p16 and genetic
instability. Other features frequently observed in Type II ECs are loss of E-cadherin expression
and the amplification and overexpression of Her2/neu. From these known molecular signatures,
three areas of interest, PI3K/PTEN/AKT/mTOR, EGFR and Her2/neu, and VEGF, have been the
target of many recently completed and ongoing clinical trials for recurrent or metastatic EC.
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PI3K/PTEN/AKT/mTOR
Because of the high prevalence of PTEN loss of function (~83%, Type I) and PI3K
mutations and amplifications (~30%, Type I) in EC, many Phase II and III clinical trials have
assessed the effectiveness of agents targeting the PI3K/PTEN/AKT/mTOR. mTOR activation is a
key survival pathway for EC cells. Currently completed Phase II clinical trials have assessed
mTOR inhibitors, everolimus (391), temsirolimus (392), and ridaforolimus (393), in EC.
Complete responses were not found in these studies, however 43% (everolimus), 44%
(temsirolimus), and 26% (ridaforolimus) of patients obtained stable disease.

These modest

responses have encouraged Phase II clinical trials to evaluate the benefit of combining
temsirolimus with chemotherapy agents, such as topotecan, paclitaxel, docetaxel, or doxorubicin
(reviewed, (390)), in recurrent and metastatic ECs. The combination of PI3K inhibitors along
with mTOR inhibitors has recently become of interest. Studies have shown that the loss of
negative feedback on PI3K observed with mTOR inhibition can be overcome by dual inhibitors
(394). New agents that are dual inhibitors of PI3K-mTOR, XL765 and PKI-587, are currently in
Phase I clinical trials (reviewed, (390)).

EGFR and Her2/neu
In EC, EGFR expression is found in 50-80% of cases and is associated with poor clinical
outcome (395-397). In Type II ECs, mostly of the non-endometrioid histotype, Her2/neu gene
amplification (10-30%) (35) and EGFR expression are common (395-397). Type II ECs are the
most problematic, as these EC types typically have disease dissemination at initial time of
diagnosis and are absent for aberrations in the PI3K/PTEN/AKT/mTOR pathway which is being
intensely studied in on-going clinical trials.

Antibodies and small molecule inhibitors targeting

EGFR and/or Her2/neu and the tyrosine kinase domains of EGFR are established targeted
therapies in cancers, such as NSCLC and breast cancer. A Phase II clinical trial examining the
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efficacy of the EGFR inhibitor, erlotinib, in recurrent and metastatic ECs was recently completed.
Partial response was reported in 12% of patients, and 43% of patients obtained stable disease
(398).

Interestingly, fluorescence in situ hybridization analysis of tumors from these patients

failed to detect EGFR amplification, and genomic DNA analysis of the responders showed wildtype EGFR (398). Moreover, 28% of patients with stable disease completely lacked EGFR
expression (398). An additional recently completed Phase II clinical trial assessing the EGFR
monoclonal antibody, cetuximab, as monotherapy in EC patients previously treated with several
lines of chemotherapy showed a partial response of 5% and a stable disease response of 10%
(399). Her2/neu amplification is prevalent in Type II ECs, occurring in 10-30% of cases (35). A
Phase II clinical trial evaluating monoclonal Her2/neu antibody, trastuzumab as a single agent in
patients with Her2/neu-amplified ECs failed to show clinical benefit (400). Phase II clinical trials
assessing EGFR inhibitor, gefitinib and Her2/neu inhibitor, lapatinib are currently enrolling
patients. Despite the unremarkable responses seen with EGFR or Her2/neu targeted agents, there
is consideration that improved responses may occur with new agents that act as dual inhibitors of
EGFR and Her2/neu (401). Phase II clinical trials assessing dual EGFR and Her2/neu inhibitors,
lapatinib and BIBW-2992 are currently underway (reviewed, (390)).

VEGF
Angiogenesis is one of the central hallmarks of cancer. Increasing blood supply to a
growing tumor not only “feeds” the growing addiction of cancer cells, but additionally provides
for their escape from the primary tumor. In EC, increased density of microvessels is associated
with poor survival (402).

Likewise, the expression of VEGF is strongly correlated with

microvessel density and vascular proliferation (403, 404). A Phase II clinical trial evaluating the
efficacy of bevacizumab in combination with carboplatin and paclitxel in recurrent or metastatic
ECs is underway at this time (reviewed, (390)). Recently or nearly completed Phase II clinical
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trials assessing tyrosine kinase inhibitors, sorafenib (405) and sunitinib (406), which additionally
target vascular growth factor receptor 2 (VEGFR2), have shown promising results.

Partial

response with sorafenib was reported in 5% of patients, with 49% of patients obtaining stable
disease (405). Preliminary data from sunitinib studies have reported a partial response rate of 15%
and stable disease in 20% of patients (406).

Both clinical trials consisted of EC patients

previously treated with several lines of chemotherapy (405, 406).

Current Areas of Clinical and Translational Interest in the Clinical Management of
Endometrial Cancer
Much of the clinical and translational laboratory-based research efforts in EC are aimed at
one or several of the following areas: 1.) evaluation of the efficacy of non-contraceptive use of
levonorgestrel (LNG)-releasing intrauterine device (IUD) for the use as a treatment alterative for
atypical endometrial hyperplasia, a precursor lesion to EC, or low grade ECs; 2.) increased
research efforts towards understanding the molecular pathways involved in Type II ECs; 3.)
clinical trials designed to determine whether chemotherapy alone, radiation alone, or combination
chemotherapy and radiation is optimal for therapy management of recurrent or metastatic ECs and
high-risk ECs; 4.) development of biomarker panels that assist with diagnosis and/or serve as
indicators of therapy response; and 5.) understanding and developing schemes to overcome
chemotherapy resistance (3, 39, 390, 407).

Potential Therapeutic Benefits or Pitfalls of the use of A2BR Agonists in Cancer

Cell-cell adhesion presence is correlated significantly with therapy sensitivity, and
more importantly the direct re-establishment of these structures or their individual proteins in
resistant cells restores chemotherapy and/or targeted therapy (EGFR inhibitors) sensitivity.
Though a highly attractive target because of its potential to resolve a common issue among all
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cancers – therapy resistance, targeting cell-cell adhesions and their individual proteins, such as
E-cadherin has been a challenge in vivo, as no pharmacological agents are currently known to
act to re-establish or stabilize these structures or proteins in carcinoma cells. Chemotherapy
regimens are heavily relied on in the treatment of metastatic EC, and of great concern, is the
high rate of therapy resistance in women receiving these agents. Our interest in the purinergic
pathway and its generation of extracellular adenosine was for two primary reasons, 1.) adenosine
has a history of inducing barrier function, a homeostatic event related to cell-cell adhesions and 2.)
a number of pharmacological agents are currently available and in use in clinical trials for
members of this pathway (reviewed, (126)). Therefore, our discovery of adenosine’s activity of
A2BR to induce filopodia that function to reform (zipper) cell-cell adhesions in carcinoma cells
provides the rationale and relevance of pharmacological targeting A2BR in metastatic patients.
Most importantly, this provides the a druggable scheme to target cell-cell adhesions in carcinoma
cells. The concept of adenosine-mediated cell-cell adhesion in carcinoma cells and its potential
for therapy benefit is truly a unique and innovative idea.
The targeting of purinergic pathway members central to extracellular adenosine activity is
currently underway in various diseases, such as chronic obstructive pulmonary disease, asthma,
Parkinson’s and Huntington’s disease , and congestive heart failure associated renal failure. In all
cases, targeting specific members in these diseases has shown some therapeutic benefit, with
pharmacological agents being well tolerated and having low toxicities. Many of these favorable
outcomes, however, have come from localized administration approaches, such as those seen with
chronic lung diseases – use of an inhaled delivery mechanism. The potential concern with
targeting purinergic pathway members in patients with metastatic cancer, specifically targeting
A2BR, is whether a systemic approach would be tolerated. Many of these pathway members have
ubiquitous expression across a wide variety of different tissues.

In addition, systemic

administration of drugs targeting the purinergic pathway could exacerbate pre-existing, non-cancer
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conditions. For example, adenosine’s activation of A2BR in the lungs of asthmatics acts as an
irritant and bronchoconstrictor. Many patients with metastatic cancer are older and therefore have
cardiovascular and renal disease. Abnormal expression of A2BR, A2AR, and A1R is found
among patients with heart and renal disease, and hyper-activity of these receptors is important in
the pathophysiologies of these diseases. For these reasons, triggering A2BR or other adenosine
receptor subtypes in tissues that are not the intended target can have profound adverse effects,
including transient heart block, bronchospasms, and seizures, all of which have been reported in
Phase I and II clinical trials for adenosine receptor agonists or antagonists. The pharmaceutical
company, Bayer, currently has an oral A2BR agonist. It is unknown, however, if such an agent
would be tolerated and beneficial in patients with metastatic cancer.

It is likely that local

approaches will be needed for restoring adenosine or A2BR activity to carcinoma cells.
Preclinical studies are needed to determine these potential concerns, as many previously deemed
un-targatable targets, such as ribonucleases, have proved to be not as toxic/systematic detrimental
as once thought. Our laboratory is currently moving forward with designing and implementing
preclinical studies for this work.
An additional therapeutic potential, is the use of an implantable intrauterine device (IUD)
containing an A2BR agonist. This could be beneficial for the subset of women with EC who are
non-surgical candidates. An IUD is a small plastic or copper device that is inserted into the

uterus and is well known as a method of birth control. Recent modifications to IUDs have
been made which include the ability of these devices to deliver pharmaceutical agents to the
uterus, especially synthetic progesterone. Delivery of A2BR agonists to uterine confined
disease may help inhibit the extra-uterine spread of the disease in these women. Using a
mouse model partially deficient for the phosphatase and tensin homolog (PTEN), we are
testing the potential benefit of administering adenosine or A2BR agonists directly to the
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uterus. Heterozygous PTEN mice develop endometrial hyperplasia at 6-8 months of age
(approximately 100% (371)).

One fourth of the mice will later develop EC (371).

Administration of these purinergic pathway members, either before or preceding hyperplasia
development, will allow us to assess whether A2BR agonists can impede disease development
or progression.
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Appendix
Appendix A
CD73 is down-regulated or remains unchanged in colon carcinomas
We have shown that CD73 down-regulation in carcinomas is not limited to EC. By using
qRT-PCR it was shown that the highly aggressive ovarian histotype, HGPSC had significantly
reduced levels of CD73 compared to normal ovary (Specific Aim 1, Figure 5.6). To determine if
down-regulation of CD73 occurred in non-gynecological carcinomas, such as colon, colon
carcinomas and patient matched adjacent normal tissue was received from The University of
Texas MD Anderson Cancer Center Tissue Biospecimen and Pathology Resource (TBPR)
Institutional Tissue Bank and assessed for CD73 expression.
regulated or remained unchanged in the majority of patients.
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CD73 transcripts were down-

Figure 14.1. CD73 expression in normal colon and colon carcinomas. CD73 transcripts were
assessed by qRT-PCR. Transcript values were normalized to 18S ribosomal RNA (rRNA) and are
presented as molecules of CD73/molecules of 18S rRNA (%18SrRNA). Individual lines represent
a single patient. CD73 transcripts were down-regulated or remained unchanged in the majority of
patients.
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Figure 14.1
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Appendix B
A2BR transcripts levels increase with 5-aza-2′-deoxycytidine treatment of hypoxic
endometrial carcinoma cells, HEC-1A, and cervical carcinoma cells, WISH-HeLa; CD73
transcript levels remain unchanged
Data from specific aim 2, sub-aim 2 (Figure 6.8) showed that hypoxia was ineffective in
inducing CD73 and A2BR expression in endometrial carcinoma cells, HEC-1A and HEC-1B.
A2BR expression increased in HEC-1B cells, but was minimal.

DNA methylation of gene

promoter regions in carcinoma cells is a common means for silencing unwanted gene expression
(reviewed, (408)). We had considered whether methylation of CpG regions near or directly within
HIF-1 binding motifs would be a likely event resulting in the inability of hypoxia to induce CD73
or A2BR expression. Using Methylator SVM based software for DNA methylation prediction,
courtesy of Harvard Bioinformatics, we identified two predicted methylated cytosines of CpG
dinucleotides to fall directly within two HIF-1 binding motifs (5'-A/GCGTG-3') of A2BR’s
promoter. Treatment of HEC-1A cells and WISH-HeLa cells with DNA demethylating agent 5Aza-2'-deoxycytidine (5’Aza-2dc) increased A2BR transcripts in hypoxia by 3-fold (HEC-1A) and
2.5-fold (WISH-HeLa) (Figure 14.2). CD73 transcripts remained unchanged. Recall from Figure
6.8, HEC-1A cells, after 24 hours, hypoxia has no effect on A2BR expression as compared to
normoxia. With 5’Aza-2dc treatment and following 24 hours of hypoxia, a 3-fold induction was
seen. WISH-HeLa cells were initially found to have a significant increase in A2BR expression at
24 hours (Figure 6.8 – 4-fold). An additional 2.5-fold induction of A2BR occurred with 5’Aza2dc treatment. These data suggest a direct or indirect role of DNA methylation in A2BR’s
expression in hypoxia.
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Figure 14.2. 5-aza-2′-deoxycytidine treatment of hypoxic endometrial carcinoma cells, HEC1A, and cervical carcinoma cells, WISH-HeLa. HEC-1A and WISH-HeLa cells were treated
with demethylation agent, 5-aza-2′-deoxycytidine (5’Aza-2dc), for 24 hours. Cells were subjected
to hypoxia conditions (1% O2, 5% CO2) during this period. CD73 and A2BR transcripts were
assessed by qRT-PCR. Transcript values were normalized to 18S ribosomal RNA (rRNA) and are
presented as molecules of transcript/molecules of 18S rRNA (%18SrRNA). CD73 transcripts did
not change with 5’Aza-2cd treatment compared to the vehicle control (DMSO), while A2BR
transcripts increased in HEC-1A and WISH-HeLa. Error bars represent ± 1 SE. (*p<0.05,
**p<0.005)
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Figure 14.2
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Appendix C
CD73 remains down-regulated in metastatic endometrial carcinoma lesions.
When treating advanced cancer, most often the primary tumor has already been surgically
removed. Therefore, treatment is actually directed to metastatic disease. The extent to which a
primary tumor resembles metastases at the molecular level is currently controversial. Much of the
work that has gone into understanding this issue has come from studies in breast cancer. In a
study aimed at determining the reason for trastuzamab failure in metastatic breast cancer patients
whose Her2/neu positivity had been determined from the primary tumor, a 15% discordance in
Her2/neu expression was found between primary tumors and their corresponding metastasis (409).
Because of our interests in the therapeutic potential of CD73’s product, adenosine, and its
activation of A2BR, we were greatly interested in whether CD73’s expression remained downregulated in metastases of EC. Our previous studies have shown that CD73 is significantly downregulated in the primary tumors of grade 3 endometrioid endometrial carcinomas (G3 EEC) and
uterine papillary serous carcinomas (UPSC). To assess CD73’s expression in EC metastases,
CD73 expression was assessed by dual labeled immunofluorescence in cryosections of 5 omental
metastases, 4 ovary metastases, and 1 pelvic wall metastasis from 10 different patients with a
known endometrial cancer primary tumor (Figure 14.3). CD73 expression in the metastasis in all
cases was found to be minimal and equal to that of the surrounding tissue.

These data suggest

that the down-regulation of CD73’s seen in EC primary tumors remains down-regulated in its
metastases.
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Figure 14.3.

CD73 and pan-cytokeratin immunofluorescence in metastatic endometrial

carcinomas. Cryosections of metastatic endometrial carcinomas were characterized for CD73
expression by immunofluorescence. Pan-cytokeratin served as a marker of carcinoma cells. The
low intensity of CD73 expression in these metastases is comparable to that observed in primary
tumors (Specific Aim 3, Figure 7.2 ) Image magnification, 20X
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Figure 14.3
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Appendix D
CD73 expression is no different among platinum sensitive or resistant ovarian high grade
papillary serous carcinoma (HGPSC) cases.
Platinum resistance is a major determinant of poor prognosis in patients with ovarian
cancer. To determine whether CD73 is an important molecular determinant of therapy sensitivity,
CD73 transcripts were quantified in platinum sensitive or resistant ovarian HGPSC cases. CD73
expression was not significantly different between the platinum sensitive and resistant groups
(Figure 14.4). However, as a group, CD73 expression in ovarian HGPSC is quite low (Specific
Aim 1, Figure 5.5), so it may not be reasonable to expect that platinum resistant tumors would have
even lower expression of this marker.
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Figure 14.4.

CD73 expression in platinum sensitive and resistant ovarian high grade

papillary serous carcinoma (HGPSC). CD73 transcript data from qRT-PCR studies of platinum
sensitive and resistant high grade papillary serous carcinomas (HGPSC) were plotted using a box
and whisker plot: bottom box, 25th percentile; top box, 75th percentile; black bar, 50th percentile
(median); whiskers, upper and lower adjacent; circles, outside fence. CD73 transcript values were
normalized to 18S ribosomal RNA (rRNA) and are presented as molecules of CD73/molecules of
18S rRNA (%18SrRNA). CD73 transcripts were not significantly different between platinum
sensitive and resistant HGPSC.
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